var title_f11_43_11952="Ultrasound of popliteal artery aneursym";
var content_f11_43_11952=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F65760&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F65760&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 472px\">",
"   <div class=\"ttl\">",
"    Ultrasound of popliteal artery aneursym",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 452px; height: 344px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFYAcQDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5UooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKUUAJRTqKAG0U6igBtFOooAbRTqKAG0U6igBtFOooAbRTqKAG0U6igBtFXNNt1uLtFkB8oHL4OMj0rZ1Hw4Snn6Y3mpjLRFhuX6etAHNUVJJG8blJFZHHUMMGm0ANop1FADaKdRQA2inUqqWICgknoBQAyiuq0rwdez2pvdRH2OzXn5+Hf6Dt9TWRrdvBFclrMKsJ4CB95Uj1Pv1oAzKKdRQA2inUUANop1FADaKdRQA2inUUANop1FADaKdRQA2inUUANoqa2i8+5ii3bfMcLnGcZOK7fx94APhSyluPtOoSeXfGyxd6f8AZhLgE+ZEd7b0468dR+ABwVFOooAbRTqKAG0U6igBtFOpDQAlFFFABSikpRQAtFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRU9rbSXDFYwpIGcE4J+lADYRJnaiuSey1o2d9c6fMkkO6NwejLkfiD1qijS28v7sujg4yK0bDVbuBJEmBljbqso3An8aANdNfttTVItas45AvWSMYYf5+tPPhvR9Rc/2XqfkuRkRzc/h2P86jhv8AwzfW7RappU9hcBQqXentkZ9WjY8/gRVSXS4yEOm3Ntd7R1AZHH1B4/I0AOufBOsQglI4pecbUcbj+BqgPDWssWCabcvtxkom4fmKtxXFxbq5SW5tpFGGVJDkn0x6VpQ6/qvkRQrqt9FEF5VuAvrzigDEj8L65IFKaXdkHofLOD+NXYfA+uPAZprdLaEHG6eRV5+nWtmfWYIZx/xOdW8hRkR+acgnryAB1qjPrOimQymC9vpT1+0SnH14NAAvhbTLRCdT1y3Lhd3l2/zfhn/61atnPp+lxBNG05jMQA11NySfYdh9KxLfV7VGMtnYWsE5PLFd5X6A8VDLfX+oytGHkkweeNv40Aa3iDVopbRI7uaWS5zwA3yqPUj1rlby8E4aP5VjHRUXqfWrV1YvECXkt1C8lQcsT9Kh8qI7SobJ/vYoAyqK0byydYt4C8dcHms6gAooooAKKKKACiiigAooooAKKKKACiiigD2Xw74K0G60LRIbixMs+paReahJqPnSBoZIz8qqA2zaOh3KSc9RXnfhHwv/AMJJ9r/4nmhaT9n2f8hS78jzN277nBzjbz6ZHrWdBreqwaZJpsGp30enS532qXDrE+euUBwfyrPoA6vXfCh8OXemsuv+H9UaeYADTLv7QYyCOXGBgHPHrg13nxK07VJLrWNL07Sp4rm9u5Lq+nbTntIbsRFiZI5JbmQFQWzhVXg/hXkGnJNJqFqlsge4aVRGp/ibIwPzr0zVtPuBqXirVrKe5vNRnlmsrxo9JkFj5szBZEjn8w4ILjBcAfXIyAcZL4N1uKwmvXgtvIijaY7b2BmaNW2mRUD7nTPAZQQexNc9Xpd7eal4f0C4tPEmj2Ykexl0i3vraZZpVZXVvKk2SlF257qH6ds15pQB1WqeDZ9L8GR63e3SR3TXccBsNnzxpJG7q7nPykhPu4zggnGcVJ4d8HxatYWDzai1ve6lJNFYwLb+YsjRqCfMfcNgJIUYDe4AqJvHviGfRTpWoX8+oWjXUVy63k0ku/y84jOWwYySCVx1VT2pbHxteWcZWLT9NLxzTz2jmNwbJpRh/KAYLjgYDBgMAigCPwd4UfxNZ63LDdLDNp9sJ44imfPYnAQHIwT265OBW/L8Lr0W8IgupLm+k0htT+yQWpd96zJGYeGySNxyQOCpGO9cloHiO/0GG8TTWSOS5MLeaQS8bRSLIpXnGdyjqDxXQ6V4wn1GOez1u7EUMlhPaNPHaNcTzGW5E7YXzFXeXzySBjPBOKAIrz4daxFeaXYwLH/aN7Zx3LWl5LFZyozySIIwsrguf3eeB/EOOmeNuIngnkhk2742KNtYMMg4OCOD9RXseh3MEPieTwxftBPcW9sulRXC2EhCWyl5XZ3W6iaM/vGDgZ4THrnyDUPJN/cm12/Z/Mby9qlRtzxgMSQMepJ9zQBXooooAKUUlKKAFor0T4afCLxB8RNLu7/Q7nTIobabyHF3K6MW2huNqHjBrR8d/AzxP4K8M3Wu6td6RJZ27IrrbzOzncwUYBQDqR3oA8qooooAKKKKACiiigAooooAKKKKACiihQSQAMk0AT2cDTSj5C0akFsHHFblnFGHdRB5kZ+7zhlNR6QURBGFZX6knoxq8VnF0zGMgnpxgCgCa2mZHFqkS2z9RKyBgPqKjfTNU+0tDvtbxnG8BWAyP0qQfv8AY6R4Pf5uhrRlIig3qI2kAG7JBKn2oA5m7+2W8hR4HTyznaY9wH6Vc0e5Xzt1wsZDLwzRHCn6LW9YztNA0kj7ZT8uFGMn1J9KRw0NorFwhjBz5f3j/jQBWvkjIBNixJ5aWGFun1xUVpcvaWh3QSNCnzYlkUqfTitK21u9gtkiS+eNWUggHqPSoltbK7CLdkSqeWYPsA/+vQBVtfFKLPxoOkzzDBAmjLBh6YHFXtYvtTuow0miaVBE/wA2I4xGqe2M1Iuh6JFOAn2iKI9HSYMSevBxxW1beHvDl+V+2trskatlm+0Aj8MrQByMGs3NpA8LX9rb2/PEEQDH2zjOKxrm+kWBodOclTyx25LH8q9MTSvBNjdFbTRru8ZM5NxKWz9egFTXFrDeuptdNt7a2RfuYCqPx6k0AeXaZod7cy4lMcQ6uZZAuKsvZ2lpcFY5/tWONy52g+2a71NKhy0UqxsucnYOR+NXLjTNPGwWyWaxAfcQ72H1PegDzjVGM8Yjtk2Lj5z2z6Vzl9Zvald2CG9Oa9PvNFV7iRomDQjlmZdqg+nv+Fc/rVtDu8lU8wFeoHQetAHDUVJcQtBM0bduh9ajoAKKKKACiiigAooooAKKKKACiiigAoorofCPjTX/AAh9r/4R2/8Asf2rZ537mOTdt3bfvqcY3N09aAMO0Li7hMUoikDrtkJwEOeDntivX/Fsl3pTzGysY21nUrqK2lujpU0CagRIr7onEzRMC6KSQiE5z3NeUpczX+ti5uWSS4uLjzJGdAVZmbJJXgYyenSvbbrSbrw9deKUt7fS7Sz0qI30U1lFKgvbgJIqEK8r7PKYyEhMDcoHQigDl59JfxVdeItNtryCGxttRkngmMZc3d/KmPJQ5ACMYnK8EgYznOa8s6cHrXomhx+NtN0rTbLw5LFBDNdvIJdN1KImeXyw2yZklIGEQkK2OrdTXLeL7K/ttYkudStbW3a/LXcYs5VlgKsxz5bKzAgEEY3HGMUAYlFFb/hrwveeItP1ibTUuLi6sI45FtbeAyvNukCHAHIwCT0PT8aAMCvQvD1snh3RYvEukxNfz3DrZRQ6nYtCGd87ntpI5tzMpTbuG0jd2JxVC68F/wBlahLHrD3CQ2+kpqNypj8mSOR0ASEhs8+YyqcjOMnAxXZTznQ7S5/su0099QsLi1e/trW0eENctG4gZGaRwwSQgkKkeSPfNAGZa2ulS+K9b0PTLqPTJ78x6bm3tpLoKQoM7iR5fkiLq2Wy52+2a8ukXZIy5VtpxlTkH6V694esdP0o6ppzvaTW95fxaSLiaGWWSafYPNUvFNEVg3n/AGicjIbFeT6lC1vqN1DJGkTxysjIhJVSCRgZ5wPfmgCtRRRQAUopKUUAfWX7Hk3l+C9bGeuof+01rq/2mZ9/wb1lc/8ALS3/APRyVwX7KE/leEdZGet9n/yGtdN+0TceZ8JtXXPV4P8A0clAHx1RRRQAUUUUAFFFFABRRRQAUUUUAFaNjauu2Vl6jI+lRaXZm7nwciNeWP8ASuhELfKpOdvT6UAQRoGbKgL2OKtWl3PC37ti3Yh/mFOhjUOflIx7dqmFuhy8YdH6HHQ0AVVszMZGaZYgTnbg4Jp7LFDGA7EnH0pC/lSK8gZoyegOMfjV64sra4WORZVHHMTLzQBnLKRGXLnbn7oP61pQu9woEKq7HHG8KGqC4jt2t/LhCo2O65z+NZ8FiZJ1TzUQk8MWwBQBrtbWjvtnhkWeM5YLJx9MVbjm0/aha1TA4/ePkGo7a1kjkVCpmdRyQwORXRR6LZLZxzXFrO79SuPl/SgCvA0bwIdOgjjk6A9R+FXnN+xdpJJkHQkcjPpW/wD8I0qeDxr9uiW9sJxAYWk3Sc5wSoGV+6euPaqcMsEscUapsjPCt6n3zQBUtrHULeMusEaA4bMsmC1X55NRkjVRFao3ZIkMjH3qnf2F08odmEqqeCzFuadJIyQCONpHkf5Sc4/DAoAWXTr5USSaSCGNiS8s8oBPsEFUktLXz/KS5kZQMsUUfOfr6VUuoMYWdG2DsW6VMyafCiDyMMFyX83k0AX764htbEQ2No8k5HLFSVX3JP8ASuO1SKbcRLIuX5bYMD6ZrpHlUqrF5MdRH0AHv61Sv0huHAVvm9F/xoA4fVtME1uXj/1yc49R6VzHTrXpN9ZSQsG3fKDxgdK47X7Fo5jcxqxjc/McdG/+vQBj0UUUAFFFFABRRRQAUUUUAFFFFABRRXZfC3WfDOi+IRceLtIbUbbjy2B3CFufmMZ4cdOvTHQ0Acnal47yBgMOHVhuHuCK9b8YX9+tz4tis9a/tCXT2u0vLG4sfIjiSadBLJBiVyw8zbw54Bzg81y3xc1Sw1r4n6jqGjXEc9jMbfyZEUhSBDGvQ4IwQRjjpXWeMoU1XUfE2n6PcWcOoLe41kx2EkLzqbhULoWnlygkZCVGzseccAGPB8V7y7vrL+2rG3NhbyvOYrczHLGGSMKqvKVRPn5VNo9K4nxBrkus/YozbW1naWUPkW9tbB/LjUsWP32ZiSzEkkmtzx94KXwpGrfa7t2N1LbeXeWf2V3CY/exje2+I54bj6VxtAHQX3h+3s9L0C+fVYZIdTZxK0cL4tdpUMDkAsRu5wMccE9av6tGnh3QTHpV2byw1+AbjdWvkTIsUwIYKHYbSy8HJzgjAIqm/ikPpujWTaJpJj0uUSoWEzGYnBcSAyFSHKgkAD2wOKk1fxcdT1Ca9l0PSEuJYJYHOJpBh02gqJJGClB9zbgL6YAFAHWeJ4ZJvBE9obhf7VsbLT7m+jjgKp9m8tUhQOWJZx5ys3ABJGPu1X0zxHrcmnf22+laSkKuJJLprlLeW8ngiIjbbI/zlGZWKxINxGDya5i+8X3t7o0lhJa2SSTQQ2s94iv508UWPLRstt42pyFBO0ZJqbQNXsrvTE0PXLYSwJ5n2KeG1ee4ikkIBCgTxKRkZG7dz2waAOo0DQfGWhFrM6Po966X6yRJd38LNBeKPlA2zL+8II+Rs7sA7TivMLp5ZbmWS4JMzOWcsMHcTzn8a9ja4Sb4jXNgdZhN/wD29FqEZj01mT7Sq5bzP3+EiRshiGY/KT0rx27cvdTO5Uszkkp0znt7UAQ0UUUAFKKSlFAH0X+zPceT4X1YZxm8B/8AHFrovjvdeb8MdUXPV4f/AEatcJ8A7nyfD2pDOM3Wf/HBW38Yrvzfh/qCbs5eL/0YtAHznRRRQAUUUUAFFFFABRRRQAU+GJ5pVjjUs7HAAplbeiWTb0ldSC33T6CgDT0e3FqFVUbn7+7rmtxLbzcttHl9OByKZawo7gO4Vj3Y4p8kUscjIpfJ44OQaALNtYNJIqw4cgYweDite30iNoh9p3xnple/1qpbNc2UKGeFkcch2XAYfWr326O4hZgJIX7ssnyn60AUL3SrPTXDoGds5ABBwayNRdr25bzwkL7cg7MZ/KtKQI4yk+9j03v39qy2WdUYy/OFPDD0oArQQFAcqrnHUnpV7S5GspnZDCfMG070DYqOK48oqGj3JkNtZatX2pWLTGeK28ggD90nKk+3pQBq6NcT2V1JPbJlm+VlRARit+01Fo5VkmhlhYncvGwZ9xj+tcFa6zcQyGW32jP93P8AKtMeIry7QB5EB6ccZ+uKAPoH4eeJ9Gvki0rUYruO4nvICu1fMikbcQFORwOeee/bHPNfEe+tF1qezsGluEE8gkQ23lRwkMQFX5ju784HQfh5VFqNzZ3kF1BO0ZidX+VyMEHPFaPiy6k/4SbWMTEhLuYFVJxnec0AaLTywuwDRnH948j6Vk39w6SgeZG2PmJBww/HpXOySyGcuznd/f3fpinLcSSyYxnjoRQBtNKJk3S/Pnsw/wAKporzzkBIEAHbg/lVSaRwrFmCr/sHgfhVZYyjecJmR/WgDolMPlgBXz/Fzkt/hTkvWhMiQW8cZcYLMMtj0FUNPv50bErpIDnDYwcf41f+12/7wyOuewHJ/OgCt5bTrmRidv3UxwCaZNpSTW0lvcBWWRcNx0+npT1nUtkttGc+v4UXOooqEIVMnbI6UAeU6tYSabfy20nIU/K3Zh2NU67TxHZy6hF5hADpkp6n2rizweaACiiigAooooAKKKKACiiigAoorofCPgvX/F/2v/hHbD7Z9l2ed++jj27t2377DOdrdPSgDEskMl5AgOC0ijJGcc17xrukXU3irUrKG0vbC7nmmvLq5g0GQDUTCwk2xF7pi4LqpCrsB4PoK8Kmin0vU3hnQJdWkxR0JBAdWwRkHnkdq9QvdF1VfFX22O7sXvvES3NvqS+S4j095IhLKvDEkrHJkH1Vhg4oA534j3d3bX93pd48N0s8/wDaSmWAxTWUk3zyRbN7bOSNyEtyAeua4iu08YQwarosOtWGoHUBZyJp9zPNZm3nkJVjE7fvHD/KjLu4b5Rkd64ugArc8FaFH4l8S2WkyahFYfanEayyRtJkkgAAKOT9SB6kVh12XwoXZ4qF3FJYLd2UEt3bx3cczh3ijaT5RGyjOEP3mAxngnAoAoeFNBsNd3wS6pNbX58xo4ltPMjCIm8vJJvGxeCMgNjGTgVc+GVhf3Wr395o8Xn6lplk97bQ/Z2mZ5AyINqqQdy+ZuB5AKjg11PhiOBvDDWo0/SVuNZjudQt7PybnDxQBsxNMtwrBcxOVUhxkZJHGK2h+F3sTqNhY6pB9uu4LSy1FJ7YrFbRXUkTBo5BJ8zK3lg5UDk4z1oAm0zQ9b0KOLR4tJ0u+v8AWrSO5nh1SZrK5XdJInkKTPGzg+XuIHXIyOleX3qGO8nRo44mWRgUjbcq89AcnIHrk/U17HcWus6TayRW+jpqpg02HT7eKWwuI7vyyzyyK6xTboyBJ85BIIaMYG414zcOHnkdYlhVmJEaZwnPQZJOB05JNAEdFFFABSikpRQB6x8H7nydFvhnrcZ/8dFa3xMu/N8HXiZ6tH/6GK5H4c3Hk6ZdDOMzZ/8AHRWh43uvM8N3KZzkp/6EKAPMKKKKACiiigAooooAKKKfBE88yRxjLscCgCxptp9pm+bIjXqf6V1tvA5Vdp5FFho7RQJGjAepPc+tX47UwYLcMOM9RQAkKENtOQzcEZq/bKIHi2xhyG5U9CKropB3g4+lX7RWkDFgOejDr+VAG817BOAkUckYxzE7bl/DvQNB0+5gZ9siznJ4YBfyrF2tHOrbmD+uODW3DqAS3dTHGEx8245A/wAKAOZ1KxFpkruMXYDnBrPQvJlWZ4z1BXnP1rY1i6h3GNDjI4KkEViyFoYVIOCD1oAjvxEihhcNM/XGMYPpVEHfvDHGRng9KLi53SZ6Z4FV1O1wzsTnqaAHxfugRknPcnrWnC3yIBt6dhWYrqJAwGQOACatRtIHQjAYnsaANQliuS2fYtn9K6TxPDE3irV2JYFrqR9qkcszEnuccn1rk5p2jYb1BYck4rb8X3u/xFcOzErKscnB5+aNT6n17n8ulAFC9SXISRCD2XOf5VTi86IscZXpnsKsi9iEO0qCwPXd0qjJch2/d5Zs9qALscxkjDyFNoOMEgE/hVaeLMhaRht68fyqOV1cF/LVX7gDIqGS5Pl7SQvfOKANOJsqSzBVAwFWrtvdI6BCVWPPZf8AOa56GQgggls/rWhG+SGB2+22gDTmlTYY13SEngYwBVRrZg29sjPfH8qkt1faTxhj6c1fdgAdoBz60Ac5cq3LPux/nvXKazbAObiJTsY/NxwDXoV3B50ZDtlO6+tZN3aROjKTvDDDDoAPQUAcBRVnULVrO5aJwcdVJ7iq1ABRRRQAUUUUAFFFFABRRVvStNvdXvorLS7Wa7upDhYoULMfy7e9AEVlP9lvILjyo5vKkWTy5QSj4OdrYIOD0OCK6sfEnxK880t3em9Z7lbqMXZaVYHG7IjVjhVKuylcYKnHYVgeJNDvvDmsz6Vq0SxXsAQyRhw23cgcDI46MKzaAN3WPEb6hpo0+203T9MsjN9pkis1kxLIAQGYu7HgMwABAGTxWFRRQAVs+Fdebw7qD3kWn2V5K0TwgXXm4RXRkfGx15Ksw5z14weaxqKAOns/GV3Z6aLSGxsN0Uc8FtcFZDLaxTZ8xEO/GDubBYMRuODTNU8X3mo6VLZy2llHLOkMdzdxq/nXCxDCB8sVGMDO1QTgZzXN0UAdTonja/0hLeKG1sZbaCJUSCRH271lEokO1gS+8A9cEAAjAArmLiV555JpTmSRi7H1J5NNpDQAlFFFABSikpRQB1fhGfyrOYZ6yf0FWvElz5mjzLnqV/8AQhWHos3lwSD1b+lS6rPvspF9x/OgDCooooAKKKKACiiigArd0OzUIZZM+Y33R6Cs/TLNrmQsR+7Tr7n0rfgRo2Jbg/SgDSs3liLAyEr/AHamS4kjlKyA7W6EiqkV391WCtjoehFWw5lUIwBHXk4oAuWpMz+WCFPbmrGPKJVG3g9cdqyAMMQueOx7VehJQZwfYjmgC7byv5oV2yuRwxxW1c20UVnunQCT0X+IfyNc/uUr+7A55w3IFWry+VLHCv8AORj5hkCgDFvWhed1hTyiOoB4qqb947YwTRB0+7vzyP8AGjyt5Zj9485zWffoFbksD6GgClMGVyRyvUc0RyydU5IPYdKaz5YAEt35p6lOvA+h60APWSYgjCdcnPFSRzCL7zHBOSQeR9DUJRGYGQkgnjI4qdUjOQBz60ATSXLHAiLYP8WM/rWv4vLtraPuJZ7K0fJOettGcdT/AJ7DpWVDGShwzbQea3PF4BvbF95/eafa4JOM4hVf024/CgDn2uGKEYB9e36U4Mvl/dAB/Cq8hAcc8g9jSA8ncMmgCUuGbaHYE/w9qdsOchkwO2eKjUBV3KBlupHWhBnBY4UnjtmgC5BK5n/eKCv+yMVbgceZy5b2PaqoIOCCeBVuwhMkvzDAHPI5oA17QswGRj05q3JHHjDSENjJpkBZBuEfH94gcVVuWBLspZj9M0AV5ZGYsNx8oegxmqMjszEpgL2/xqcRSlC0x8qP09ar3EqoCsKH/ebigDK1e1FzbkD/AFqcqf6VyxGCQetdhNu8sknP0FYOqWrDNwikKThuOhoAzaKKKACiiigAooooAK6fwF431fwRqT3ejPEVmAWeGVNySqOgPcdTyCK5iigDofiD4k/4S7xdfa59l+ym6EeYd+/aVjVDzgZ+7np3rnqKKACiiigAooooAKKKKACkNLSGgBKKKKAClFJSigCzbS7EI96dPNviIqrRQAUUUUAFFFFABT4o2lkVIxlm6CmVq6bEIk3uoLN69hQBfsowkKxw/K69Q3RjWjBJxsdR/unt9DVSCRHORzircZEqbGUkr0PcUAPQR5O4cfrThuh/1b7k9GFOVBsO3gj16GmuAUHzcfWgCdJFJDEgHHNXYJF3DpzWSFIGOo7VcthKeAUGOvB5oAvT5jw6guG6gHpWTdzMJDu79jVx38pT5mMetZk0pMm9lITpntQBPFd4X5kUg+lZ92/nuVjByOxrvPBnw51bxTYapeRWOpQWkGnzXlpNHas6XcqMAIkboSfm6ZPyniuXuPC2v29w1vPoWqxXQIUxtaSBsnGOMd8j86AMKKDcRu249KWSL5gN2SP1rXi8Ma8zJs0XUzuwF/0V8nJUDHHfen/fS+oqzbeFPEFwqNHoupuWC7cWkh3bthXHHfzY8f76+ooA5uZEAUL5gcdc0igkHHXPX0rpz4O8SyhPL0PVGDAbS9uwBztx1HP30P0YetR/8IR4kXYW0qcA4IcsqgZxjJJ4+8v/AH0PUUAZKecI8FucdAetbficK8WhscMG06Pr7O49fanw+ENdkAzaBScBcTx85Kgfxf7a/nWtrvhTUrnTvD29reF/7P25e7hGCblwucyccSx+mMn+6xoA4h1VHGdoJ6YFR3HlmQjcAAOdtbaeHNUmSJZZtPIkA2+bqNunUIR95xjiRM+nzZxtbBb+E7ohS82jx5x8zava8A7e3mZ/jH5N/dbABjQgFiANox361I0OGBLkkdBjpW7F4TuSR/xMNEXOOTqcGecej+/6Gp4fDDNIn/E40XdxkfbBxnb1OP8Aa/8AHW9KAMKKOZztQMw7nFblgiW8bAsd3fIqSLw/Kzxlta0m3DletwxAz5fXCnp5nP8AuP6c6NhocHlxtNrulRFwpY75GKAhDyFQnI3nP+4/oMgFKWYlclgVHrULu/HzKpPTIwB+Fep/C3RfD2oeLtPsZ9R0q+DiTdbFLje+IWb5SYwvB65b+E4zxny7XoIrW8EVtqtrqcbLvM1ssiqCSflPmIpzxngY569aAKssiIeX3t/eJqpPIxPy7SfccU5vLHBwT7c1G+0E5y3stAEBO7O45PrUcsYdCpG7cCDuPAFOMpyTjao7GmO64yxJoA5a8gNvOycleqn1FQ10OowC4hOcKy8qf6VzxGDg0AFFFFABRRRQB7J4S8QSf8IGula3qen2mh2+nXLW8lhqjw3nnO5IjkhWT58nPDRlcHr1z574R/4RP/S/+Ew/t3+D7P8A2X5X+1u3+Z/wHGPf2rnaKAOo8V/8IX9ih/4RL/hIvtfmfvP7T8jZswfu+XznOOvauXoooAKKKKACiiigAooooAKQ0tIaAEooooAKUUlKKAFooooAKKKKACiinwxtLIqL1J/KgCewg8yUM4+Rf1PpWyI93KnFSJbRxW4ER3R9/r70RkKfm5X19KAFhkCN86LzwSBVlWXqvHvULonXk/TmpLXy5wQpG8dCD1oAsqrEAh6fygwzA++M5qqhaOQg8Cp1ZW//AF0APAZTldo/lViLzCMt+lCltgJwKdJJgBtpDeqGgCvPLuBQlfoapWyhbpYywidmABc/Lye+egqW+aSUq4PzDqcdarSLI6YPKjkUAfQvxM8dX+jaELSLUNH1w3tpPZ3F9BeRSGJplTKwRxtuSNRH1YcseccZ+fJtY1IL5bX9zsAwMyt049/9lf8AvkelMQybMIzbR2zxVWZiQxb5vbvQA9L64PzCeTg4yJD7f4D8hQ2X+bJ3dyTVMDYRtIHtVncWx1980ARzON3DMzfU1Kiho9y8H9KikwDhQefQU0uyHByQO2cUAXojEYXGzLdjnHNXdZkZ/D3h3ncVinjOWzjEzHH3j/e9B171lCQJCZAwweozW3fxmfwhoTb1JWa6jA3dsxt0z/tHsKAMCcOqKB5eevPWlgaX+I5B7UrRSJjKH64qW3tpp8lCgC9SzAYoAngGWUnt2Bq7DjPGOaiitCEJ8xDgc4OKjUFTh8gHpg4oA0Ey/CB2PfA4pZEZduSQB14xzVdJJIxhSQDTC0kjjMhVR3zk0AaVjql1pOoR3unTz215GCEmiba65BU4P0JH41R+/kAhMnndzSRxPKcpuIH8QXJqRI1XJzz3zQBHKQuFD5+lLuUAKoyT0H9aSUKGy7naew703cowQpA7Z70AOMWSDJg46DtUN08eeSCR09BTZZHc4XqaYsZEZ3AE0AVWYySYXBC/pWZqcAP75O/DD+tbyogi56fzqJlj2FCuQ3B96AOWoqe9tzbTlDyOoPqKgoAKKKKACuw+GPgk+Oddaw/tO0sEjAZvNbMkg54jT+I8c8jFcfTo5HikWSJ2SRCGVlOCCOhBoA6j4o+HbTwp461LRdPkmktrURbXmILktEjEnAA6se1crVrVNRvNVvpLzUrmW6u5AoeaVtzNtUKMnvwAPwqrQAUUUUAFFFFABRRRQAUhpaQ0AJRRRQAUopKUUALRRRQAUUUUAFamnw7E3Nw7dM9hVbToFllDS8Rjvjqa1/JKnOMg+nINAD4xkdSj9ODwaljhPdqciqmDj5D17ipnjKnjoe1AEAjdGBA6ehpzEqRIiqW79jUwZduCpBPcVGfvcgGgBZW8zqDu9qWIsRlMsB19qjZRHyDg0kbv5mRjd78ZoAvQtuO3p75pPlBLZKuKjy7DJG36dKJAAMqWz79KAEkZi4ODz3yKYdyvgNtHpULMRy33fYZp8OJnCo/z9t3FACuVPViF78ZqKKO2LMBKycdxxVia2ZDkqc9881VltXJPJ/GgCrMsfmDbzg/eAq7bxxyx5ZoSfVnIP5VUe3IJGDmlg3R4yin8KAJZ1AXC4H0PFVm/1n70HPqRRdSOWwvyj2qu5nkIMjuwHTPOKAJSY9rBuQfStuTcPBGkvHksmo3a5z0BjtyP1B/WsOC2MnDMdp/u9666O3ifwPGPMWMQai+QT/eiXH/oB7d6AMe1ujsPnAyf73NSiFGfeEVc9kqqCM4iOVHt1q9aSlSNpC+xFADTFtIIyPqKZ5JJJ8zkc5J5q1KZDudmXA7VUQSz7hgAd8cAUASqD0DIOOrGlRN7hWfPrt7VEse3KFgFHXNaVhCuCQOnTvmgDQiEps/KhCRL+bNVOexdY8u4GPQV02j6cJ18yU/P/CoHSqmvQeTIE37z/dHagDl5Y8ZySfc1EOW5/M1pGOPfyMe5qvceXkCN1HuaAKpXBO4AfWq8xZ/lRCyj8KvHy1+Vj9SSMmmGUAEjhaAKBkLMExjHYUkjLGc7ckelTL+8clFIHc9BTmCLxnIHpxmgDMvYjdW5DAIRyufWsBgVJDDBHBFdO0bM5b+mAKzNVtQB58QJ/v8A+NAGXRRRQAUUV0PhHxR/wjf2v/iR6Fq32jZ/yFLTz/L27vucjGd3PrgelAHPUVNe3H2q9uLjyoofOkaTyoV2omTnao7AdAKhoAKKKKACiiigAooooAKQ0tIaAEooooAKUUlKKAFooooAKfFG0siovU0ytKyiaFA4AYsOVPagC1DEFURp8pA596twM8fB+7UIIcDHykeoq2hB4cfj2NAEq89R8p9Ks5GwKMexqGPbt2k49KryFg5BzQBZkC4wQQaj5UYU7h6HrTA3y8hvrUsMiltrMAe2elAAFyOQvtzinou37w6fjmrBVsj5Vx9aildEBBJRvQjg0AI5jMZ8v5T79KqOZI1OG6+hyKnzEyY+TefWq7oQcAcelAAkrDuBUomt2H7yEA/314qJlC42D6g1G4D/ACqSCeuKALQkQcli6j3qb7c0alUXcD6gGs+Kyd3wrE1YitXV+STj0PegBJNSLMBLEGxwCowRUTSo5yVA/nXSafZi4hHnyBFHcrUF9ocbndbyqSO46GgDCjliDfMqke4qwt4oOEiiK/7SZpJ9MuI23nDgenOKr+U+RxyfwoAstdHBzbQgH+JVwRWmJS/gu5BXcBqEJAJwOY5MnGfYdvxHfNtLaOVG3u6uOgAyK3bG0T/hENVRid3221c4b0S4HTP+16Hr1HcA54gIisI1J/2auWdwu04wrDrxzT7e0RmKtMFYdAc063tQGYEKCD2wSaAEk/fDeCcDuxohWJjsVGkP+zxWglmzkNsQ49TxWvb2LiLEmPoowKAMO2sGlfLRNGoPGcc10NlpmId+eB1AGTVzR9HnurhUQoVP8TtjH4V1Mum6TYwiKa7kab+IKMc/j/hQBzouFt4AsKqT0BPb8K5zVIy7GV5Sz+ldJq/9lxxny4CT23Ekn61yd7cRKjADn+6KAMzJZyO/8qhmUKeMs/oKcZnboij0yc4pA2B/dHc4yTQA20t0R/NuRuYdFHP51DcyNNNn5Qo6D0pJ5yxKRnHq2elLEoVPkHHrjrQA3LdBgL6k0i7fMG35m9hT2Xd8xII/QUiS7UO0g5644zQASLkEkYAqo43AqANh4Oe9TOryEFmPsDx+lMkZU4XG7+VAHO31sbaYr/CeVPtVet69iWeAoeX6hvesFgVYgjBHBFABSqpZgqglicAAZJNJXqPwF17w74c1u+1DxLe2dsVVFg86xkuJCfm3GN0z5ZHy5yDnPGMGgDzbULG7067e11C2mtblApaKZCjqCAwyDyMgg/jVeuv+Lmu2PiX4h6vq2ku8llcGIRu6FS22JEJweRyprkKACiiigAooooAKKKKACkNLSGgBKKKKAClFJSigBaKKfBE00iovU0AWNPhWSTdJkKOn1rSWNk5HI9qYsHlqoUYC1bjHyZHPqBQBYtlhnQq/7uQd+xpTGyZBXOOhFJBbh8SRv9RV6O2OMxyYPpQBTTp6VNHHu6nmrcnMX7xF3D+JeKqRnLEKQfbvQAmzByMClCgnJC/iKlJKrnbuNNjkWVSFQZ7oRkGgCeJMLyykex/yaJVLL0B9M1FCoB/dqykdVNT5YK3Bx3GMUAUWiZfvLj8KYE+VtgXOOmcVekaOS3wxB/HBFUo2Ckhs49aAIt2VIXO4dVxz+VQhSzZCH8q0PkfG3Dehpgjkjyd2V9CKAIY1MjYHDDsa0YiyDcrKuOox1q3ptpb3fzFV8wf3uK6Gz8PGaEsCcDrs5P0oAz9OmSdPkcCTurck1o6XbRXbNHPM1vtP3ZFIz9DjFK3h6zX5obm4LDqhADCr1vpw8kMl24A6rJk0ARapoDwW3nwXEEqd1DgsBXM3Vi/PmW/XkMvNdQ+mjiXE8ue4Q4pxsb27ZYrS3G31bjFAHH28ccJGQVPq1b+kS+Z4b1wRbcAwNzzyHI9fetU+DL24x9olhRieAgLfma9J8KfD/SIvAviO3k1KaSW6W082VLFS1uVkJIT5/myeCfl4GcdqAPB0gEkxzksewHFa1jpkA+aeMsvUCMAZ/HrXcy+BrCydgl/PcDJA3oIyR74JxS/2DawgLLOUHYA5P6UAczY6fGXMkm2KNfuqzAmrw0yXUJFWGYiMnqBV59MskcgyBlHPAK/zq5H9lSIK/mJGOnknBNAF25uYdK0z7NauqybcFlUBifrXJh5DJmV0Unu5pms6rElx5cSl8fwliT+JrFur6SVTsiEYHU4JJoAj8QOizFYpvNb+JugH0xXPNMCCmBv9RzUtxJLM5DK2zsPWqErOPl6AdqAHfLGcKdzd80xm5LO5dvTsKavQAAnP4VIdwHDDPt0oAjLxgY2GkDl26Myjoo4pRGQRuZanjRQvXA74HWgCLaz43gBPTsKcIml4hXIXueAKnLbjnj8egqOQuV2sxZf7o4FAFWQHJG4Me7dqaqKoOFBPrjpUqhiSSPy7UjllGSF9s0AVmjL/AHRj3NZmr2yACWJ97j/WY6VrS5K/McsfSqnl9Rxg8YoA5+irF9bG2mK/wnlTWz4R8F6/4v8Atf8Awjth9s+y7PO/fRx7d27b99hnO1unpQBz1FTXtrNY3txaXSbLiCRopFyDtZTgjI4PI7VDQAUUUUAFFFFABRRRQAUhpaQ0AJRRRQAUopKUUALV7TZooshuHbuao0UAdJG6nH6VMyjhkHPoK563umj+V/mX9RWxaXasODmgC7A3O9c57g8GrSOSMqBn0ziq6OrntmpUO08DNAExYOmGGPrToogRg/KR0b0pgZG4Awfenxsyclfl/lQAok2PtkQZ/vKcZqVEBO4DP4UKYm5Kg05URH3ROQfQ0AOO9W3bSfrTZtzDIcVYcq4yoKHvjpTET5iTgD1BoAyLm2eTj5CfXoaIYgo2kgn61oSrgnHOKoui+aCzY+vagB/lxRN+8Tk9GHGKu2VrLIcxKp9w1PVYpoSoIYkd8VEmnyRfOgAHqknNAHV6RdXsDCGbT4LxPRk+YD2Iro7K801mObC6tZuh2TZH5Ef1rhLe7vYgAs2cdzww/GtS31LU5m2/aiVHQuuSKAOqlj82UvbwMoHdiCT9aNl5csNsKRgcZ65/M1kW8upYG+a3kT0JK5qxdzMEDwhVcclUkBoA6MTvaW4/0qBmHBEgbAqSDUEUglbRmb0BAJ+lYFjcPMqsksyN33DA/WrcVrPK3+j+VM5PI+61AG4fEEkcbq4hZR0SIlcVFD4g1C6jMVjbTnPDFR/U1EtncxZM9pCigfec8/pWfdXlru2NJIGH9yQEfligC3dTXFuWNyHEh7yHj86wri+SSbe00gI/559KV9sjZiYuo5xL0pH8x1KwLg+icD+lAEUWor5xSFHmY8j5TzUWr6ndOjJMywKBwka5J/rUa2bqS7y+S3chv61HBaRzSspuC3vnFAHPxByxKRtyc5b71SzKgj/eMR/s9a0L21hgkIgaQkddxyDWRN5sj4aNdvqCKAKk7FhiNdqe3U1lzRbnJERU+pOSa1bzbEu5iIx0HHJ/CqeYwNxk5PtyaAINqRoN7nd6YpkkwUZRD+NJNhJNwJyf71Nkl9wx7nsKAFiOE3Nyx7YqVZsDGC8noo6fU1WEhI4GR7cVOrME245PYUAKZt/CAZ7802SNtvLBRSZEfUAUrJLMBwI4+2aAIzLuIiiyx9KWSJUPzHzH/QU4KIRhSB6k9TVeWQOu3nHp60AOJDcM20eo6n6VVuZPLGF+Ueg608sqDc7AAVJb6XquraZf6hpGnzTWNihe4u2AWNAMZAJwCeQdoyfagDKvpEa32ydeo9c1lV0Vr4O8QX+kf2rBYmS1aOSZCZkEkiIcO6Rlt7KpPJAIFc7QAUUUUAFFFFABRRRQAUUUUAFIaWkNACUUUUAFKKSlFAC0UUUAFOR2jbKHBptFAGla6gAw84Ee4rehl82ING2R6iuPqW3uJbc5icr6jsaAOyR3A3Mm4dDipo50zwpUGues9cK4E6D/AHhWxDcR3CBkII9RQBoIiswKuqk+tWBFJ2CN9DWfER0dAR6VKriNsxu6j0LZFAFw71GOVPowyKB5TKROWSTsQODVZpnPG7g9sCmndt+duPWgB+Q5KgqSPXvTSAOg/IU1enXNKpO/J5X1oAa0nPycGpbeB5G3BifUHFQySMkg2qhyfzq9bCJMOkcscnqjcfkaALNus33WSQqevXFaEULKP3Z2n0bmq6TOEw00mD6mtC3ZzGNsQI/vMc0APiDAgSs+xu69KsPaZxtbcT05qS3uBH+7WUCQ9uopzyysQJN6lecpwDQBKYituI5baXzCOGDZH5VFbRmFgsQlaQ+1StdDaGIJ2/3h/hTo7y6dN0ZREP8AcUZoAsGxuJQHusmIdUk6f0ps62pUJbxxK/oAf6VRklnklJmV3QdSW6VbtplmXESqEH91cGgCVbAPGC2d390UTWwhTlRz23c/lV221O1hHlS2k87D+LzdgH9aoavqEcylYYFhz/tsxFAGZfNAAF2FvUMAAKy2id5i0a7Yx3q+07eXsSJm9WxVYs7H9wgJHWgDNvpCx8sgt/vZxVdmit0yFUv2A4q7fz3MoKkkKP7owDWTMWyFIGf92gCGcySZkmdV9OM1UI4+U598VakgLYLMfbFQXKkDABwPegCGSNmTgimFUK/PKVUdcdTUi52EHpTSqFeeR6CgBkMkakrFwPU8mpDIxGM4TvjvUW1Avyjr2pwJJ2xqWPpQAGRg3yBF/wBo8mmMXJyzt7mklnWLhsKR1x2rNuNVQHCLv9s4FAF6SRFGScn1zWbc6jGpIj+Y/wCe9Z9zdS3B+c4X+6vAqCgCWeeSdsyN9B2Fdf4A1zRdG03xBDq82orNqdk9iotbVJVjVip3ktKuTkEbcfj2ri6KAPVdF+ImkWOk6W81vftqmmaZc6bDGiJ5MwkPyuzbsrgE5AU5PcVxfhHxR/wjf2v/AIkehat9o2f8hS08/wAvbu+5yMZ3c+uB6Vz1FAHUeK/F/wDwkVlDb/8ACPeHdK8uTzPN0yy8h24I2sdxyOc49q5eiigAooooAKKKKACiiigApDS0hoASiiigApRSUooAWiiigAooooAKKKKACnxSvE+6J2RvUHFMooA17fXJkwJ1WT3HBrSttUtp2AZthPrwa5aigDt8qCMuGB6GhGIfC/lnFcbDcTRf6uRgPTPFX4tYkAAmQMB3BxQB1aGRlO0Z+lKshU8Ehu+BWPp+s2yyDzGOD2bjFapuLWbBjlQg9g1AErBpPvlWQ9yKu2oiT5VCsf8AZaqUBWNsqCc+pre0uCW4I2xxqvU9M0AP8mCWD7rxN67uDUltEFAUSbsds1oixVP+W5P+w0YP6ipF0kSDMSsrdckgUAZ7KN2CRk9BnrVu2YBcOH3dOajeyuYX/eICvYqc1aFrIY9ysqHuXGRQBYtYsZwoYnp8vNa+mafdHJW2BQ9Sw/pXPJJcBtqiHA6mNMZrRtpLtQBHIyH3fFAG5JBDEcTQIv8AwDJp00ghhyqDb/dxt/QGsd55wubm5kK+nX9aUXkIGIbmJGPdjzQA++NpNblpI3hbH3gSK5p4tjM0c6MOyvwa0p4RJIXlkeY/3sEgfpVdIYRJ5hnc/wCztoAooTI2J4mYn+ENjP40t5FBGmIgIuOQspYmrFzK0uVjCjHcjmsW8tbuMl3xs+goAbJKy/6sgD0A5qrJOQcSIM/Wo5WYpydo9BxVAruk2rk+pZsUATzO7ngc+ueBVRjkEDB9W5P6mr7wpFbkzTpGPQ4ArEutStYcj7UHI6BBn/61AE8u44UNzTCu3gkmsibW1wRBASf7zt/QVnXF/cz8PIQPReBQB0FxeQW4+dxu/ug5NZdxq7spSBdi/WsqigB8kryffYmmUUUAFFFFABRRRQAV0XhHSdA1T7X/AMJF4l/sLy9nk/6BJdedndu+4RtxhevXd7VztFAE17HDDeXEdrP9ot0kZY5thTzFB4baeRkc4PSoaKKACiiigAooooAKKKKACkNLSGgBKKKKAClFJSigBaKKKACiiigAooooAKKKKACiiigAooooAKASDkHBoooAtw6jdw42Ttx/e5/nWnaeKLuCRXZI2I7rlTWDRQB6bpfxLgQBdR06R/8AajkBP6it6D4i+GpgN63duf8AbTP8s14pRQB7wvjnw/dxiP7csfpvQj9cVLDrOl3A41eweLsHmVT+teBUUAfREb2MseUu7fZ1BEw5+lI91aqMfbYR7tKDXzxRQB7rNdWxfEt1BPz3kGP51I11bhOIrb2YMBXg1FAHu0OraaYj52o2UW30uFNZ+peJNJVQI9UtST3GWP6CvGaKAPTLjxbpUaZS5kmY9QkRH6msO78VwO37mCZh/ttj/GuPooA35fE90c+VFGgPr8xrOl1a9lOTMV/3BtqjRQA55HkOZHZz6sc02iigAooooAKKKKACiiigAooooAKKKKACuh8I+C9f8X/a/wDhHbD7Z9l2ed++jj27t2377DOdrdPSueooAmvbWaxvbi0uk2XEEjRSLkHaynBGRweR2qGiigAooooAKKKKACiiigApDS0hoASiiigApRSUooA9W+CMEt6JrCPVbzS47vVrKKWa0naF2QQXj+XuB/iKqPrivW/ibpknhpbW90jX9chaS1v42tZdUnlVytjO6yDe5IKsinI6Eg8YrwXwddQ2fg3W5p7C3vtupWG1J3lQI3l3ZDAxujZGPXHPTpjp7LVdY1qG81mPwxa38NjbTRTXdzd3sixxPGUkQGS5xko54HPOR60AcH/wnHiz/oaNd/8ABhL/APFUf8Jx4s/6GjXf/BhL/wDFV0GjRW+szzQ6b4L0WaSGF7hx9pu1xGoyx5uR09OtUo7/AEuWRY4/B+ju7EKqrLekknoAPtFAGZ/wnHiz/oaNd/8ABhL/APFUf8Jx4s/6GjXf/BhL/wDFV0utWlvojKmpeD/DsUpODEuoXEkiHGcOi3RZDz/EBVi00c3mmtfWvgjQZYRC1xsW+uPN8pTguIvtW8qCDztxQByX/CceLP8AoaNd/wDBhL/8VR/wnHiz/oaNd/8ABhL/APFV2C6J5mk3Opw+DvDM1naxrLO8OqyyGJW6blW7LAn0IzWB/aekf9Clov8A3+vf/kigDO/4TjxZ/wBDRrv/AIMJf/iqP+E48Wf9DRrv/gwl/wDiq0f7T0j/AKFLRf8Av9e//JFH9p6R/wBClov/AH+vf/kigDO+I3/JQvFH/YUuv/RrVz1dD8Rv+SheKP8AsKXX/o1q56gAooooAKKKKACiiprIBryBWAIMigg9+aAIaK+hPidpumWmmeK30HTNLuLzTL61Pkx6XBE2nR7Q5fhT58bnghxgc5GBXCfFedItH8Jx21jpdsL/AEiG8uGt9Pghd5SWy25UBA46Age1AHm1Fe36cfDOj+BvB95r9vpP2S6s703MB08PdXjhyseyUIShUkcl149e1rQ9D02Sbw1FDo2mXHgqfSTLqmqSQIWjm2sZC1wRuidWCgKGHXp6AHg1Fe4zf8IvovhHw7Nq0GlG0utJnLQf2cDd3Uu4iNxKE+THGSXH0Ncv8GdK0wTax4k8SRWkmkaTBgLexl4XnkO1AwCsSOvRSRkHFAHm1FegePfD9po/xOt0sUifRdSmhvbPav7toJWBwB6A7hj0FeiaxH4VTx8mgz2ejXF42vW6W1taaasQtoMjekzeWok3Z6Zf60AfPdFfQuq6J4bvbnRmmtLCXS08Qz219eQ2cVl9kVcqltIsfBQnB8wnpjpmsO+0m7GiXU2o+G9Nttfj1mKLRrZbCOMXaEnchQACWLGDvOf96gDxaivXvixpOm2Xh2W48M6dYm0fVJY9RnijVntLhVX9wjY+WLO4jGM8DjjPkNABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFIaWkNACUUUUAFKKSlFAHceDdMv9V8F69BpdldXs66hYuY7aJpGC+XdjJCgnGSOfcV2PgbRdQ0jT9di1TQPFSy6jZvZKLbR2kVFJU7yWZcngjbj8a4LQP+RD1z/sJWH/oq7rsvhpoFlqVncXmv6TbjQrcu11qk9xLGUGz5Y4grAM+7nkN1xxxkAl+Hula14f1i9n1Hw14ka2uLKa0DQaa7OpcAA7TgfrVCw8Na3ofifTtQ0zw94hvoLSaO4xc6U8LMVYErgFx265/Cq3w50fTtZ1nVYb2Bp7eHTrm4hDOVIZRlSdpHPt0rB8N6fHq3iHTNOml8mK7uY4Gk/uhmAJ+vNAHrXiQTeIFtbLUvDXja4sft817LO1gRcQI6nbBFncCgYg5OOBwKy/C2n3mhaRqEf/CM+KJ572yktpLc6OAC7cZFwP3ipgD5AuM9c1U8d+DrdbWOTwtprnZqM2mm3WGY3UjxqSTgyOHXCk7lVfpV7QfB2iXOi6PDPZGSbUNKur6S/wDNcNDJGflVQDswOh3A9eooAzNQ03XI/A1j4f0fwv4ijMkputSll09x50vRFXAPyKPXGTzgVc8LWuvab4WuNK/sbxbpF492Lj+0NN02RpJE248psshwDzw34VzupaXpQ+GGm6tZ2csWoPqD2s0sk5feBGG4GAFGT0wT7mqeleG7WXwrJr+q381tZC7+xoltbC4kL7d2SC6BRj3/AAoA9Nj1bXYtFWxj8N+LFC6AunKBYOFF0rZWUc8Adm+8PSuQ+IWla74k8Q/2jZeF/ECBreJJTNp8gZ5FUBmOAc5x1pY/h1bHSVu5NalWQ6OustGLIECLOGUN5nLDtwAfauY8a+Hj4Z1s2AuftUbQxzxy+XsJV1BGVycH8TQBkfEb/koXij/sKXX/AKNauerofiN/yULxR/2FLr/0a1c9QAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABSGlpDQAlFFFABSikpaAOo8M6lpMOg6npusTX9v9puba4jktbZJ/9WkykENImM+aCCCehrc03xJpul25g0zxd4us4Cxcx29ksa7j3wLoDPArzvNGaAO8s9Y0OxvXvbLxL4ot7x87p4tPRJGycnLC6ycmm6hqug6lci51HxH4mu7gAKJZ9OjkfA6DJus1wuaM0AeiSeJtOkure5k8X+L3ubYFYJWslLxAjBCn7VlcjjioYdc0aHTpNPh8UeKo7CTO+2WwQRtnrlftWDXA5ozQB6HJ4j0yTTRp0ni3xa+nhQgtmslMW0dBs+1YwMDjHao9L1zRtJMn9leKPFVl5n3/ALNYJFu+u26Ga4DNGaAO/wD7d0cx7D4o8VbPI+y7fsCY8n/nnj7V9z/Z6VBe6h4dvphLfa/4kuZQoQPNpkbsFHAGTddBXD5ozQBreLNRh1jxTrOp2yyLBe3s1xGsgAYK7lgDgkZwfU1lUmaM0ALRSZozQAtFJmjNAC0UmaM0ALRSZozQAtFJmjNAC0UmaM0ALRSZozQAtFJmjNAC0UmaM0ALRSZozQAtFJmjNAC0UmaM0ALRSZozQAtFJmjNAC0UmaM0ALRSZozQAtFJmjNAC0UmaM0ALRSZozQAtFJmjNAC0hozRQAlFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAf/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Ultrsound demonstrating a 6.37 x 6.01 centimeter popliteal artery aneurysm.",
"    <div class=\"footnotes\">",
"     %: percent.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_43_11952=[""].join("\n");
var outline_f11_43_11952=null;
var title_f11_43_11953="Influenza virus vaccine (live attenuated): Patient drug information";
var content_f11_43_11953=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"12\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Influenza virus vaccine (live attenuated): Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/54/19303?source=see_link\">",
"     see \"Influenza virus vaccine (live attenuated): Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?14/10/14502?source=see_link\">",
"     see \"Influenza virus vaccine (live attenuated): Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F9560232\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      FluMist&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F11239606\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      FluMist&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt adi-os drugH1Div\" id=\"F10031428\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     CDC Information",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705779",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Vaccine Information Statements (VIS) are made by the staff of the Centers for Disease Control and Prevention (CDC). Each VIS gives information to properly inform the adult receiving the vaccine or, in the case of a minor, the child's parent or legal representative about the risks and benefits of each vaccine. Before a doctor vaccinates a child or an adult, the provider is required by the National Childhood Vaccine Injury Act to give a copy of the VIS. You can also get foreign language versions.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705986",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <a href=\"file://www.immunize.org/vis/vis_flu_live.asp\" target=\"_blank\">",
"        Vaccine Information Statements (VIS)",
"       </a>",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11957 Version 26.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.146-E8BDD971E0-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_43_11953=[""].join("\n");
var outline_f11_43_11953=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9560232\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11239606\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031428\">",
"      CDC Information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?18/54/19303?source=related_link\">",
"      Influenza virus vaccine (live attenuated): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?14/10/14502?source=related_link\">",
"      Influenza virus vaccine (live attenuated): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f11_43_11954="Electrograms AVRT";
var content_f11_43_11954=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F59861&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F59861&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Intracardiac electrograms during orthodromic atrioventricular reentrant tachycardia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 267px; height: 344px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This patient with the Wolff-Parkinson-White syndrome had an orthodromic atrioventricular reentrant tachycardia (AVRT) induced during electrophysiologic study. The exploratory catheter (Exp), located at the free wall of the right ventricle (RV), demonstrates a potential from the accessory pathway (AP), which occurs after RV activation and before right atrial (RA) activation. Based on the timing of the atrial electrograms, initial retrograde atrial activation is in the RA, followed by atrial activation (*) at AV node and the bundle of His (HBE), and last within the left atrium (LA), recorded by a catheter in the coronary sinus (CS).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_43_11954=[""].join("\n");
var outline_f11_43_11954=null;
var title_f11_43_11955="Sutures PI";
var content_f11_43_11955=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F74759&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F74759&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 538px\">",
"   <div class=\"ttl\">",
"    Stitches",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 518px; height: 626px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Stitches (also called \"sutures\") help a cut heal faster. Doctors use a special type of needle and thread to bring the ends of the skin together (as shown in A). Picture B shows a cut that has been closed with stitches.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_43_11955=[""].join("\n");
var outline_f11_43_11955=null;
var title_f11_43_11956="Spigelian hernia 4";
var content_f11_43_11956=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F55169&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F55169&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 610px\">",
"   <div class=\"ttl\">",
"    Spigelian hernia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 590px; height: 287px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Spigelian hernia. A) Usual site of occurrence. B) Transverse section of abdominal wall showing site of defect.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Mulholland, MW, Lillemoe, KD. Greenfield's Surgery: Scientific Principles And Practice, Fourth Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2006. Copyright &copy; 2006 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_43_11956=[""].join("\n");
var outline_f11_43_11956=null;
var title_f11_43_11957="Laronidase: Drug information";
var content_f11_43_11957=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Laronidase: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?36/21/37203?source=see_link\">",
"    see \"Laronidase: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?0/55/884?source=see_link\">",
"    see \"Laronidase: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F6187724\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F187005\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Aldurazyme&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F854886\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Aldurazyme&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F187019\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Enzyme",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F187006\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Premedicate with antipyretic and/or antihistamines 1 hour prior to start of infusion.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MPS I (Hurler syndrome, Hurler-Scheie, and Scheie forms): I.V.: 0.58 mg/kg once weekly; dose should be rounded up to the nearest whole vial",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F187013\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?0/55/884?source=see_link\">",
"      see \"Laronidase: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Premedicate with antipyretic and/or antihistamines 1 hour prior to start of infusion.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MPS I (Hurler syndrome, Hurler-Scheie, and Scheie forms): Children &ge;6 months: I.V.: 0.58 mg/kg once weekly; dose should be rounded up to the nearest whole vial",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F3062777\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F14322916\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F14322917\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F186987\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution [preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Aldurazyme&reg;: 2.9 mg/5 mL (5 mL) [contains polysorbate 80; derived from or manufactured using Chinese hamster ovary cells]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F186974\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F186989\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer using PVC container and PVC infusion set with in-line, low protein-binding 0.2 micrometer filter. Antipyretics and/or antihistamines should be administered 60 minutes prior to infusion. Volume and infusion rate are based on body weight; deliver infusion over ~3-4 hours. Vital signs should be monitored every 15 minutes, if stable; rate may be increased as follows:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &le;20 kg: Total infusion volume: 100 mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     2 mL/hour for 15 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     4 mL/hour for 15 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     8 mL/hour for 15 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     16 mL/hour for 15 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     32 mL/hour for remainder of infusion (~3 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &gt;20 kg: Total infusion volume: 250 mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     5 mL/hour for 15 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     10 mL/hour for 15 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     20 mL/hour for 15 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     40 mL/hour for 15 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     80 mL/hour for remainder of infusion (~3 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     A total infusion volume of 100 mL NS and slower infusion rate may be considered for patients with cardiac or respiratory compromise who weigh up to 30 kg. In case of infusion-related reaction in any patient, decrease the rate of infusion, temporarily discontinue the infusion, and/or administer additional antipyretics/antihistamines.",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F187025\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in NS.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F186988\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of Hurler and Hurler-Scheie forms of mucopolysaccharidosis I (MPS I); treatment of Scheie form of MPS I in patients with moderate-to-severe symptoms",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F187017\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Unless otherwise noted, frequency of adverse reactions is reported for patients &ge;6 years of age.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Flushing (11% to 23%), poor venous access (14%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Fever 11% (children 6 months to 5 years: 30%), chills (children 6 months to 5 years: 20%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Rash (13% to 36%; children 6 months to 5 years: &ge;5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Injection site reaction (18%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Hyper-reflexia (14%), paresthesia (14%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Otic: Otitis media (children 6 months to 5 years: 20%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Upper respiratory tract infection (32%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Antibody development to laronidase (97%); infusion reactions (32% to 49%; may be severe; children 6 months to 5 years: 35%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Hypertension (children 6 months to 5 years: 10%), tachycardia (children 6 months to 5 years: 10%), chest pain (9%), edema (9%), facial edema (9%), hypotension (9%), pallor (children 6 months to 5 years: &ge;5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Headache (9%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Pruritus (4%), urticaria (4%), hyperhidrosis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain/discomfort (9%), diarrhea (7%), vomiting (4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Thrombocytopenia (9%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: Bilirubinemia (9%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Abscess (9%), injection site pain (9%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Tremor (children 6 months to 5 years: &ge;5%), arthralgia (4%), back pain, musculoskeletal pain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Corneal opacity (9%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Oxygen saturation decreased (children 6 months to 5 years: 10%), crepitations (children 6 months to 5 years: &ge;5%),  respiratory distress (children 6 months to 5 years: &ge;5%), wheezing (children 6 months to 5 years: &ge;5%), bronchospasm, cough, dyspnea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Feeling warm/cold (7%), allergic reaction (severe/serious 1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Anaphylaxis, angioedema, cardiac failure, cardiorespiratory arrest, cyanosis, erythema, extravasation, pneumonia, respiratory failure",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F186992\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     There are no contraindications listed within the manufacturer&rsquo;s U.S. labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     Canadian labeling: Severe hypersensitivity to laronidase or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F186978\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypersensitivity/anaphylactoid reactions:",
"     <b>",
"      [U.S. Boxed Warning]: Anaphylactic reactions have been observed during infusion, immediate treatment for hypersensitivity reactions should be available during administration. Additional monitoring may be required in patients with compromised respiratory function or acute respiratory disease; may be at increased risk for acute exacerbation of respiratory symptoms due to infusion reaction.",
"     </b>",
"     Reactions, which may include airway obstruction, bradycardia, bronchospasm, hypotension, hypoxia, respiratory distress/failure, stridor, tachypnea, and urticaria, may be severe and tend to occur during or within 3 hours after administration. Immediately discontinue infusion if severe reactions occur; medical support should be available during administration. Risks and benefits should be carefully considered prior to readministration following a severe hypersensitivity reaction. Patients who initially experience severe reactions may require prolonged monitoring. In the case of anaphylaxis, caution should be used if epinephrine is being considered; many patients with MPS I have pre-existing heart disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Infusion reactions: Infusion reactions may occur; use caution and consider delaying treatment in patients with acute febrile/respiratory illness; may result in increased risk for infusion-related reactions. Pretreatment with antipyretics and antihistamines is recommended. Decrease infusion rate, temporarily discontinue infusion, and/or administer additional antipyretics and antihistamines to manage infusion reactions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Fluid overload: Use with caution in patients at risk for fluid overload or in conditions where fluid restriction is indicated (eg, acute underlying respiratory illness, compromised cardiac and/or respiratory function); conditions may be exacerbated during infusion. Extended observation may be necessary for some patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; MPS I: Appropriate use: Has not been studied in patients with mild symptoms of the Scheie form of MPS I. Not indicated for the CNS manifestations of the disorder.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sleep apnea: Use with caution in patients with sleep apnea; evaluate patients prior to initiation of therapy. Apnea treatment options should be readily available (eg, CPAP or supplemental oxygen) during infusion or with use of sedating antihistamines.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Registry: A patient registry has been established and all patients are encouraged to participate. Registry information may be obtained at www.MPSIregistry.com or by calling 800-745-4447.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299577\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F186981\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F186983\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F186994\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects were not observed in animal reproduction studies. Patients are encouraged to enroll in the MPS I registry (800-745-4447 or www.MPSIregistry.com).",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F187009\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323284\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Aldurazyme Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2.9 mg/5 mL (5 mL): $930.00",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F186985\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Vital signs; injection site reactions, infusion reactions",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F6038666\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Aldurazyme (AT, AU, BE, BG, CH, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HK, HN, IE, IL, IT, KP, MT, MY, NL, NO, NZ, PL, PT, RU, SE, SG, SK, TH, TR, TW)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F186977\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Laronidase is a recombinant (replacement) form of &alpha;-L-iduronidase derived from Chinese hamster cells. &alpha;-L-iduronidase is an enzyme needed to break down endogenous glycosaminoglycans (GAGs) within lysosomes. A deficiency of &alpha;-L-iduronidase leads to an accumulation of GAGs, causing cellular, tissue, and organ dysfunction as seen in MPS I. Improved pulmonary function and walking capacity have been demonstrated with the administration of laronidase to patients with Hurler, Hurler-Scheie, or Scheie (with moderate-to-severe symptoms) forms of MPS.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F186991\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 0.24-0.6 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 1.5-3.6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Clearance: 1.7 to 2.7 mL/minute/kg; during the first 12 weeks of therapy the clearance of laronidase increases proportionally to the amount of antibodies a given patient develops against the enzyme. However, with long-term use (&ge;26 weeks) antibody titers have no effect on laronidase clearance.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Kakkis ED, Muenzer J, Tiller GE, et al, &ldquo;Enzyme-Replacement Therapy in Mucopolysaccharidosis I,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2001, 18;344(3):182-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/43/11957/abstract-text/11172140/pubmed\" id=\"11172140\" target=\"_blank\">",
"        11172140",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wraith JE, Beck M, Lane R, et al, &ldquo;Enzyme Replacement Therapy in Patients Who Have Mucopolysaccharidosis I and Are Younger Than 5 Years: Results of a Multinational Study of Recombinant Human {alpha}-L-Iduronidase (Laronidase),&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2007, 120(1):e37-46.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/43/11957/abstract-text/17606547/pubmed\" id=\"17606547\" target=\"_blank\">",
"        17606547",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10232 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-211.167.112.14-E421669322-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_43_11957=[""].join("\n");
var outline_f11_43_11957=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6187724\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F187005\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F854886\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F187019\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F187006\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F187013\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3062777\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14322916\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14322917\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186987\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186974\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186989\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F187025\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186988\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F187017\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186992\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186978\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299577\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186981\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186983\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186994\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F187009\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323284\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186985\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6038666\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186977\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186991\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10232\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10232|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?36/21/37203?source=related_link\">",
"      Laronidase: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?0/55/884?source=related_link\">",
"      Laronidase: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f11_43_11958="Dipyridamole: Pediatric drug information";
var content_f11_43_11958=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Dipyridamole: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?40/25/41366?source=see_link\">",
"    see \"Dipyridamole: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?22/43/23220?source=see_link\">",
"    see \"Dipyridamole: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F161435\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Persantine&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F161436\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Dipyridamole FC&reg;;",
"     </li>",
"     <li>",
"      Dipyridamole For Injection;",
"     </li>",
"     <li>",
"      Persantine&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1052349\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antiplatelet Agent",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Vasodilator, Coronary",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1052341\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?40/25/41366?source=see_link\">",
"      see \"Dipyridamole: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral: 3-6 mg/kg/day in 3 divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Doses of 4-10 mg/kg/day have been used investigationally to treat proteinuria in pediatric renal disease",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Mechanical prosthetic heart valves: 2-5 mg/kg/day [used in combination with an oral anticoagulant in children who have systemic embolism despite adequate oral anticoagulant therapy (INR 2.5-3.5), and used in combination with low-dose oral anticoagulation (INR 2-3) plus aspirin in children in whom full-dose oral anticoagulation is contraindicated] (Monagle, 2001).",
"     <b>",
"      Note:",
"     </b>",
"     The",
"     <i>",
"      Chest",
"     </i>",
"     guidelines (Monagle, 2004) do not mention the use of dipyridamole for prophylaxis for mechanical prosthetic heart valves in children; an oral anticoagulant plus aspirin is recommended for the patient groups mentioned above.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Prophylaxis of thromboembolism after cardiac valve replacement (adjunctive use): Oral: 75-100 mg 4 times/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dipyridamole stress test (for evaluation of myocardial perfusion): I.V.: 0.142 mg/kg/minute for a total of 4 minutes (0.57 mg/kg total); maximum dose: 60 mg; inject thallium 201 within 5 minutes after end of injection of dipyridamole",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F161411\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution: 5 mg/mL (2 mL [DSC], 10 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 25 mg, 50 mg, 75 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Persantine&reg;: 25 mg, 50 mg, 75 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F161396\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1052353\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral: Administer with water on an empty stomach 1 hour before or 2 hours after meals; may take with milk or food to decrease GI upset",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Parenteral: I.V.: Dilute in at least a 1:2 ratio with NS,",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, or D",
"     <sub>",
"      5",
"     </sub>",
"     W; infusion of undiluted dipyridamole may cause local irritation; see Dosing: Usual for infusion rates",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F864340\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     W, NS. Do not mix with other drugs in syringe or infusion container.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1052345\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Do not freeze; protect I.V. preparation from light",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1052352\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Maintain patency after surgical grafting procedures including coronary artery bypass; with warfarin to decrease thrombosis in patients after artificial heart valve replacement; for chronic management of angina pectoris; with aspirin to prevent coronary artery thrombosis; in combination with aspirin or warfarin to prevent other thromboembolic disorders; dipyridamole may also be given 2 days prior to open heart surgery to prevent platelet activation by extracorporeal bypass pump; diagnostic agent I.V. (dipyridamole stress test) for coronary artery disease",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F161486\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Dipyridamole may be confused with disopyramide",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Persantine&reg; may be confused with Periactin",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (Quality of evidence - moderate; Strength of recommendation - strong).",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Persantine [U.S., Canada, Belgium, Denmark, France] may be confused with Permitil brand name for sildenafil [Argentina]",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F161484\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Oral:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Angina pectoris, flushing",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Headache, dizziness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Pruritus, rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal distress, diarrhea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Liver dysfunction",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Postmarketing and/or case reports: Alopecia, arthritis, cholelithiasis, dyspepsia, fatigue, hepatitis, hypersensitivity reaction, hypotension, larynx edema, malaise, myalgia, nausea, palpitation, paresthesia, tachycardia, thrombocytopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      I.V.:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Blood pressure lability, ECG abnormalities (ST-T changes, extrasystoles), pain, exacerbation of angina pectoris, hyper-/hypotension, tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Dizziness, fatigue, flushing, headache",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Nausea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Paresthesia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Dyspnea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Abdominal pain, abnormal coordination, allergic reaction (pruritus, rash, urticaria), appetite increased, arrhythmia (ventricular tachycardia, bradycardia, AV block, SVT, atrial fibrillation, asystole), arthralgia, asthenia, back pain, breast pain, bronchospasm, cardiomyopathy, cough, depersonalization, diaphoresis, dry mouth, dysgeusia, dyspepsia, dysphagia, earache, ECG abnormalities (unspecified), edema, eructation, flatulence, hypertonia, hyperventilation, injection site reaction, intermittent claudication leg cramping, malaise, MI, myalgia, orthostatic hypotension, palpitation, perineal pain, pharyngitis, pleural pain, renal pain, rhinitis, rigor, syncope, tenesmus, thirst, tinnitus, tremor, vertigo, vision abnormalities, vomiting",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1052357\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to dipyridamole or any component",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1052340\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with hypotension (may further decrease blood pressure due to peripheral vasodilation); use with caution in patients with CAD (may aggravate chest pain)",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F9837685\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Inhibits",
"     </b>",
"     BCRP, P-glycoprotein",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F161405\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetylcholinesterase Inhibitors: Dipyridamole may diminish the therapeutic effect of Acetylcholinesterase Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Adenosine: Dipyridamole may enhance the therapeutic effect of Adenosine. Dose reduction of adenosine may be needed.  Management: Reduction of the initial dose of adenosine may be warranted.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): May enhance the anticoagulant effect of other Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticoagulants: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers: Dipyridamole may enhance the bradycardic effect of Beta-Blockers.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levobunolol; Metipranolol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosutinib: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Bosutinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Colchicine: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Colchicine. Colchicine distribution into certain tissues (e.g., brain) may also be increased.  Management: Colchicine is contraindicated in patients with impaired renal or hepatic function who are also receiving a p-glycoprotein inhibitor.  In those with normal renal and hepatic function, reduce colchicine dose as directed.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Collagenase (Systemic): Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Collagenase (Systemic). Specifically, the risk of injection site bruising and/or bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dabigatran Etexilate: P-glycoprotein/ABCB1 Inhibitors may increase serum concentrations of the active metabolite(s) of Dabigatran Etexilate.  Management: Dabigatran dose reductions may be needed.  Specific recommendations vary considerably according to US vs Canadian labeling, specific P-gp inhibitor, renal function, and indication for dabigatran treatment.  Refer to full monograph or dabigatran labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dabigatran Etexilate: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Dabigatran Etexilate. Agents with Antiplatelet Properties may increase the serum concentration of Dabigatran Etexilate. This mechanism applies specifically to clopidogrel.  Management: Increase monitoring for signs/symptoms of bleeding. The Canadian product monograph for dabigatran specifically recommends avoiding concomitant use with GIIb/IIIa inhibitors or ticlopidine, or with aspirin used for stroke prevention in atrial fibrillation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May enhance the anticoagulant effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Drotrecogin Alfa (Activated): Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Drotrecogin Alfa (Activated). Bleeding may occur.  Management: When possible, avoid use of drotrecogin within 7 days of use of any IIb/IIIa antagonists, higher dose aspirin (more than 650 mg/day), or use of other antiplatelet agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Everolimus: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Everolimus.  Management: Everolimus dose reductions are required for patients being treated for subependymal giant cell astrocytoma or renal cell carcinoma.  See prescribing information for specific dose adjustment and monitoring recommendations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Glucosamine: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Anticoagulant/Antiplatelet Properties) (eg, Alfalfa, Anise, Bilberry): May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Bleeding may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypotensive Agents: May enhance the adverse/toxic effect of other Hypotensive Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ibritumomab: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to impaired platelet function and an increased risk of bleeding.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. An increased risk of bleeding may occur. Nonsteroidal Anti-Inflammatory Agents may diminish the cardioprotective effect of Agents with Antiplatelet Properties. This interaction is likely specific to aspirin, and not to other antiplatelet agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Omega-3 Fatty Acids: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentosan Polysulfate Sodium: May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Specifically, the risk of bleeding may be increased by concurrent use of these agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Substrates: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pomalidomide: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Pomalidomide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prucalopride: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Prucalopride.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Regadenoson: Dipyridamole may enhance the therapeutic effect of Regadenoson.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rivaroxaban: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Rivaroxaban.  Management: Avoid concurrent use of clopidogrel with rivaroxaban unless the anticipated benefits outweigh the risks of bleeding.  Avoid concurrent use of rivaroxaban with other antiplatelet agents whenever possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rivaroxaban: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Rivaroxaban.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Salicylates. Increased risk of bleeding may result.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Silodosin: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Silodosin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thrombolytic Agents: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tipranavir: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topotecan: BCRP/ABCG2 Inhibitors may increase the serum concentration of Topotecan.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tositumomab and Iodine I 131 Tositumomab: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Tositumomab and Iodine I 131 Tositumomab. Specifically, the risk of bleeding-related adverse events may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     VinCRIStine (Liposomal): P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of VinCRIStine (Liposomal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin E: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F161407\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F161420\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects were not observed in animal studies.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1052348\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Blood pressure, heart rate",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1052339\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inhibits the activity of adenosine deaminase and phosphodiesterase, which causes an accumulation of adenosine, adenine nucleotides, and cyclic AMP; these mediators then inhibit platelet aggregation and may cause vasodilation; may also stimulate release of prostacyclin or PGD",
"     <sub>",
"      2",
"     </sub>",
"     ; causes coronary vasodilation",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1052356\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Slow and variable",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Distributes to breast milk",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     V",
"     <sub>",
"      d",
"     </sub>",
"     : Adults: 2-3 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 91% to 99%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: In the liver to glucuronide conjugate",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: 27% to 66%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life, terminal: 10-12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration: Oral: 75 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: In feces via bile as glucuronide conjugates and unchanged drug",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1052347\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?22/43/23220?source=see_link\">",
"      see \"Dipyridamole: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Notify physician or pharmacist if taking other medications that affect bleeding, such as warfarin or NSAIDs; avoid alcohol",
"    </p>",
"   </div>",
"   <div class=\"block exp drugH1Div\" id=\"F161415\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Extemporaneous Preparations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     A 10 mg/mL oral suspension may be made with tablets and one of three different vehicles (cherry syrup, a 1:1 mixture of Ora-Sweet&reg; and Ora-Plus&reg;, or a 1:1 mixture of Ora-Sweet&reg; SF and Ora-Plus&reg;). Crush twenty-four 50 mg tablets in a mortar and reduce to a fine powder. Add 20 mL of the chosen vehicle and mix to a uniform paste; mix while adding the vehicle in incremental proportions to",
"     <b>",
"      almost",
"     </b>",
"     120 mL; transfer to a calibrated bottle, rinse mortar with vehicle, and add quantity of vehicle sufficient to make 120 mL. Label &ldquo;shake well&rdquo; and &ldquo;protect from light&rdquo;. Stable for 60 days when stored in amber plastic prescription bottles in the dark at room temperature or refrigerated.",
"    </p>",
"    <div class=\"reference\">",
"     Allen LV and Erickson III MA, &ldquo;Stability of Baclofen, Captopril, Diltiazem, Hydrochloride, Dipyridamole, and Flecainide Acetate in Extemporaneously Compounded Oral Liquids,&rdquo;",
"     <i>",
"      Am J Health Syst Pharm",
"     </i>",
"     , 1996, 53:2179-84.",
"     <span class=\"pubmed-id\">",
"      8879325",
"     </span>",
"    </div>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Monagle P, Chan A, Massicotte P, et al, \"Antithrombotic Therapy in Children: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy,\"",
"      <i>",
"       Chest",
"      </i>",
"      , 2004, 126(3 Suppl):645S-687S.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/43/11958/abstract-text/15383489 /pubmed\" id=\"15383489 \" target=\"_blank\">",
"        15383489",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Monagle P, Michelson AD, Bovill E, et al, &ldquo;Antithrombotic Therapy in Children,&rdquo;",
"      <i>",
"       Chest",
"      </i>",
"      , 2001, 119(1 Suppl):344S-370S.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/43/11958/abstract-text/11157659 /pubmed\" id=\"11157659 \" target=\"_blank\">",
"        11157659",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rao PS, Solymar L, Mardini MK, et al, &ldquo;Anticoagulant Therapy in Children With Prosthetic Valves,&rdquo;",
"      <i>",
"       Ann Thorac Surg",
"      </i>",
"      , 1989, 47(4):589-92.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/43/11958/abstract-text/2712632/pubmed\" id=\"2712632\" target=\"_blank\">",
"        2712632",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Stanek EJ, Melko GP, and Charland SL, \"Xanthine Interference With Dipyridamole-Thallium-201 Myocardial Imaging,\"",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 1995, 29(4):425-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/43/11958/abstract-text/7633022/pubmed\" id=\"7633022\" target=\"_blank\">",
"        7633022",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ueda N, Kawaguchi S, Niinomi Y, et al, &ldquo;Effect of Dipyridamole Treatment on Proteinuria in Pediatric Renal Disease,&rdquo;",
"      <i>",
"       Nephron",
"      </i>",
"      , 1986, 44(3):174-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/43/11958/abstract-text/3785481/pubmed\" id=\"3785481\" target=\"_blank\">",
"        3785481",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13241 Version 39.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-213.131.41.98-E13A3EE944-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_43_11958=[""].join("\n");
var outline_f11_43_11958=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161435\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161436\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052349\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052341\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161411\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161396\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052353\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F864340\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052345\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052352\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161486\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161484\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052357\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052340\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9837685\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161405\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161407\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161420\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052348\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052339\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052356\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052347\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161415\">",
"      Extemporaneous Preparations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13241\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13241|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?40/25/41366?source=related_link\">",
"      Dipyridamole: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?22/43/23220?source=related_link\">",
"      Dipyridamole: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f11_43_11959="Erythrasma";
var content_f11_43_11959=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Erythrasma",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/43/11959/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/43/11959/contributors\">",
"     Sylvia Brice, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/43/11959/contributors\">",
"     Mariah Brown, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/43/11959/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/43/11959/contributors\">",
"     Robert P Dellavalle, MD, PhD, MSPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/43/11959/contributors\">",
"     Ted Rosen, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/43/11959/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/43/11959/contributors\">",
"     Abena O Ofori, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?11/43/11959/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 31, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Erythrasma is a superficial infection of the skin caused by",
"    <em>",
"     Corynebacterium minutissimum",
"    </em>",
"    , a gram-positive, non-spore forming bacillus. The disorder typically presents as macerated, scaly plaques between the toes or erythematous to brown patches or thin plaques in intertriginous areas. Erythrasma is managed with short courses of either topical or systemic therapy.",
"   </p>",
"   <p>",
"    The epidemiology, clinical manifestations, diagnosis, and treatment of erythrasma, as well as a brief overview of other",
"    <em>",
"     C. minutissimum",
"    </em>",
"    infections will be discussed here.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY AND RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prevalence of erythrasma is difficult to assess, as many patients do not seek treatment or may have subclinical infection. In one study of 754 college students, 19 percent were infected with erythrasma [",
"    <a class=\"abstract\" href=\"UTD.htm?11/43/11959/abstract/1\">",
"     1",
"    </a>",
"    ]. Another study of 874 patients in an institutional setting found a prevalence rate as high as 43 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?11/43/11959/abstract/2\">",
"     2",
"    </a>",
"    ]. The prevalence of interdigital erythrasma in other cohorts ranges from 20 percent in patients attending a dermatology clinic to greater than 50 percent in soldiers [",
"    <a class=\"abstract\" href=\"UTD.htm?11/43/11959/abstract/3,4\">",
"     3,4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Erythrasma often occurs in healthy adults [",
"    <a class=\"abstract\" href=\"UTD.htm?11/43/11959/abstract/1\">",
"     1",
"    </a>",
"    ], but diabetic, elderly, or immunocompromised patients have increased risk for the disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?11/43/11959/abstract/5\">",
"     5",
"    </a>",
"    ]. The infection can be a presenting sign of type II diabetes, occurring before persistent glucose abnormalities [",
"    <a class=\"abstract\" href=\"UTD.htm?11/43/11959/abstract/6\">",
"     6",
"    </a>",
"    ]. Conditions that lead to increased occlusion and moisture of intertriginous areas are also believed to contribute to erythrasma, including obesity, hyperhidrosis and living in tropical climates. Erythrasma is rare in children [",
"    <a class=\"abstract\" href=\"UTD.htm?11/43/11959/abstract/7,8\">",
"     7,8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Erythrasma is caused by",
"    <em>",
"     C. minutissimum",
"    </em>",
"    , a component of the normal skin flora.",
"    <em>",
"     C. minutissimum",
"    </em>",
"    is a gram positive, non-spore forming, aerobic or facultative bacillus. The bacterium is catalase-positive, and will ferment glucose and mannose in all cases and sucrose in some cases [",
"    <a class=\"abstract\" href=\"UTD.htm?11/43/11959/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Under conditions of moisture and occlusion,",
"    <em>",
"     C. minutissimum",
"    </em>",
"    proliferates in the upper levels of the stratum corneum. There is a single case report of extensive erythrasma resulting from a different species of corynebacteria,",
"    <em>",
"     C. afermentans",
"    </em>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?11/43/11959/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Erythrasma most commonly involves the pedal (foot) interdigital areas, followed by the groin and axilla. In a study of college students, interdigital, groin, or axillary lesions were seen in 85, 16, and 10 percent of students diagnosed with the disorder, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?11/43/11959/abstract/1\">",
"     1",
"    </a>",
"    ]. Another study involving institutionalized patients identified a similar trend among the patients with erythrasma; 70 percent exhibited",
"    <strong>",
"    </strong>",
"    pedal interdigital disease, 42 percent had groin disease, and 36 percent had axillary involvement [",
"    <a class=\"abstract\" href=\"UTD.htm?11/43/11959/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Interdigital",
"    </span>",
"    &nbsp;&mdash;&nbsp;Erythrasma is the most common cause of interdigital bacterial infections on the feet. This variant of erythrasma commonly presents as scaling and chronic maceration of the web spaces (",
"    <a class=\"graphic graphic_picture graphicRef71848 \" href=\"UTD.htm?32/29/33233\">",
"     picture 1",
"    </a>",
"    ). The web space between the fourth and fifth toes is frequently affected. Interdigital erythrasma may be asymptomatic or pruritic [",
"    <a class=\"abstract\" href=\"UTD.htm?11/43/11959/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Interdigital erythrasma may occur with concomitant dermatophyte or candidal infection. In a study of 300 consecutive patients presenting to a dermatology clinic, 14 percent of the patients had interdigital erythrasma, 14 percent had an isolated dermatophyte infection, 4 percent had a dermatophyte and interdigital erythrasma, and 0.7 percent had",
"    <em>",
"     Candida albicans",
"    </em>",
"    and interdigital erythrasma on microbiological examination [",
"    <a class=\"abstract\" href=\"UTD.htm?11/43/11959/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Intertriginous",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intertriginous erythrasma presents with well-defined, erythematous patches or thin plaques in the axillae, inframammary region, umbilicus, or groin (",
"    <a class=\"graphic graphic_picture graphicRef51713 graphicRef80242 graphicRef59529 \" href=\"UTD.htm?23/42/24234\">",
"     picture 2A-C",
"    </a>",
"    ). With time, lesion color often changes to brown. Involved areas often have easily visible fine scale and wrinkling that may give the skin a \"cigarette paper\" appearance. Affected areas are asymptomatic or mildly pruritic.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Disciform",
"    </span>",
"    &nbsp;&mdash;&nbsp;A rare disciform variant of erythrasma has been reported, consisting of generalized, round plaques not confined to intertriginous areas (",
"    <a class=\"graphic graphic_picture graphicRef85723 \" href=\"UTD.htm?39/60/40904\">",
"     picture 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/43/11959/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. Disciform erythrasma has been reported to occur more frequently in black females living in tropical climates [",
"    <a class=\"abstract\" href=\"UTD.htm?11/43/11959/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Genital/perianal",
"    </span>",
"    &nbsp;&mdash;&nbsp;Erythrasma has been implicated as an often overlooked cause of chronic pruritus ani. Older studies evaluating patients at referral clinics for pruritus ani have documented rates of erythrasma ranging from 12 to 18 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?11/43/11959/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/48/15110?source=see_link\">",
"     \"Approach to the patient with anal pruritus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Rarely, erythrasma may also affect the vulva, causing chronic pruritus that may be misdiagnosed as a candidal infection [",
"    <a class=\"abstract\" href=\"UTD.htm?11/43/11959/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Diagnostic procedures",
"    </span>",
"    &nbsp;&mdash;&nbsp;On physical examination, the clinical appearance will often suggest the diagnosis of erythrasma. The diagnosis can be confirmed by the presence of coral-red fluorescence under Wood's lamp examination (365 nm) (",
"    <a class=\"graphic graphic_picture graphicRef62143 \" href=\"UTD.htm?37/27/38321\">",
"     picture 4",
"    </a>",
"    ). This fluorescence is due to the production of porphyrins by",
"    <em>",
"     C. minutissimum",
"    </em>",
"    . A false negative test can be obtained if the patient has bathed on the day of the examination, as the porphyrins are water soluble and can be washed away [",
"    <a class=\"abstract\" href=\"UTD.htm?11/43/11959/abstract/16\">",
"     16",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/51/31543?source=see_link\">",
"     \"Dermatologic procedures\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The Wood's lamp examination is the preferred method to confirm a diagnosis of erythrasma. For patients with interdigital involvement, microscopic examination of a skin scraping with potassium hydroxide (KOH preparation) is also suggested to assess for concomitant dermatophyte infection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/51/31543?source=see_link\">",
"     \"Dermatologic procedures\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other procedures may also verify the diagnosis of erythrasma. Gram stain of a skin scraping will reveal gram-positive filaments and rods. Although rarely indicated, the bacterium can be cultured on media containing 20 percent fetal bovine serum, 2 percent agar and 78 percent tissue culture medium 199 [",
"    <a class=\"abstract\" href=\"UTD.htm?11/43/11959/abstract/17\">",
"     17",
"    </a>",
"    ].",
"    <em>",
"     C. minutissimum",
"    </em>",
"    can also be visualized on skin biopsy (",
"    <a class=\"graphic graphic_picture graphicRef71545 \" href=\"UTD.htm?26/55/27506\">",
"     picture 5",
"    </a>",
"    ). The organism is difficult to detect on hematoxylin and eosin stained slides; visualization may be enhanced by use of special stains such as periodic acid-Schiff and Giemsa.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other dermatologic diagnoses have clinical features that are similar to erythrasma. The differential diagnosis includes the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Seborrheic dermatitis (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/40/3721?source=see_link\">",
"       \"Overview of dermatitis\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Inverse psoriasis (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/62/27625?source=see_link\">",
"       \"Epidemiology, clinical manifestations, and diagnosis of psoriasis\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Candidiasis (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/59/30648?source=see_link\">",
"       \"Candidal intertrigo\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Dermatophytosis (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/58/7082?source=see_link\">",
"       \"Dermatophyte (tinea) infections\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Tinea (pityriasis) versicolor (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/15/3320?source=see_link\">",
"       \"Tinea versicolor\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Parapsoriasis (may resemble disciform variant) (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/46/20200?source=see_link\">",
"       \"Parapsoriasis (small plaque and large plaque parapsoriasis)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Pityriasis rotunda (may resemble disciform variant)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The characteristic coral-red fluorescence of erythrasma upon illumination with a Wood's lamp is useful for eliminating the disorders in the differential diagnosis. In addition, close attention to other clinical signs, when present, may pinpoint the correct diagnosis. Seborrheic dermatitis and inverse psoriasis can mimic the appearance of intertriginous erythrasma. Seborrheic dermatitis is suggested by the presence of characteristic lesions on the scalp, eyebrows,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    nasolabial folds. Inverse psoriasis plaques tend to have a more shiny appearance than erythrasma, and the identification of other cutaneous signs of psoriasis is revealing.",
"   </p>",
"   <p>",
"    In the absence of diagnostic testing, interdigital tinea pedis can be indistinguishable from interdigital erythrasma. A KOH preparation is useful for identifying dermatophytosis, tinea versicolor, and candidiasis. Although dermatophyte or candidal infections may coexist with erythrasma, a positive KOH preparation in the absence of coral-red fluorescence suggests an isolated fungal infection. Additionally, tinea cruris often exhibits an active scaling border, a clinical feature not associated with erythrasma.",
"   </p>",
"   <p>",
"    Small plaque parapsoriasis and large plaque parapsoriasis are characterized by chronic, asymptomatic or mildly pruritic erythematous patches that typically occur on the trunk and proximal extremities. Small plaque parapsoriasis lesions are typically less than 5 cm in diameter; lesions greater than 10 cm in size may occur in the large plaque variant. In contrast to small plaque parapsoriasis, which has a benign disease course, patients with large plaque parapsoriasis exhibit a risk of progression to mycosis fungoides. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/32/4618?source=see_link\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of mycosis fungoides\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Pityriasis rotunda is an uncommon disorder most frequently seen in Africa, Asia, and the Mediterranean [",
"    <a class=\"abstract\" href=\"UTD.htm?11/43/11959/abstract/18\">",
"     18",
"    </a>",
"    ]. Multiple 2 to 10 cm, round to oval, hyperpigmented or hypopigmented plaques appear on the trunk and proximal limbs. Skin lesions may persist for years. The cause is unknown.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Erythrasma responds to a variety of topical and oral therapies, although recurrence is common. A number of topical and oral antimicrobial agents are recommended but evidence supporting or comparing treatment efficacy is limited. Thus, factors considered during selection of therapy include the extent of disease, the patient's ability to use and tolerate a specific therapy, and drug cost or availability.",
"   </p>",
"   <p>",
"    In general, we suggest systemic treatment with an oral antibiotic such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/57/10138?source=see_link\">",
"     clarithromycin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"     erythromycin",
"    </a>",
"    for patients with widespread disease. For patients with localized disease, topical therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"     clindamycin",
"    </a>",
"    , an azole antifungal, or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/24/42373?source=see_link\">",
"     benzoyl peroxide",
"    </a>",
"    is usually sufficient. Because topical azole antifungals can be effective for the treatment of both erythrasma and tinea, these drugs may be considered as an initial therapeutic choice in cases in which a clinician is unable to distinguish between the two conditions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Topical agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple topical antimicrobial agents are prescribed for the treatment of erythrasma, including antibacterials and azole antifungals.",
"   </p>",
"   <p>",
"    Topical",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"     clindamycin",
"    </a>",
"    1% applied two to three times per day for one week cleared erythrasma in a case report [",
"    <a class=\"abstract\" href=\"UTD.htm?11/43/11959/abstract/19\">",
"     19",
"    </a>",
"    ]; treatment for 14 days is recommended elsewhere [",
"    <a class=\"abstract\" href=\"UTD.htm?11/43/11959/abstract/5\">",
"     5",
"    </a>",
"    ]. Topical",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"     erythromycin",
"    </a>",
"    has also been recommended [",
"    <a class=\"abstract\" href=\"UTD.htm?11/43/11959/abstract/7,20\">",
"     7,20",
"    </a>",
"    ], although one observational report found incomplete clearance [",
"    <a class=\"abstract\" href=\"UTD.htm?11/43/11959/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Topical",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/9/21651?source=see_link\">",
"     fusidic acid",
"    </a>",
"    was highly effective when applied twice daily for up to two weeks in randomized trials and a small observational study [",
"    <a class=\"abstract\" href=\"UTD.htm?11/43/11959/abstract/21-24\">",
"     21-24",
"    </a>",
"    ]. Fusidic acid is not approved for use in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?11/43/11959/abstract/23\">",
"     23",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Systemic therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/24/42373?source=see_link\">",
"     benzoyl peroxide",
"    </a>",
"    wash or 5% gel is also reported to be effective based upon clinical experience [",
"    <a class=\"abstract\" href=\"UTD.htm?11/43/11959/abstract/25\">",
"     25",
"    </a>",
"    ]; no formal studies have been performed.",
"   </p>",
"   <p>",
"    Various azole antifungals improve erythrasma. In randomized trials of topical antifungal therapies that included small numbers of patients with erythrasma, treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/41/7827?source=see_link\">",
"     oxiconazole",
"    </a>",
"    , miconazole,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/6/34914?source=see_link\">",
"     tioconazole",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/56/4995?source=see_link\">",
"     econazole",
"    </a>",
"    twice daily for 7 to 60 days cleared more than 90 percent of erythrasma [",
"    <a class=\"abstract\" href=\"UTD.htm?11/43/11959/abstract/26-29\">",
"     26-29",
"    </a>",
"    ]. Once daily treatment with oxiconazole was also efficacious [",
"    <a class=\"abstract\" href=\"UTD.htm?11/43/11959/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Whitfield's ointment (a fungistatic and keratolytic agent containing 12% benzoic acid and 6% salicylic acid) applied for one week cleared 98 percent of affected sites in one small randomized trial [",
"    <a class=\"abstract\" href=\"UTD.htm?11/43/11959/abstract/30\">",
"     30",
"    </a>",
"    ]. Treatment may cause significant irritation on intertriginous skin, particularly with longer treatment durations [",
"    <a class=\"abstract\" href=\"UTD.htm?11/43/11959/abstract/5,21\">",
"     5,21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although a few studies performed between 1965 and 1970 suggested that certain antibacterial soaps were effective for erythrasma (including a soap bar containing a 2% mixture of dibromsalan, tribromsalan, clofluocarbon, and triclocarban; and a soap bar containing 0.75%",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/62/33763?source=see_link\">",
"     hexachlorophene",
"    </a>",
"    and 0.75% triclocarban), the efficacy of other antibacterial soaps for erythrasma is uncertain. We typically do not use antibacterial soap as primary therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?11/43/11959/abstract/31-33\">",
"     31-33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Systemic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with multi-site disease may find oral therapy less cumbersome than topical treatment. We typically use oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/57/10138?source=see_link\">",
"     clarithromycin",
"    </a>",
"    or oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"     erythromycin",
"    </a>",
"    for these patients.",
"   </p>",
"   <p>",
"    In a placebo-controlled randomized trial that assessed the efficacy of oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"     erythromycin",
"    </a>",
"    (1 g per day for 14 days), a single 1 g dose of oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/57/10138?source=see_link\">",
"     clarithromycin",
"    </a>",
"    , and topical 2%",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/9/21651?source=see_link\">",
"     fusidic acid",
"    </a>",
"    (applied twice daily for 14 days) in adults with erythrasma, all treatments resulted in reductions in Wood&rsquo;s light reflection scores superior to those seen with the placebo cream and placebo tablets [",
"    <a class=\"abstract\" href=\"UTD.htm?11/43/11959/abstract/24\">",
"     24",
"    </a>",
"    ]. Fusidic acid was associated with the lowest reflection scores at day 14, and a significant difference in scores between patients treated with erythromycin and clarithromycin was not detected. The percentages of patients who achieved a complete response (reflection score of 0) in the fusidic acid, clarithromycin, erythromycin, placebo cream, and placebo tablet groups were 97, 67, 53, 13, and 3 percent, respectively.",
"   </p>",
"   <p>",
"    Successful treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/57/10138?source=see_link\">",
"     clarithromycin",
"    </a>",
"    has also been documented with a single 1 gram dose of clarithromycin in three adults with inguinal erythrasma [",
"    <a class=\"abstract\" href=\"UTD.htm?11/43/11959/abstract/34\">",
"     34",
"    </a>",
"    ]. One patient was concomitantly treated with topical",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/36/12870?source=see_link\">",
"     chlorhexidine gluconate",
"    </a>",
"    wash.",
"   </p>",
"   <p>",
"    Oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"     erythromycin",
"    </a>",
"    has been effective in an additional small randomized trial and case reports [",
"    <a class=\"abstract\" href=\"UTD.htm?11/43/11959/abstract/8,13,15,16,30,35\">",
"     8,13,15,16,30,35",
"    </a>",
"    ]",
"    <strong>",
"     .",
"    </strong>",
"    For adults, erythromycin is usually prescribed at a dose of 250 mg four times per day for 14 days [",
"    <a class=\"abstract\" href=\"UTD.htm?11/43/11959/abstract/5\">",
"     5",
"    </a>",
"    ]. Gastrointestinal distress (nausea, diarrhea, abdominal pain) is a common side effect of therapy. Although it has not been studied specifically for the treatment of erythrasma, enteric coated erythromycin (333 mg three times daily) is an alternative formulation of erythromycin that can minimize gastrointestinal side effects. Antibiotic susceptibility tests performed on",
"    <em>",
"     C. minutissimum",
"    </em>",
"    obtained from 40 Turkish patients suggests that antibiotic resistance may be a factor in patients who fail to respond to erythromycin therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?11/43/11959/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/49/2840?source=see_link\">",
"     Tetracycline",
"    </a>",
"    (250 mg four times per day) has also been used to treat erythrasma, although it may be less beneficial than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"     erythromycin",
"    </a>",
"    for intertriginous lesions",
"    <strong>",
"    </strong>",
"    and may also be accompanied by gastrointestinal side effects [",
"    <a class=\"abstract\" href=\"UTD.htm?11/43/11959/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/54/1897?source=see_link\">",
"     Chloramphenicol",
"    </a>",
"    has been reported to be effective in the treatment of erythrasma. However, the medication can cause bone marrow suppression and is no longer available in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?11/43/11959/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Photodynamic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Photodynamic therapy (PDT) has been reported as a potential treatment for erythrasma [",
"    <a class=\"abstract\" href=\"UTD.htm?11/43/11959/abstract/37\">",
"     37",
"    </a>",
"    ]. This technique takes advantage of the natural porphyrins produced by",
"    <em>",
"     C. minutissimum",
"    </em>",
"    . Using a red light emitting PDT device with a peak of 635 nm, patients were reported to have a reduction in size of their erythrasma lesions, but less than 25 percent of the treated patients had complete clearance [",
"    <a class=\"abstract\" href=\"UTD.htm?11/43/11959/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;At the time of diagnosis, patients should be thoroughly examined to identify all lesions. Persistent disease in untreated sites may contribute to disease recurrence [",
"    <a class=\"abstract\" href=\"UTD.htm?11/43/11959/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Occlusion and moisture are thought to contribute to the development of erythrasma. Thus, one might deduce that the reduction of chronic moisture in susceptible areas would have a protective effect. Control of hyperhidrosis with aluminum chloride prevented the recurrence of the infection in an unspecified number of patients in one observational study [",
"    <a class=\"abstract\" href=\"UTD.htm?11/43/11959/abstract/38\">",
"     38",
"    </a>",
"    ]. However, no high quality evidence to support this theory is available.",
"   </p>",
"   <p>",
"    The use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/24/42373?source=see_link\">",
"     benzoyl peroxide",
"    </a>",
"    cleansers or antibacterial soaps as a prophylactic measure has been suggested by some authors [",
"    <a class=\"abstract\" href=\"UTD.htm?11/43/11959/abstract/20,25,32\">",
"     20,25,32",
"    </a>",
"    ]. However, data to confirm the efficacy of benzoyl peroxide and most commercially available antibacterial soaps for prophylaxis are lacking.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     OTHER CUTANEOUS CORYNEBACTERIUM INFECTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <em>",
"     Corynebacterium",
"    </em>",
"    species account for a high percentage of the skin's natural bacterial flora and also cause the skin infections trichomycosis axillaris (also called trichobacteriosis) and pitted keratolysis [",
"    <a class=\"abstract\" href=\"UTD.htm?11/43/11959/abstract/7\">",
"     7",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In trichomycosis axillaris, tan, yellow, reddish, or black concretions composed of corynebacteria appear on the shafts of axillary or pubic hair (",
"      <a class=\"graphic graphic_picture graphicRef64304 \" href=\"UTD.htm?34/57/35732\">",
"       picture 6",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Pitted keratolysis is most commonly caused by",
"      <em>",
"       Micrococcus sedentarius",
"      </em>",
"      , but",
"      <em>",
"       Corynebacterium",
"      </em>",
"      species have also been implicated. The disorder is an infection of the stratum corneum of the plantar feet and web spaces that leads to the appearance of multiple, coalescing crater-like pits (",
"      <a class=\"graphic graphic_picture graphicRef81393 \" href=\"UTD.htm?37/32/38402\">",
"       picture 7",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The coexistence of erythrasma, pitted keratolysis, and trichomycosis axillaris has been documented [",
"    <a class=\"abstract\" href=\"UTD.htm?11/43/11959/abstract/35,38\">",
"     35,38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Erythrasma is a superficial skin infection caused by",
"      <em>",
"       Corynebacterium minutissimum",
"      </em>",
"      . The disorder occurs in healthy adults, but individuals with diabetes mellitus or immunodeficiency may be at increased risk. In some cases, erythrasma may be a presenting sign of diabetes. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology and risk factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Interdigital disease is the most common manifestation of the disorder, and presents as scaly, macerated skin in the web spaces of the feet. Coinfection with dermatophytes or",
"      <em>",
"       Candida",
"      </em>",
"      may occur. Erythematous to brown patches or plaques in the axillae, inframammary areas, umbilicus, or groin characterize the intertriginous variant. Lesions of erythrasma are asymptomatic or mildly pruritic. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Clinical presentation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The skin findings plus examination with a Wood's lamp revealing coral red fluorescence are usually sufficient for the diagnosis (",
"      <a class=\"graphic graphic_picture graphicRef62143 \" href=\"UTD.htm?37/27/38321\">",
"       picture 4",
"      </a>",
"      ). For patients with interdigital involvement, microscopic examination of a skin scraping with potassium hydroxide (KOH preparation) is also suggested to assess for concomitant dermatophyte infection. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Limited evidence is available to support or compare treatment options. Treatment decisions are often based upon the extent of disease, the patient's ability to use and tolerate a specific therapy and drug cost or availability. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with localized erythrasma, we suggest treatment with topical",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"       clindamycin",
"      </a>",
"      1% two to three times daily for 14 days (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Topical azole antifungals and topical",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/24/42373?source=see_link\">",
"       benzoyl peroxide",
"      </a>",
"      are additional treatment options. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Topical agents'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with more extensive involvement, we suggest treatment with oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/57/10138?source=see_link\">",
"       clarithromycin",
"      </a>",
"      or oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"       erythromycin",
"      </a>",
"      &nbsp;(",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Systemic therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/43/11959/abstract/1\">",
"      Somerville DA. Erythrasma in normal young adults. J Med Microbiol 1970; 3:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/43/11959/abstract/2\">",
"      Somerville DA, Seville RH, Cunningham RC, et al. Erythrasma in a hospital for the mentally subnormal. Br J Dermatol 1970; 82:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/43/11959/abstract/3\">",
"      Allen S, Christmas TI, McKinney W, et al. The Auckland skin clinic tinea pedis and erythrasma study. N Z Med J 1990; 103:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/43/11959/abstract/4\">",
"      Svejgaard E, Christophersen J, Jelsdorf HM. Tinea pedis and erythrasma in Danish recruits. Clinical signs, prevalence, incidence, and correlation to atopy. J Am Acad Dermatol 1986; 14:993.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/43/11959/abstract/5\">",
"      Holdiness MR. Management of cutaneous erythrasma. Drugs 2002; 62:1131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/43/11959/abstract/6\">",
"      Montes LF, Dobson H, Dodge BG, Knowles WR. Erythrasma and diabetes mellitus. Arch Dermatol 1969; 99:674.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/43/11959/abstract/7\">",
"      Blaise G, Nikkels AF, Hermanns-L&ecirc; T, et al. Corynebacterium-associated skin infections. Int J Dermatol 2008; 47:884.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/43/11959/abstract/8\">",
"      SARKANY I, TAPLIN D, BLANK H. The etiology and treatment of erythrasma. J Invest Dermatol 1961; 37:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/43/11959/abstract/9\">",
"      Golledge CL, Phillips G. Corynebacterium minutissimum infection. J Infect 1991; 23:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/43/11959/abstract/10\">",
"      Dellion S, Morel P, Vignon-Pennamen D, Felten A. Erythrasma owing to an unusual pathogen. Arch Dermatol 1996; 132:716.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/43/11959/abstract/11\">",
"      Morales-Trujillo ML, Arenas R, Arroyo S. [Interdigital erythrasma: clinical, epidemiologic, and microbiologic findings]. Actas Dermosifiliogr 2008; 99:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/43/11959/abstract/12\">",
"      Tschen JA, Ramsdell WM. Disciform erythrasma. Cutis 1983; 31:541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/43/11959/abstract/13\">",
"      Engber PB, Mandel EH. Generalized disciform erythrasma. Int J Dermatol 1979; 18:633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/43/11959/abstract/14\">",
"      Bowyer A, McColl I. Erythrasma and pruritus ani. Acta Derm Venereol 1971; 51:444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/43/11959/abstract/15\">",
"      Bowyer A, McColl I. The role of erythrasma in pruritus ani. Lancet 1966; 2:572.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/43/11959/abstract/16\">",
"      Mattox TF, Rutgers J, Yoshimori RN, Bhatia NN. Nonfluorescent erythrasma of the vulva. Obstet Gynecol 1993; 81:862.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/43/11959/abstract/17\">",
"      Sindhuphak W, MacDonald E, Smith EB. Erythrasma. Overlooked or misdiagnosed? Int J Dermatol 1985; 24:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/43/11959/abstract/18\">",
"      Grimalt R, Gelmetti C, Brusasco A, et al. Pityriasis rotunda: report of a familial occurrence and review of the literature. J Am Acad Dermatol 1994; 31:866.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/43/11959/abstract/19\">",
"      Cochran RJ, Rosen T, Landers T. Topical treatment for erythrasma. Int J Dermatol 1981; 20:562.",
"     </a>",
"    </li>",
"    <li>",
"     Halpern AV, Heymann WR. Bacterial diseases. In: Dermatology, 2nd ed, Bolognia JL, Jorizzo JL, Rapini RP, et al (Eds), Elsevier, 2008. p.1075.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/43/11959/abstract/21\">",
"      Somerville DA, Noble WC, White PM, et al. Sodium fusidate in the treatment of erythrasma. Br J Dermatol 1971; 85:450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/43/11959/abstract/22\">",
"      Hamann K, Thorn P. Systemic or local treatment of erythrasma? A comparison between erythromycin tablets and Fucidin cream in general practice. Scand J Prim Health Care 1991; 9:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/43/11959/abstract/23\">",
"      Macmillan AL, Sarkany I. Specific topical therapy for erythrasma. Br J Dermatol 1970; 82:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/43/11959/abstract/24\">",
"      Avci O, Tanyildizi T, Kusku E. A comparison between the effectiveness of erythromycin, single-dose clarithromycin and topical fusidic acid in the treatment of erythrasma. J Dermatolog Treat 2013; 24:70.",
"     </a>",
"    </li>",
"    <li>",
"     Craft N, Lee PK, Zipoi MT, et al. Superficial cutaneous infections and pyodermas. In: Fitzpatrick's Dermatology in General Medicine, 7th ed, Wolff K, Goldsmith LA, Katz SI, et al (Eds), McGraw Hill, 2008. p.1694.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/43/11959/abstract/26\">",
"      Ramelet AA, Walker-Nasir E. One daily application of oxiconazole cream is sufficient for treating dermatomycoses. Dermatologica 1987; 175:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/43/11959/abstract/27\">",
"      Pitcher DG, Noble WC, Seville RH. Treatment of erythrasma with miconazole. Clin Exp Dermatol 1979; 4:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/43/11959/abstract/28\">",
"      Grigoriu D, Grigoriu A. Double-blind comparison of the efficacy, toleration and safety of tioconazole base 1% and econazole nitrate 1% creams in the treatment of patients with fungal infections of the skin or erythrasma. Dermatologica 1983; 166 Suppl 1:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/43/11959/abstract/29\">",
"      Clayton YM, Hay RJ, McGibbon DH, Pye RJ. Double blind comparison of the efficacy of tioconazole and miconazole for the treatment of fungal infection of the skin or erythrasma. Clin Exp Dermatol 1982; 7:543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/43/11959/abstract/30\">",
"      Seville RH, Somerville DA. The treatment of erythrasma in a hospital for the mentally subnormal. Br J Dermatol 1970; 82:502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/43/11959/abstract/31\">",
"      Dodge BG, Knowles WR, McBride ME, et al. Treatment of erythrasma with an antibacterial soap. Arch Dermatol 1968; 97:548.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/43/11959/abstract/32\">",
"      Kooistra JA. Prophylaxis and control of erythrasma of the toe webs. J Invest Dermatol 1965; 45:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/43/11959/abstract/33\">",
"      Taber D, Yackovich F. Use of an antibacterial soap in the treatment of erythrasma of the toe webs. Cutis 1969; 5:991.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/43/11959/abstract/34\">",
"      Wharton JR, Wilson PL, Kincannon JM. Erythrasma treated with single-dose clarithromycin. Arch Dermatol 1998; 134:671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/43/11959/abstract/35\">",
"      Shelley WB, Shelley ED. Coexistent erythrasma, trichomycosis axillaris, and pitted keratolysis: an overlooked corynebacterial triad? J Am Acad Dermatol 1982; 7:752.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/43/11959/abstract/36\">",
"      Turk BG, Turkmen M, Aytimur D. Antibiotic susceptibility of Corynebacterium minutissimum isolated from lesions of Turkish patients with erythrasma. J Am Acad Dermatol 2011; 65:1230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/43/11959/abstract/37\">",
"      Darras-Vercambre S, Carpentier O, Vincent P, et al. Photodynamic action of red light for treatment of erythrasma: preliminary results. Photodermatol Photoimmunol Photomed 2006; 22:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/43/11959/abstract/38\">",
"      Rho NK, Kim BJ. A corynebacterial triad: Prevalence of erythrasma and trichomycosis axillaris in soldiers with pitted keratolysis. J Am Acad Dermatol 2008; 58:S57.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4031 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-8BB6C55152-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_43_11959=[""].join("\n");
var outline_f11_43_11959=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H18\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY AND RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Interdigital",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Intertriginous",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Disciform",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Genital/perianal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Diagnostic procedures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Topical agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Systemic therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Photodynamic therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      OTHER CUTANEOUS CORYNEBACTERIUM INFECTIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DERM/4031\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/4031|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?32/29/33233\" title=\"picture 1\">",
"      Interdigital erythrasma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?42/36/43587\" title=\"picture 2A\">",
"      Intertriginous erythrasma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?41/46/42725\" title=\"picture 2B\">",
"      Erythrasma in axilla",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?29/13/29905\" title=\"picture 2C\">",
"      Erythrasma in axilla 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?39/60/40904\" title=\"picture 3\">",
"      Disciform erythrasma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?37/27/38321\" title=\"picture 4\">",
"      Erythrasma fluorescence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?26/55/27506\" title=\"picture 5\">",
"      Erythrasma biopsy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?34/57/35732\" title=\"picture 6\">",
"      Trichomycosis axillaris",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?37/32/38402\" title=\"picture 7\">",
"      Pitted keratolysis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/48/15110?source=related_link\">",
"      Approach to the patient with anal pruritus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/59/30648?source=related_link\">",
"      Candidal intertrigo",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/32/4618?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of mycosis fungoides",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/51/31543?source=related_link\">",
"      Dermatologic procedures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/58/7082?source=related_link\">",
"      Dermatophyte (tinea) infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/62/27625?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of psoriasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/40/3721?source=related_link\">",
"      Overview of dermatitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/46/20200?source=related_link\">",
"      Parapsoriasis (small plaque and large plaque parapsoriasis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/15/3320?source=related_link\">",
"      Tinea versicolor",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f11_43_11960="H E no duct portal tract";
var content_f11_43_11960=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F79064&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F79064&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Idiopathic adulthood ductopenia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 322px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    High power view of an H&amp;E stain of a liver biopsy from a patient with idiopathic adulthood ductopenia. The portal triad has an artery and vein easily visible, but no bile duct of comparable size is present.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of John Hart, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_43_11960=[""].join("\n");
var outline_f11_43_11960=null;
var title_f11_43_11961="Treatment of pulmonary sarcoidosis with glucocorticoids";
var content_f11_43_11961=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of pulmonary sarcoidosis with glucocorticoids",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/43/11961/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/43/11961/contributors\">",
"     Talmadge E King, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/43/11961/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/43/11961/contributors\">",
"     Kevin R Flaherty, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/43/11961/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/43/11961/contributors\">",
"     Helen Hollingsworth, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?11/43/11961/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 8, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sarcoidosis is a multisystem disease of unknown etiology characterized by tissue infiltration with noncaseating granulomas. The granulomas may occur in any organ, but the most frequently affected sites are the lungs, lymph nodes, skin, eyes, and liver. Patients with pulmonary sarcoidosis are most often asymptomatic at presentation. When symptomatic, patients usually report dyspnea, cough, or nonspecific chest discomfort. Spontaneous resolution of the disease is common, but progressive lung disease occurs in approximately 25 percent and disabling organ failure in up to 10 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?11/43/11961/abstract/1-4\">",
"     1-4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Glucocorticoids (also called corticosteroids) have long been the most commonly used agents for the treatment of pulmonary sarcoidosis, as they appear to attenuate the granulomatous inflammatory process. The key questions regarding the treatment of sarcoidosis with glucocorticoids are the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      What are the indications for treatment?",
"     </li>",
"     <li>",
"      When should therapy be started?",
"     </li>",
"     <li>",
"      What is the optimal duration of therapy?",
"     </li>",
"     <li>",
"      How should the disease course and the response to therapy be monitored?",
"     </li>",
"     <li>",
"      Does treatment alter the course of pulmonary sarcoidosis?",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    An overview of the treatment of sarcoidosis with glucocorticoids will be presented here. The clinical manifestations and diagnostic evaluation of sarcoidosis and the treatment of sarcoidosis with alternatives to glucocorticoids are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/25/21914?source=see_link\">",
"     \"Clinical manifestations and diagnosis of sarcoidosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/11/38074?source=see_link\">",
"     \"Treatment of pulmonary sarcoidosis with alternatives to glucocorticoids\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     OVERVIEW OF INITIAL THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients with pulmonary sarcoidosis do not require treatment, as a high proportion have asymptomatic, nonprogressive disease or experience a spontaneous remission. For those with more severe lung involvement, therapy of sarcoidosis is aimed at reducing the burden of granulomatous inflammation and preventing the development of irreversible end-organ damage (eg, honeycombing and fibrotic lung disease), while avoiding excess toxicity from medications. Unfortunately, no specific treatment for sarcoidosis exists, as the cause of sarcoidosis is unknown.",
"   </p>",
"   <p>",
"    Oral glucocorticoids have been the most commonly used agents for the relief of symptoms and control of potentially disabling respiratory impairment from pulmonary sarcoidosis, even if they do not cure the disease [",
"    <a class=\"abstract\" href=\"UTD.htm?11/43/11961/abstract/4-6\">",
"     4-6",
"    </a>",
"    ]. Once begun, glucocorticoid therapy is usually continued in tapering doses for 12 months, longer if the patient has recurrence of symptoms and radiographic opacities.",
"   </p>",
"   <p>",
"    Prior to initiating therapy, patients are assessed for comorbid diseases that may contribute to their symptoms but not respond to glucocorticoid therapy (eg, infection, heart failure, thromboembolic disease, pulmonary hypertension) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/43/11961/abstract/6\">",
"     6",
"    </a>",
"    ]. Testing generally includes pulmonary function tests, high resolution computed tomography (HRCT) scan, and often an echocardiogram. Dyspnea that is out of proportion to the spirometric findings or a diffusing capacity that is lower than expected based on the amount of interstitial disease on chest imaging might suggest pulmonary hypertension or thromboembolic disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/31/16889?source=see_link&amp;anchor=H7#H7\">",
"     \"Pulmonary hypertension associated with interstitial lung disease\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This is also a good time to ask the patient again about any possible occupational exposure to beryllium or any exposure that could cause hypersensitivity pneumonitis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/45/22234?source=see_link&amp;anchor=H3#H3\">",
"     \"Chronic beryllium disease (berylliosis)\", section on 'Exposure'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     MECHANISM OF ACTION OF GLUCOCORTICOIDS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The exact mechanism of action of glucocorticoids in the treatment of sarcoidosis is unknown. Based on pathologic studies, sarcoid granulomas have a tightly packed central area, composed of macrophages, epithelioid cells, and multinucleated giant cells. This central area is surrounded by lymphocytes, monocytes, mast cells, and fibroblasts. Sarcoid granulomas can resolve without apparent sequelae or undergo obliterative fibrosis, resulting in the development of fibrosis, such as the interstitial fibrosis seen advanced sarcoidosis affecting the lung. Several cytokines produced by these inflammatory cells have been implicated in the pathogenesis of granuloma formation and the subsequent development of fibrosis, including IL-2, interferon-gamma, tumor necrosis factor (TNF)-alpha, and granulocyte-macrophage colony stimulating factor (GM-CSF). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/14/6376?source=see_link\">",
"     \"Pathogenesis of sarcoidosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Glucocorticoids appear to exert their effects on sarcoid granulomas through transcriptional regulation of glucocorticoid-receptor target genes and also non-genomic signal transduction pathways in lymphocytes and alveolar macrophages (",
"    <a class=\"graphic graphic_figure graphicRef67246 \" href=\"UTD.htm?9/18/9505\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/43/11961/abstract/4,5,7-9\">",
"     4,5,7-9",
"    </a>",
"    ]. A number of the cytokines mentioned above that appear to participate in granulomatous inflammation are modulated by glucocorticoids. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/42/7849?source=see_link&amp;anchor=H3#H3\">",
"     \"Glucocorticoid-resistant asthma\", section on 'Mechanisms of glucocorticoid action'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H110264147\">",
"    <span class=\"h1\">",
"     ORAL GLUCOCORTICOID THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oral glucocorticoid therapy generally improves symptoms (eg, cough and dyspnea) and radiographic abnormalities, at least initially. However, the known side effects of glucocorticoids and the uncertain effect of therapy on long-term outcome make it important to select patients carefully.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H110264106\">",
"    <span class=\"h2\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Assessment of the benefits of glucocorticoid therapy in the treatment of sarcoidosis remains problematic for the following reasons [",
"    <a class=\"abstract\" href=\"UTD.htm?11/43/11961/abstract/10-14\">",
"     10-14",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A large number of patients with sarcoidosis undergo spontaneous remission or have a benign clinical course. It has been estimated that spontaneous remission occurs in approximately 60 to 80 percent of patients with radiographic Stage I disease, 50 to 60 percent with Stage II disease, and less than 30 percent in Stage III disease (",
"      <a class=\"graphic graphic_table graphicRef56321 \" href=\"UTD.htm?13/22/13675\">",
"       table 1",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?11/43/11961/abstract/15\">",
"       15",
"      </a>",
"      ]. However, no clear predictors of spontaneous remission or progression of disease have been identified. The marked variability in presentation and clinical course make it difficult to evaluate whether an apparent response to therapy reflects a treatment effect or the natural course of that patient&rsquo;s disease.",
"     </li>",
"     <li>",
"      There is no easy way to assess disease activity or severity, and symptoms may be discordant with results of pulmonary function testing and chest imaging, which makes it difficult to interpret the results of clinical studies or the response to therapy in an individual patient.",
"     </li>",
"     <li>",
"      There is a concern that early administration of systemic glucocorticoid therapy may actually increase the likelihood that the patient will develop relapsing disease, rather than a sustained remission [",
"      <a class=\"abstract\" href=\"UTD.htm?11/43/11961/abstract/16-18\">",
"       16-18",
"      </a>",
"      ]. A prospective series of 215 patients with recent onset sarcoidosis examined the effect of glucocorticoid therapy in the first six months of diagnosis on the need for ongoing therapy at the end of two years [",
"      <a class=\"abstract\" href=\"UTD.htm?11/43/11961/abstract/19\">",
"       19",
"      </a>",
"      ]. Among 95 who were not initially treated with glucocorticoids, only 8 percent were receiving therapy after two years. In contrast, of 110 patients who were on systemic therapy at baseline, 47 percent were on therapy after two years. One explanation for this observation is that treatment limited the body&rsquo;s innate ability to clear the disease, thus necessitating long-term therapy. An alternate explanation is that patients, who were not randomly assigned to treatment groups, were selected for therapy based on subtle indications that they had more severe disease [",
"      <a class=\"abstract\" href=\"UTD.htm?11/43/11961/abstract/2\">",
"       2",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Glucocorticoids have substantial adverse effects, particularly during long-term therapy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/47/27386?source=see_link\">",
"       \"Major side effects of systemic glucocorticoids\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, the balance of evidence suggests that oral glucocorticoids improve respiratory symptoms and radiographic abnormalities, although not necessarily pulmonary function tests [",
"    <a class=\"abstract\" href=\"UTD.htm?11/43/11961/abstract/5,20-23\">",
"     5,20-23",
"    </a>",
"    ]. The results of individual trials have been variable, probably due to variations in patient populations,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    dose, and duration of therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?11/43/11961/abstract/5,24,25\">",
"     5,24,25",
"    </a>",
"    ]. The best evidence in favor of glucocorticoid therapy for pulmonary sarcoidosis comes from the largest systematic review that included 13 randomized trials comparing oral glucocorticoid therapy (equivalent to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/48/33536?source=see_link\">",
"     prednisolone",
"    </a>",
"    4 to 40 mg daily for 3 to 24 months) with placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?11/43/11961/abstract/23\">",
"     23",
"    </a>",
"    ]. The analysis found that oral glucocorticoids improved chest radiograph opacities (RR 1.46 [95% CI, 1.01-2.09]), symptoms, and spirometry. However, lung function test results could not be grouped for statistical analysis and at least two of the trials examined found no improvement in lung function [",
"    <a class=\"abstract\" href=\"UTD.htm?11/43/11961/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. Diffusing capacity was only assessed in a couple of trials, one without benefit and one found a modest improvement among patients with stage II disease (",
"    <a class=\"graphic graphic_table graphicRef56321 \" href=\"UTD.htm?13/22/13675\">",
"     table 1",
"    </a>",
"    ) treated for 18 months, but not at interval assessments before 18 months [",
"    <a class=\"abstract\" href=\"UTD.htm?11/43/11961/abstract/13,26,27\">",
"     13,26,27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A paucity of data prevents a clear analysis of the effect of one to two years of oral glucocorticoids on long-term disease outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?11/43/11961/abstract/23\">",
"     23",
"    </a>",
"    ]. In a small trial that examined this question, 25 patients were assigned to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    or placebo (by alternating treatment groups rather than randomization) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/43/11961/abstract/24\">",
"     24",
"    </a>",
"    ]. The prednisone group received 60 mg per day for one month, then 20 mg per day for five months or longer, depending on clinical course. After ten years, symptoms were improved in both groups and radiographic stage was not different between the groups, although the only subjects with a normal chest radiograph were in the untreated group. Spirometric values were not different between the groups and diffusing capacity improved in both groups. It is possible that the method of assigning treatment groups introduced bias and affected the results.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Indications for therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;When assessing the indications for glucocorticoid therapy, it is helpful to keep in mind that certain features help to predict the likely course of disease. A longer period of watchful waiting prior to initiating therapy may be possible in patients with more favorable characteristics. Favorable characteristics include Stage I disease, especially when associated with erythema nodosum, absence of symptoms, and European descent. Unfavorable prognostic features, in contrast, include the presence of symptoms (especially dyspnea), multisystem involvement (three or more organs involved), increasing chest radiographic opacities, extrapulmonary disease involving skin, bone, or joints (especially if age greater than 30 years), and African descent (only 12 percent with Stage I disease show rapid recovery) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/43/11961/abstract/28,29\">",
"     28,29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The usual indication for therapy of pulmonary sarcoidosis is a combination of [",
"    <a class=\"abstract\" href=\"UTD.htm?11/43/11961/abstract/3,30\">",
"     3,30",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Bothersome pulmonary symptoms (eg, cough, shortness of breath, chest pain or discomfort, hemoptysis).",
"     </li>",
"     <li>",
"      Deteriorating lung function, as assessed by serial testing at three to six month intervals, that demonstrates one or more of the following: a fall in total lung capacity (TLC) of 10 percent or more; a fall in forced vital capacity (FVC) of 15 percent or more; a decrease in diffusing capacity (DLCO) of 20 percent or more; or worsened gas exchange at rest (eg, a decrease in oxygen saturation on pulse oximetry of four or more percent) or with exercise.",
"     </li>",
"     <li>",
"      Progressive radiographic changes, including: worsening of interstitial opacities, development of cavities, progression of fibrosis with honeycombing, or development of signs of pulmonary hypertension.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Rarely, patients will present with severe enough initial disease that they should be started on glucocorticoid therapy without waiting for documented radiographic or physiologic progression. These patients typically have bothersome and worsening symptoms, values of FVC and forced expiratory volume in one second (FEV",
"    <sub>",
"     1",
"    </sub>",
"    ) below 70 percent of predicted, a diffusing capacity below 60 percent of predicted,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    an oxygen saturation of 90 percent or less, and widespread radiographic opacities.",
"   </p>",
"   <p>",
"    Therapy is not indicated in the following groups of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?11/43/11961/abstract/30\">",
"     30",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Asymptomatic patients with Stage I radiographic changes (",
"      <a class=\"graphic graphic_table graphicRef56321 \" href=\"UTD.htm?13/22/13675\">",
"       table 1",
"      </a>",
"      ). Approximately 60 to 80 percent of such patients have a spontaneous remission.",
"     </li>",
"     <li>",
"      Asymptomatic patients with Stage II (",
"      <a class=\"graphic graphic_table graphicRef56321 \" href=\"UTD.htm?13/22/13675\">",
"       table 1",
"      </a>",
"      ) radiographic changes and normal or mildly abnormal lung function (mild restrictive or obstructive findings with normal gas exchange). These patients are followed for three to six months to identify progression of disease before instituting therapy. In this setting, it is important to document progressive impairment of lung function or gas exchange before starting therapy, because approximately 50 percent of untreated patients with Stage II radiographic changes will have",
"      <strong>",
"       radiographic resolution",
"      </strong>",
"      by 36 months. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Inhaled glucocorticoid therapy'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Asymptomatic patients with Stage III disease (",
"      <a class=\"graphic graphic_table graphicRef56321 \" href=\"UTD.htm?13/22/13675\">",
"       table 1",
"      </a>",
"      ) and normal or mildly abnormal lung function. These patients can also be closely followed for three to six months. However, because only approximately 33 percent of untreated patients with Stage III radiographic changes show disease resolution after five years, the majority of these patients will require therapy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A multicenter British study examined the question of whether patients with asymptomatic pulmonary parenchymal disease (Stage II or III) would have a better long-term outcome if they received long-term (18 months) glucocorticoid therapy aimed at optimizing the radiographic appearance, rather than continued observation with treatment initiation if symptoms worsened or lung function deteriorated [",
"    <a class=\"abstract\" href=\"UTD.htm?11/43/11961/abstract/31\">",
"     31",
"    </a>",
"    ]. At five years, the average vital capacity was higher by 9 percent of the predicted value in the long-term glucocorticoid group. However, two-thirds of those who received glucocorticoid therapy experienced adverse effects, including weight gain, cushingoid features, and gastrointestinal disturbances.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23610885\">",
"    <span class=\"h2\">",
"     Extrapulmonary sarcoidosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;In some patients with pulmonary sarcoidosis, the lung involvement is not severe enough to warrant treatment, but the concomitant extrapulmonary disease may indicate the need for therapy. The decision to treat extrapulmonary sarcoidosis should be based on the specific organ systems affected and on the degree of impairment identified through clinical and laboratory examination. Treatment of ocular, neurologic, myocardial, or renal sarcoidosis or hypercalcemia is indicated even when symptoms are slight, because severe loss of vision, fatal arrhythmias, or insidious renal damage may ensue [",
"    <a class=\"abstract\" href=\"UTD.htm?11/43/11961/abstract/32\">",
"     32",
"    </a>",
"    ]. The therapy of sarcoidosis affecting specific extrapulmonary organ systems is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/16/2310?source=see_link\">",
"     \"Hypercalcemia in granulomatous diseases\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/19/17722?source=see_link\">",
"     \"Cardiac sarcoidosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/8/20616?source=see_link\">",
"     \"Neurologic sarcoidosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/31/40438?source=see_link\">",
"     \"Renal disease in sarcoidosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other potential indications for therapy include severe discomfort or inability to work as a result of fever, weakness, fatigue, arthralgia, disfiguring skin disease, upper airway disease, or hepatic insufficiency.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Dosage and administration",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal dose of glucocorticoids is not known, so choosing a dose requires balancing the likelihood of response against the risk of adverse effects [",
"    <a class=\"abstract\" href=\"UTD.htm?11/43/11961/abstract/5,10,13,33\">",
"     5,10,13,33",
"    </a>",
"    ]. The following approach is based on expert opinion as there are insufficient published data to support a specific approach.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H110264223\">",
"    <span class=\"h3\">",
"     Initial therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Therapy is usually initiated with oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    at a daily dose of 0.3 to 0.6",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    ideal body weight (usually 20 to 40",
"    <span class=\"nowrap\">",
"     mg/day),",
"    </span>",
"    depending on the severity of disease activity [",
"    <a class=\"abstract\" href=\"UTD.htm?11/43/11961/abstract/34\">",
"     34",
"    </a>",
"    ]. For patients with shortness of breath on exertion and slowly worsening radiographic opacities, the lower dose is usually adequate. For patients with rapidly progressive disease and severe impairment (eg, oxygen dependent), we favor using the higher end of the dose range.",
"   </p>",
"   <p>",
"    The initial dose is continued for four to six weeks and then the patient is re-assessed. If the symptoms, radiographic abnormalities, and pulmonary function tests (eg, spirometry, diffusing capacity, ambulatory oximetry) are stable or improved, the dose is tapered (by 5 to 10 mg decrements every four to eight weeks) down to 0.2 to 0.4",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    (usually 10 to 20",
"    <span class=\"nowrap\">",
"     mg/day).",
"    </span>",
"    If these parameters are unimproved, we continue the initial dose another four to six weeks. (See",
"    <a class=\"local\" href=\"#H348701692\">",
"     'Assessing the response'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    High-dose oral glucocorticoid therapy (80 to 100",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    may rarely be warranted in patients with acute respiratory failure or concomitant cardiac, neurologic, ocular, or upper airway disease [",
"    <a class=\"abstract\" href=\"UTD.htm?11/43/11961/abstract/35-37\">",
"     35-37",
"    </a>",
"    ]. This level is continued until the disease is under control (usually 4 to 12 weeks). Once improvement is achieved, the dose is tapered as described for the maintenance phase above. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/8/20616?source=see_link\">",
"     \"Neurologic sarcoidosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/19/17722?source=see_link\">",
"     \"Cardiac sarcoidosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H110264349\">",
"    <span class=\"h3\">",
"     Maintenance therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;No formal data is available to guide maintenance dosing of oral glucocorticoids. Based on clinical experience, a maintenance dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    in the range of 0.25 to 0.5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    (usually 10 to 20 mg) per day will prevent worsening of disease [",
"    <a class=\"abstract\" href=\"UTD.htm?11/43/11961/abstract/38\">",
"     38",
"    </a>",
"    ]. During the maintenance phase, the patient is reassessed at four to twelve week intervals for evidence of symptomatic worsening or development of glucocorticoid-related adverse effects. (See",
"    <a class=\"local\" href=\"#H348701692\">",
"     'Assessing the response'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H348702040\">",
"     'Adverse effects'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Recurrence of symptoms, such as cough, dyspnea and chest pain, is common (occurring in about 60 percent of patients), so we continue the maintenance dose for at least six to eight months, giving a total treatment period of about one year. Frequently, a brief course of higher doses (increases of 10 to 20 mg above the maintenance dose given for two to four weeks) is required to relieve an episode of recurrent symptoms. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/37/22103?source=see_link\">",
"     \"Glucocorticoid withdrawal\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The majority of patients are able to discontinue systemic glucocorticoids after one year [",
"    <a class=\"abstract\" href=\"UTD.htm?11/43/11961/abstract/39\">",
"     39",
"    </a>",
"    ]. However, approximately one-third will develop a relapse and require another course of therapy, and a small number of patients require more long-term or indefinite maintenance therapy to control their symptoms. [",
"    <a class=\"abstract\" href=\"UTD.htm?11/43/11961/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Alternate day therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Alternate day therapy with oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    has been advised to reduce the risk of side effects from the glucocorticoids, but few data are available to support its efficacy. Likely, the benefits are comparable to similar doses of daily glucocorticoid therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?11/43/11961/abstract/41\">",
"     41",
"    </a>",
"    ]. A starting dose of 40 mg of prednisone every other day for three months has been used [",
"    <a class=\"abstract\" href=\"UTD.htm?11/43/11961/abstract/28\">",
"     28",
"    </a>",
"    ]. Following improvement, the dose is lowered by 5 to 10 mg increments at three-month intervals. Treatment is continued for one year to achieve an inactive status and is then discontinued if the patient is stable. Alternate day therapy with prednisone has also been used for maintenance after initial daily therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H348701692\">",
"    <span class=\"h2\">",
"     Assessing the response",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal tools and timing for assessing the response to therapy in pulmonary sarcoidosis are unknown [",
"    <a class=\"abstract\" href=\"UTD.htm?11/43/11961/abstract/4\">",
"     4",
"    </a>",
"    ]. Due to the absence of a well-defined assessment tool, a combination of symptoms, physical examination, radiographic abnormalities, and pulmonary function tests is used to assess disease activity (",
"    <a class=\"graphic graphic_table graphicRef67386 \" href=\"UTD.htm?9/59/10173\">",
"     table 2",
"    </a>",
"    ). Many experts believe that symptoms are the most important parameter to follow, although this approach depends on the reliability of the individual patient in perceiving and reporting symptoms. A difficult situation can arise when a patient experiences subjective improvement with glucocorticoid therapy without objective change. Due to the toxicity of glucocorticoid therapy, we try to avoid having symptoms be the lone factor in determining whether to continue treatment.",
"   </p>",
"   <p>",
"    The pulmonary function tests that we follow at three to four month intervals are spirometry, diffusing capacity (DLCO), and ambulatory oximetry. We obtain lung volume measurements every 12 to 24 months.",
"   </p>",
"   <p>",
"    A favorable response to glucocorticoid therapy is defined by:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A decrease in symptoms, especially dyspnea, cough, hemoptysis, chest pain, or fatigue.",
"     </li>",
"     <li>",
"      A reduction in or clearing of radiographic abnormalities.",
"     </li>",
"     <li>",
"      Physiologic improvement, including a 10 to 15 percent or greater increase in forced vital capacity (FVC) or total lung capacity (TLC), a 20 percent or greater increase in diffusing capacity (DLCO), or an improvement in gas exchange (eg, a 4 mmHg or greater increase in the arterial PO",
"      <sub>",
"       2",
"      </sub>",
"      or a decline of 4 mmHg or more in the alveolar-arterial oxygen gradient at rest or during exercise)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Stabilization of radiographic abnormalities and lung function for prolonged periods of time (three to six months) should also be considered a positive response to treatment.",
"   </p>",
"   <p>",
"    A failure to respond to therapy (or a relapse) is often defined as:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      A fall of 10 percent or more in FVC or TLC",
"     </li>",
"     <li>",
"      Worsening of radiographic opacities, especially with development of cavities, honeycombing, or signs of pulmonary hypertension",
"     </li>",
"     <li>",
"      Decreased gas exchange at rest or with exercise",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Sarcoidal granulomas produce angiotensin-converting enzyme (ACE), and ACE levels are elevated in 60 percent of patients with sarcoidosis [",
"    <a class=\"abstract\" href=\"UTD.htm?11/43/11961/abstract/4\">",
"     4",
"    </a>",
"    ]. However, following serum ACE levels has not been demonstrated to be useful in the management of sarcoidosis, despite initial enthusiasm for monitoring ACE levels to assess disease activity [",
"    <a class=\"abstract\" href=\"UTD.htm?11/43/11961/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition to monitoring the activity of pulmonary disease, it is also important to monitor patients with sarcoidosis for development of extrapulmonary disease. A general guideline and list of tests is provided in the table (",
"    <a class=\"graphic graphic_table graphicRef67386 \" href=\"UTD.htm?9/59/10173\">",
"     table 2",
"    </a>",
"    ). An approach to monitoring sarcoidosis is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/25/21914?source=see_link&amp;anchor=H41#H41\">",
"     \"Clinical manifestations and diagnosis of sarcoidosis\", section on 'Monitoring'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H110264535\">",
"    <span class=\"h2\">",
"     Duration of therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The proper length of therapy in patients who respond to treatment is not known [",
"    <a class=\"abstract\" href=\"UTD.htm?11/43/11961/abstract/5,29,42\">",
"     5,29,42",
"    </a>",
"    ]. Therapy must be given for at least three to six months to be effective and to prevent relapse. Relapses are frequent following reduction or withdrawal of therapy. Consequently, we usually aim for at least one year of therapy. Lifelong low dose treatment (&le;0.25",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day, or 0.25 to 0.5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    on alternate days) may be required by a minority of patients who suffer frequent relapses.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H369563725\">",
"    <span class=\"h2\">",
"     Relapses",
"    </span>",
"    &nbsp;&mdash;&nbsp;Symptomatic relapses may occur during tapering of therapy or after discontinuation and are typically accompanied by declines in lung function, progression of radiographic abnormalities, or both. These parameters usually improve, at least partially, with retreatment.",
"   </p>",
"   <p>",
"    If there is relapse of the disease after tapering of the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    , the dose is increased to the last effective dose and continued for a subsequent three to six months. If there is no improvement after three months, prednisone is increased back to the initial effective dose (20 to 40 mg daily) until there is improvement (usually three to six months). A retrospective study of 36 patients with acute exacerbations of pulmonary sarcoidosis (defined by criteria similar to those used for acute exacerbations IPF: decrease of pulmonary function tests (PFTs) more than 10 percent, worsening of symptoms not attributable to an identified cause, radiological worsening) have shown that treatment with the equivalent of prednisone 20",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    for approximately 21 days resulted in improvement of symptoms and return of lung function to baseline [",
"    <a class=\"abstract\" href=\"UTD.htm?11/43/11961/abstract/43\">",
"     43",
"    </a>",
"    ]. Subsequent tapering is more gradual than the taper that resulted in a relapse. (See",
"    <a class=\"local\" href=\"#H110264349\">",
"     'Maintenance therapy'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    If reactivation occurs after discontinuing",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    , oral glucocorticoids are reinstituted following the dosing described for initial therapy. (See",
"    <a class=\"local\" href=\"#H110264223\">",
"     'Initial therapy'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Patients who improve and remain stable for more than one year following cessation of therapy have a low rate of relapse [",
"    <a class=\"abstract\" href=\"UTD.htm?11/43/11961/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H348702040\">",
"    <span class=\"h2\">",
"     Adverse effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Numerous adverse effects have been attributed to chronic systemic glucocorticoid therapy (",
"    <a class=\"graphic graphic_table graphicRef65998 \" href=\"UTD.htm?15/62/16365\">",
"     table 3",
"    </a>",
"    ). The identification and prevention of these adverse effects are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/47/27386?source=see_link&amp;anchor=H5#H5\">",
"     \"Major side effects of systemic glucocorticoids\", section on 'Toxicity of systemic glucocorticoids by organ system or symptom complex'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Prevention of glucocorticoid-induced bone loss is a more complicated issue in patients with sarcoidosis compared with other glucocorticoid-requiring diseases, due endogenous production of vitamin D by sarcoid granulomas and the risk of hypercalcemia with calcium supplementation. The bisphosphonate,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/10/24743?source=see_link\">",
"     alendronate",
"    </a>",
"    , has been shown to decrease bone loss when given to patients with sarcoidosis who are taking glucocorticoids [",
"    <a class=\"abstract\" href=\"UTD.htm?11/43/11961/abstract/44\">",
"     44",
"    </a>",
"    ]. We usually add alendronate in response to a low or decreasing bone density.",
"   </p>",
"   <p>",
"    To assess the need for vitamin D supplementation, 25 hydroxy and 1,25 dihydroxy vitamin D levels are assessed and repleted, if low. Close monitoring of serum and urine calcium is used during calcium supplementation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/36/17994?source=see_link\">",
"     \"Prevention and treatment of glucocorticoid-induced osteoporosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H348701894\">",
"    <span class=\"h2\">",
"     Failure of therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients who are unable to tolerate the adverse effects of glucocorticoids, whose disease cannot be controlled on the equivalent of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    10 to 15 mg or less, or who have evidence of disease progression despite a moderate dose of prednisone, an alternative immunosuppressive agent may be of benefit [",
"    <a class=\"abstract\" href=\"UTD.htm?11/43/11961/abstract/34\">",
"     34",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/11/38074?source=see_link\">",
"     \"Treatment of pulmonary sarcoidosis with alternatives to glucocorticoids\"",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    When disease refractory to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    is suspected, we evaluate for other disease processes that may contribute to persistent symptoms, pulmonary function impairment, or radiographic abnormalities (eg, infection, heart failure, thromboembolic disease, pulmonary hypertension). Testing typically includes pulmonary function tests, high resolution computed tomography, and often an echocardiogram. This is also a good time to ask the patient about any possible beryllium exposure. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/45/22234?source=see_link&amp;anchor=H3#H3\">",
"     \"Chronic beryllium disease (berylliosis)\", section on 'Exposure'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     INHALED GLUCOCORTICOID THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inhaled glucocorticoids have been evaluated for the treatment of pulmonary sarcoidosis, but results are conflicting [",
"    <a class=\"abstract\" href=\"UTD.htm?11/43/11961/abstract/12,13,26,34,45-51\">",
"     12,13,26,34,45-51",
"    </a>",
"    ]. Inhaled glucocorticoids appear to modulate the alveolitis of sarcoidosis [",
"    <a class=\"abstract\" href=\"UTD.htm?11/43/11961/abstract/49,50\">",
"     49,50",
"    </a>",
"    ] and provide clinical benefit in some subjects; however, significant changes in lung function have not been seen [",
"    <a class=\"abstract\" href=\"UTD.htm?11/43/11961/abstract/26,46,47,51\">",
"     26,46,47,51",
"    </a>",
"    ]. As an example, one double-blind placebo-controlled trial of 2000",
"    <span class=\"nowrap\">",
"     mcg/day",
"    </span>",
"    of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/45/39632?source=see_link\">",
"     fluticasone",
"    </a>",
"    in 44 patients found no significant differences in lung function, although significant improvements in cough, breathlessness, wheeze, and general health perception were noted [",
"    <a class=\"abstract\" href=\"UTD.htm?11/43/11961/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/7/32880?source=see_link\">",
"     Budesonide",
"    </a>",
"    (800 to 1600 mcg twice daily) has been the most frequently studied inhaled glucocorticoid [",
"    <a class=\"abstract\" href=\"UTD.htm?11/43/11961/abstract/26\">",
"     26",
"    </a>",
"    ]. Inhaled",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/45/39632?source=see_link\">",
"     fluticasone",
"    </a>",
"    can be used as alternative therapy.",
"   </p>",
"   <p>",
"    Many clinicians advise a trial (eg, for four to eight weeks) of inhaled glucocorticoids for:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cough with or without airway hyperreactivity.",
"     </li>",
"     <li>",
"      Stage I or II disease (",
"      <a class=\"graphic graphic_table graphicRef56321 \" href=\"UTD.htm?13/22/13675\">",
"       table 1",
"      </a>",
"      ) with only mild pulmonary symptoms or lung function abnormalities.",
"     </li>",
"     <li>",
"      Use as an alternative to long-term low dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      (5 to 10 mg daily).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     LONG-TERM OUTCOME",
"    </span>",
"    &nbsp;&mdash;&nbsp;The overall death rate from sarcoidosis is less than 5 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?11/43/11961/abstract/4\">",
"     4",
"    </a>",
"    ]. Causes of death in sarcoidosis include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Progressive pulmonary fibrosis and cor pulmonale (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/17/36119?source=see_link\">",
"       \"Cor pulmonale\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Pulmonary hemorrhage from aspergillomas developing in damaged lung tissue (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/50/31529?source=see_link\">",
"       \"Treatment of chronic pulmonary aspergillosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Myocardial involvement is a rare cause of death (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/19/17722?source=see_link\">",
"       \"Cardiac sarcoidosis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Lung transplantation may be an option for patients with progressive pulmonary fibrosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/11/38074?source=see_link&amp;anchor=H15#H15\">",
"     \"Treatment of pulmonary sarcoidosis with alternatives to glucocorticoids\", section on 'Lung transplantation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?20/14/20705?source=see_link\">",
"       \"Patient information: Sarcoidosis (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?5/35/5683?source=see_link\">",
"       \"Patient information: Sarcoidosis (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24690322\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Most patients with pulmonary sarcoidosis do not require treatment, as a high proportion have asymptomatic, nonprogressive disease or experience a spontaneous remission. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Overview of initial therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For asymptomatic patients with pulmonary sarcoidosis and no significant extrapulmonary involvement, we recommend not initiating therapy with oral glucocorticoids (",
"      <a class=\"graphic graphic_table graphicRef56321 \" href=\"UTD.htm?13/22/13675\">",
"       table 1",
"      </a>",
"      ) (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). Careful monitoring of symptoms, chest radiograph, and pulmonary function is continued at three to six month intervals. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Indications for therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with pulmonary sarcoidosis causing bothersome symptoms, worsening radiographic opacities (Stage II or III, (",
"      <a class=\"graphic graphic_table graphicRef56321 \" href=\"UTD.htm?13/22/13675\">",
"       table 1",
"      </a>",
"      )), and increasing pulmonary function impairment, we recommend initiation of oral glucocorticoids rather than continued observation (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). The usual dose of oral glucocorticoids is the equivalent of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      0.3 to 0.6",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      ideal body weight (usually 20 to 40",
"      <span class=\"nowrap\">",
"       mg/day).",
"      </span>",
"      (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Indications for therapy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H110264223\">",
"       'Initial therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients who present with disabling symptoms, widespread radiographic abnormalities (Stage II or III (",
"      <a class=\"graphic graphic_table graphicRef56321 \" href=\"UTD.htm?13/22/13675\">",
"       table 1",
"      </a>",
"      )), and moderate to severe impairment of pulmonary function, we suggest initiation of oral glucocorticoid therapy, rather than waiting for evidence of progression (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H110264223\">",
"       'Initial therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The initial dose of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      is continued for four to six weeks. If the symptoms, radiographic abnormalities, and pulmonary function tests are unimproved, we continue the initial dose for another four to six weeks. If these parameters are stable or improved, the dose of prednisone is tapered gradually (See",
"      <a class=\"local\" href=\"#H110264223\">",
"       'Initial therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      No formal data is available to guide maintenance dosing of oral glucocorticoids. We typically taper",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      by 5 to 10 mg increments until a dose of 0.25 to 0.5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      (usually 10 to 20 mg) per day, as tolerated. This dose is continued for the maintenance dose for at least six to eight months, giving a total treatment period of about one year. (See",
"      <a class=\"local\" href=\"#H110264349\">",
"       'Maintenance therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The optimal assessment tools and timing are unknown. We monitor a combination of symptoms, physical examination, radiographic abnormalities, and pulmonary function tests (spirometry, diffusing capacity (DLCO), and ambulatory oximetry) at four to six week intervals during initial therapy and at 6 to 12 week intervals while on systemic glucocorticoids. (See",
"      <a class=\"local\" href=\"#H348701692\">",
"       'Assessing the response'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with cough (with or without airway hyperreactivity), Stage I or II radiographic disease (",
"      <a class=\"graphic graphic_table graphicRef56321 \" href=\"UTD.htm?13/22/13675\">",
"       table 1",
"      </a>",
"      ), and mild pulmonary lung function abnormalities, we suggest initiating therapy with inhaled glucocorticoids (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). The usual dose is the equivalent of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/7/32880?source=see_link\">",
"       budesonide",
"      </a>",
"      800 to 1600 mcg twice daily. The inhaled glucocorticoid can be discontinued after four to eight weeks, if there is no evidence of benefit. Inhaled glucocorticoids may also be used as an alternative to long-term low dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      (eg, 5 to 10 daily) for chronic control of pulmonary sarcoid. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Inhaled glucocorticoid therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Chronic systemic glucocorticoid therapy has numerous adverse effects (",
"      <a class=\"graphic graphic_table graphicRef65998 \" href=\"UTD.htm?15/62/16365\">",
"       table 3",
"      </a>",
"      ). The identification and prevention of these adverse effects are discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/47/27386?source=see_link&amp;anchor=H5#H5\">",
"       \"Major side effects of systemic glucocorticoids\", section on 'Toxicity of systemic glucocorticoids by organ system or symptom complex'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For patients who are unable to tolerate the adverse effects of glucocorticoids, whose disease cannot be controlled on the equivalent of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      10 to 15 mg or less, or who have evidence of disease progression despite a moderate dose of prednisone, an alternative immunosuppressive agent may be of benefit. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/11/38074?source=see_link\">",
"       \"Treatment of pulmonary sarcoidosis with alternatives to glucocorticoids\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/43/11961/abstract/1\">",
"      Baughman RP. Pulmonary sarcoidosis. Clin Chest Med 2004; 25:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/43/11961/abstract/2\">",
"      Baughman RP, Lower EE, du Bois RM. Sarcoidosis. Lancet 2003; 361:1111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/43/11961/abstract/3\">",
"      Statement on sarcoidosis. Joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee, February 1999. Am J Respir Crit Care Med 1999; 160:736.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/43/11961/abstract/4\">",
"      Iannuzzi MC, Rybicki BA, Teirstein AS. Sarcoidosis. N Engl J Med 2007; 357:2153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/43/11961/abstract/5\">",
"      du Bois RM. Corticosteroids in sarcoidosis: friend or foe? Eur Respir J 1994; 7:1203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/43/11961/abstract/6\">",
"      Baughman RP, Costabel U, du Bois RM. Treatment of sarcoidosis. Clin Chest Med 2008; 29:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/43/11961/abstract/7\">",
"      Scheinman RI, Cogswell PC, Lofquist AK, Baldwin AS Jr. Role of transcriptional activation of I kappa B alpha in mediation of immunosuppression by glucocorticoids. Science 1995; 270:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/43/11961/abstract/8\">",
"      Auphan N, DiDonato JA, Rosette C, et al. Immunosuppression by glucocorticoids: inhibition of NF-kappa B activity through induction of I kappa B synthesis. Science 1995; 270:286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/43/11961/abstract/9\">",
"      L&ouml;wenberg M, Verhaar AP, van den Brink GR, Hommes DW. Glucocorticoid signaling: a nongenomic mechanism for T-cell immunosuppression. Trends Mol Med 2007; 13:158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/43/11961/abstract/10\">",
"      Sharma OP. Pulmonary sarcoidosis and corticosteroids. Am Rev Respir Dis 1993; 147:1598.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/43/11961/abstract/11\">",
"      Judson MA. An approach to the treatment of pulmonary sarcoidosis with corticosteroids: the six phases of treatment. Chest 1999; 115:1158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/43/11961/abstract/12\">",
"      Paramothayan NS, Lasserson TJ, Jones PW. Corticosteroids for pulmonary sarcoidosis. Cochrane Database Syst Rev 2005; :CD001114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/43/11961/abstract/13\">",
"      Paramothayan S, Jones PW. Corticosteroid therapy in pulmonary sarcoidosis: a systematic review. JAMA 2002; 287:1301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/43/11961/abstract/14\">",
"      Reich JM. Mortality of intrathoracic sarcoidosis in referral vs population-based settings: influence of stage, ethnicity, and corticosteroid therapy. Chest 2002; 121:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/43/11961/abstract/15\">",
"      Newman LS, Rose CS, Maier LA. Sarcoidosis. N Engl J Med 1997; 336:1224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/43/11961/abstract/16\">",
"      Izumi, T. Are corticosteroids harmful to sarcoidosis?. Sarcoidosis 1994; 11 Suppl 1:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/43/11961/abstract/17\">",
"      Israel HL, Gottlieb JE. Outcome of the treatment for sarcoidosis. Am J Respir Crit Care Med 1995; 151:920.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/43/11961/abstract/18\">",
"      Gottlieb JE, Israel HL, Steiner RM, et al. Outcome in sarcoidosis. The relationship of relapse to corticosteroid therapy. Chest 1997; 111:623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/43/11961/abstract/19\">",
"      Baughman RP, Judson MA, Teirstein A, et al. Presenting characteristics as predictors of duration of treatment in sarcoidosis. QJM 2006; 99:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/43/11961/abstract/20\">",
"      Turner-Warwick M, McAllister W, Lawrence R, et al. Corticosteroid treatment in pulmonary sarcoidosis: do serial lavage lymphocyte counts, serum angiotensin converting enzyme measurements, and gallium-67 scans help management? Thorax 1986; 41:903.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/43/11961/abstract/21\">",
"      Sharma OP, Colp C, Williams MH Jr. Course of pulmonary sarcoidosis with and without corticosteriod therapy as determined by pulmonary function studies. Am J Med 1966; 41:541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/43/11961/abstract/22\">",
"      Israel HL, Fouts DW, Beggs RA. A controlled trial of prednisone treatment of sarcoidosis. Am Rev Respir Dis 1973; 107:609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/43/11961/abstract/23\">",
"      Paramothayan, NS, Lasserson, TJ, Jones, P. Corticosteroids for pulmonary sarcoidosis. Cochrane Database Syst Rev 2010; :CD001114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/43/11961/abstract/24\">",
"      Harkleroad LE, Young RL, Savage PJ, et al. Pulmonary sarcoidosis. Long-term follow-up of the effects of steroid therapy. Chest 1982; 82:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/43/11961/abstract/25\">",
"      Young RL, Harkleroad LE, Lordon RE, Weg JG. Pulmonary sarcoidosis: a prospective evaluation of glucocorticoid therapy. Ann Intern Med 1970; 73:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/43/11961/abstract/26\">",
"      Pietinalho A, Tukiainen P, Haahtela T, et al. Oral prednisolone followed by inhaled budesonide in newly diagnosed pulmonary sarcoidosis: a double-blind, placebo-controlled multicenter study. Finnish Pulmonary Sarcoidosis Study Group. Chest 1999; 116:424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/43/11961/abstract/27\">",
"      Zaki MH, Lyons HA, Leilop L, Huang CT. Corticosteroid therapy in sarcoidosis. A five-year, controlled follow-up study. N Y State J Med 1987; 87:496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/43/11961/abstract/28\">",
"      DeRemee RA. The present status of treatment of pulmonary sarcoidosis: a house divided. Chest 1977; 71:388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/43/11961/abstract/29\">",
"      Hunninghake GW, Gilbert S, Pueringer R, et al. Outcome of the treatment for sarcoidosis. Am J Respir Crit Care Med 1994; 149:893.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/43/11961/abstract/30\">",
"      Bradley B, Branley HM, Egan JJ, et al. Interstitial lung disease guideline: the British Thoracic Society in collaboration with the Thoracic Society of Australia and New Zealand and the Irish Thoracic Society. Thorax 2008; 63 Suppl 5:v1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/43/11961/abstract/31\">",
"      Gibson GJ, Prescott RJ, Muers MF, et al. British Thoracic Society Sarcoidosis study: effects of long term corticosteroid treatment. Thorax 1996; 51:238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/43/11961/abstract/32\">",
"      Burns TM. Neurosarcoidosis. Arch Neurol 2003; 60:1166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/43/11961/abstract/33\">",
"      Baughman, RP, Lower, EE, Lynch, JP III. Treatment modalities for sarcoidosis. Clin Pulm Med 1994; 1:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/43/11961/abstract/34\">",
"      Schutt AC, Bullington WM, Judson MA. Pharmacotherapy for pulmonary sarcoidosis: a Delphi consensus study. Respir Med 2010; 104:717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/43/11961/abstract/35\">",
"      Sabbagh F, Gibbs C, Efferen LS. Pulmonary sarcoidosis and the acute respiratory distress syndrome (ARDS). Thorax 2002; 57:655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/43/11961/abstract/36\">",
"      Chirakalwasan N, Dallal MM. Pulmonary sarcoidosis presenting with acute respiratory failure. South Med J 2005; 98:382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/43/11961/abstract/37\">",
"      Lavergne F, Clerici C, Sadoun D, et al. Airway obstruction in bronchial sarcoidosis: outcome with treatment. Chest 1999; 116:1194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/43/11961/abstract/38\">",
"      Johns CJ, Zachary JB, Ball WC Jr. A ten-year study of corticosteroid treatment of pulmonary sarcoidosis. Johns Hopkins Med J 1974; 134:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/43/11961/abstract/39\">",
"      Fazzi P. Pharmacotherapeutic management of pulmonary sarcoidosis. Am J Respir Med 2003; 2:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/43/11961/abstract/40\">",
"      Rizzato G, Montemurro L, Colombo P. The late follow-up of chronic sarcoid patients previously treated with corticosteroids. Sarcoidosis Vasc Diffuse Lung Dis 1998; 15:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/43/11961/abstract/41\">",
"      DeRemee RA. Sarcoidosis. Mayo Clin Proc 1995; 70:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/43/11961/abstract/42\">",
"      Takada K, Ina Y, Noda M, et al. The clinical course and prognosis of patients with severe, moderate or mild sarcoidosis. J Clin Epidemiol 1993; 46:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/43/11961/abstract/43\">",
"      McKinzie BP, Bullington WM, Mazur JE, Judson MA. Efficacy of short-course, low-dose corticosteroid therapy for acute pulmonary sarcoidosis exacerbations. Am J Med Sci 2010; 339:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/43/11961/abstract/44\">",
"      Gonnelli S, Rottoli P, Cepollaro C, et al. Prevention of corticosteroid-induced osteoporosis with alendronate in sarcoid patients. Calcif Tissue Int 1997; 61:382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/43/11961/abstract/45\">",
"      Selroos OB. Use of budesonide in the treatment of pulmonary sarcoidosis. Ann N Y Acad Sci 1986; 465:713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/43/11961/abstract/46\">",
"      Alberts C, van der Mark TW, Jansen HM. Inhaled budesonide in pulmonary sarcoidosis: a double-blind, placebo-controlled study. Dutch Study Group on Pulmonary Sarcoidosis. Eur Respir J 1995; 8:682.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/43/11961/abstract/47\">",
"      Zych D, Pawlicka L, Zielinski J. Inhaled budesonide vs prednisone in the maintenance treatment of pulmonary sarcoidosis. Sarcoidosis 1993; 10:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/43/11961/abstract/48\">",
"      Milman N, Graudal N, Grode G, Munch E. No effect of high-dose inhaled steroids in pulmonary sarcoidosis: a double-blind, placebo-controlled study. J Intern Med 1994; 236:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/43/11961/abstract/49\">",
"      Spiteri MA, Newman SP, Clarke SW, Poulter LW. Inhaled corticosteroids can modulate the immunopathogenesis of pulmonary sarcoidosis. Eur Respir J 1989; 2:218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/43/11961/abstract/50\">",
"      Erkkil&auml; S, Fr&ouml;seth B, Hellstr&ouml;m PE, et al. Inhaled budesonide influences cellular and biochemical abnormalities in pulmonary sarcoidosis. Sarcoidosis 1988; 5:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/43/11961/abstract/51\">",
"      du Bois RM, Greenhalgh PM, Southcott AM, et al. Randomized trial of inhaled fluticasone propionate in chronic stable pulmonary sarcoidosis: a pilot study. Eur Respir J 1999; 13:1345.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4359 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-0E3ADE63EF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_43_11961=[""].join("\n");
var outline_f11_43_11961=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H24690322\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      OVERVIEW OF INITIAL THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      MECHANISM OF ACTION OF GLUCOCORTICOIDS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H110264147\">",
"      ORAL GLUCOCORTICOID THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H110264106\">",
"      Efficacy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Indications for therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23610885\">",
"      Extrapulmonary sarcoidosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Dosage and administration",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H110264223\">",
"      - Initial therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H110264349\">",
"      - Maintenance therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Alternate day therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H348701692\">",
"      Assessing the response",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H110264535\">",
"      Duration of therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H369563725\">",
"      Relapses",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H348702040\">",
"      Adverse effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H348701894\">",
"      Failure of therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      INHALED GLUCOCORTICOID THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      LONG-TERM OUTCOME",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24690322\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/4359\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/4359|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?9/18/9505\" title=\"figure 1\">",
"      Mechanism glucocorticoid action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/4359|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?13/22/13675\" title=\"table 1\">",
"      Stages of sarcoidosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?9/59/10173\" title=\"table 2\">",
"      Sarcoid monitoring",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?15/62/16365\" title=\"table 3\">",
"      Glucocorticoid side effects",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/19/17722?source=related_link\">",
"      Cardiac sarcoidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/45/22234?source=related_link\">",
"      Chronic beryllium disease (berylliosis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/25/21914?source=related_link\">",
"      Clinical manifestations and diagnosis of sarcoidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/17/36119?source=related_link\">",
"      Cor pulmonale",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/37/22103?source=related_link\">",
"      Glucocorticoid withdrawal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/42/7849?source=related_link\">",
"      Glucocorticoid-resistant asthma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/16/2310?source=related_link\">",
"      Hypercalcemia in granulomatous diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/47/27386?source=related_link\">",
"      Major side effects of systemic glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/8/20616?source=related_link\">",
"      Neurologic sarcoidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/14/6376?source=related_link\">",
"      Pathogenesis of sarcoidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?5/35/5683?source=related_link\">",
"      Patient information: Sarcoidosis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?20/14/20705?source=related_link\">",
"      Patient information: Sarcoidosis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/36/17994?source=related_link\">",
"      Prevention and treatment of glucocorticoid-induced osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/31/16889?source=related_link\">",
"      Pulmonary hypertension associated with interstitial lung disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/31/40438?source=related_link\">",
"      Renal disease in sarcoidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/50/31529?source=related_link\">",
"      Treatment of chronic pulmonary aspergillosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/11/38074?source=related_link\">",
"      Treatment of pulmonary sarcoidosis with alternatives to glucocorticoids",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f11_43_11962="What's new in oncology";
var content_f11_43_11962=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   What's new in oncology",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/43/11962/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/43/11962/contributors\">",
"     Don S Dizon, MD, FACP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/43/11962/contributors\">",
"     April F Eichler, MD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/43/11962/contributors\">",
"     Michael E Ross, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/43/11962/contributors\">",
"     Diane MF Savarese, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?11/43/11962/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 11, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    The following represent additions to UpToDate from the past six months that were considered by the editors and authors to be of particular interest. The most recent What's New entries are at the top of each subsection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     BREAST CANCER",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h2\">",
"     Cardiotoxicity in women with breast cancer after radiation therapy",
"    </span>",
"   </p>",
"   <p>",
"    A&nbsp;case-control study of women treated for breast cancer with surgery and radiation therapy (RT) found that incidental radiation to the heart is associated with an increased risk&nbsp;for a significant coronary event (myocardial infarction, revascularization, or death from ischemic heart disease)&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?11/43/11962/abstract/1\">",
"     1",
"    </a>",
"    ].&nbsp;The increased risk can be seen after relatively-low doses of radiation and the presence of cardiac risk factors markedly increased the impact of radiation. Despite this, the absolute risk associated with RT appears to be small and to be outweighed by the benefits in patients for whom radiation is typically recommended.&nbsp;(See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/21/34137?source=see_link&amp;anchor=H8#H8\">",
"     \"Cardiotoxicity of radiation therapy for malignancy\", section on 'Effect of radiation dose to the heart'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Detection of breast cancer near the nipple areolar complex",
"    </span>",
"   </p>",
"   <p>",
"    For women undergoing mastectomy for breast cancer who wish to preserve the nipple areolar complex (NAC), a nipple sparing procedure may be appropriate for&nbsp;selected cases&nbsp;(eg, unifocal tumor less than 2 cm in diameter, greater than 2 cm from nipple). However, the best way to assess tumor distance from the nipple is not established. &nbsp;MRI was not superior to a clinical breast examination in detecting cancer in or near the NAC in a retrospective review of 71 patients undergoing 77 mastectomy procedures, 23 percent of whom had cancer involving or within 1 cm of the NAC, confirmed histopathologically [",
"    <a class=\"abstract\" href=\"UTD.htm?11/43/11962/abstract/2\">",
"     2",
"    </a>",
"    ]. The preoperative history and physical examination detected 61 percent of&nbsp;patients with NAC involvement, while&nbsp;MRI detected 56 percent. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/18/12586?source=see_link&amp;anchor=H7005321#H7005321\">",
"     \"Mastectomy\", section on 'Nipple-sparing mastectomy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/18/12586?source=see_link&amp;anchor=H7006000#H7006000\">",
"     \"Mastectomy\", section on 'Choice of mastectomy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Adjuvant trastuzumab and the risk of brain metastases in women with HER2-positive breast cancer",
"    </span>",
"   </p>",
"   <p>",
"    Women with HER-2 positive, nonmetastatic breast cancer should receive adjuvant trastuzumab in addition to chemotherapy. However, concern has been raised that women treated with adjuvant trastuzumab are at aincreased&nbsp;risk&nbsp;for brain metastasis.&nbsp;This increased risk was not confirmed in a retrospective study reviewing data from a large randomized trial of trastuzumab versus observation&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?11/43/11962/abstract/3\">",
"     3",
"    </a>",
"    ]. In addition, adjuvant trastuzumab use was associated with a lower incidence of CNS events in subsequent years compared to those who were not treated with trastuzumab (47 versus 57 percent, respectively), although this difference was not statistically significant. These data support the use of trastuzumab in the adjuvant setting for HER2-positive breast cancer. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/0/19464?source=see_link&amp;anchor=H2#H2\">",
"     \"Management of brain metastases in breast cancer\", section on 'Risk factors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Repeat sentinel lymph node dissection after previous axillary procedures",
"    </span>",
"   </p>",
"   <p>",
"    Repeat sentinel lymph node dissection (SLND) in patients with recurrent breast&nbsp;cancer&nbsp;had not been&nbsp;well studied. In a retrospective review of 150 patients with a previous SLND or axillary lymph node dissection (ALND), lymphatic mapping (lymphoscintigraphy) using 99mTc-colloidal albumin identified a sentinel node in 63 percent, and the sentinel node was successfully removed in 52 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?11/43/11962/abstract/4\">",
"     4",
"    </a>",
"    ]. Micrometastases were identified in 18 patients (23 percent), and a confirmation ALND in all 18 patients identified no additional positive axillary lymph nodes. Thus, repeat SLND&nbsp;appears to be technically feasible, and we suggest use of this procedure in patients who have recurrent breast cancer and previous axillary procedures. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/47/36602?source=see_link&amp;anchor=H10349110#H10349110\">",
"     \"Sentinel lymph node dissection for breast cancer: Indications and outcomes\", section on 'Recurrent breast cancer and previous axillary procedures'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     CYP2D6 genotypes, SSRIs, and breast cancer treatment with tamoxifen",
"    </span>",
"   </p>",
"   <p>",
"    Tamoxifen is converted to its active metabolites by two rate-limiting enzymes, cytochrome P450 2D6 (CYP2D6) and UDP-glucuronyltransferase-2B7 (UGT2B7). An unplanned analysis of a large randomized trial in women with breast cancer showed&nbsp;that poor metabolizers (defined by the presence of specific CYP2D6 genotypes)&nbsp;had a significantly higher risk of a breast cancer event (recurrence, contralateral breast or second non-breast cancer, or death) compared to&nbsp;faster metabolizers during treatment with tamoxifen&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?11/43/11962/abstract/5\">",
"     5",
"    </a>",
"    ]. Although the relationship between CYP2D6 metabolism and breast cancer outcomes for women on tamoxifen have not been consistently demonstrated, we prefer not to treat&nbsp;breast cancer&nbsp;patients with agents that are known to be potent or moderate CYP2D6&nbsp;inhibitors (eg, some selective serotonin reuptake inhibitors). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/2/7210?source=see_link&amp;anchor=H125175232#H125175232\">",
"     \"Mechanisms of action of selective estrogen receptor modulators\", section on 'Altered tamoxifen metabolism'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Lapatinib following adjuvant chemotherapy for HER2-positive breast cancer",
"    </span>",
"   </p>",
"   <p>",
"    For women with human epidermal growth factor 2 (HER2)-positive breast cancer, standard adjuvant&nbsp;treatment consists of trastuzumab plus chemotherapy.&nbsp;The results of a phase III trial suggest that the oral HER2-directed agent,&nbsp;lapatinib,&nbsp;should not be used instead of&nbsp;trastuzumab in the adjuvant setting [",
"    <a class=\"abstract\" href=\"UTD.htm?11/43/11962/abstract/6\">",
"     6",
"    </a>",
"    ]. In this trial,&nbsp;women with stage I to III HER2-positive breast cancer who had completed adjuvant chemotherapy were randomly assigned to lapatinib or observation. With a median follow-up of approximately four years, there was no difference in recurrence rates&nbsp;or overall survival with the addition of lapatinib. We await the results of the Adjuvant Lapatinib",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    Trastuzumab Treatment Optimization (ALTTO) study to evaluate if the combination of lapatinib plus trastuzumab improves outcomes compared to either agent administered alone. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/7/11384?source=see_link&amp;anchor=H330927470#H330927470\">",
"     \"Adjuvant medical therapy for HER2-positive breast cancer\", section on 'Lapatinib'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Lapatinib plus capecitabine for brain metastases in patients with HER2-positive breast cancer",
"    </span>",
"   </p>",
"   <p>",
"    The standard treatment for patients with brain metastases from breast cancer is radiation therapy (RT). However, the results of a single-arm phase II trial suggest that for women with human epidermal growth factor 2 (HER2)-positive breast cancer, systemic treatment&nbsp;using&nbsp;the&nbsp;oral HER2-directed agent, lapatinib,&nbsp;may&nbsp;be a reasonable alternative to RT [",
"    <a class=\"abstract\" href=\"UTD.htm?11/43/11962/abstract/7\">",
"     7",
"    </a>",
"    ].&nbsp;In the LANDSCAPE trial,&nbsp;women with previously untreated brain metastases from HER2-positive metastatic disease received&nbsp;lapatinib plus capecitabine. Treatment&nbsp;resulted in a high response rate although there was also substantial toxicity (eg, diarrhea and hand-foot syndrome). Over 90 percent of these patients were alive at six months. These data suggest that the combination of lapatinib and capecitabine is active as a first-line treatment for patients with brain metastases from HER2-positive breast cancer. Whether lapatinib plus capecitabine should be the preferred regimen in the first-line treatment of these&nbsp;patients requires further evaluation comparing this combination to&nbsp;whole brain RT. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/35/44601?source=see_link&amp;anchor=H11#H11\">",
"     \"Treatment of brain metastases in favorable prognosis patients\", section on 'Efficacy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/35/44601?source=see_link&amp;anchor=H17#H17\">",
"     \"Treatment of brain metastases in favorable prognosis patients\", section on 'WBRT after definitive therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Duration of adjuvant tamoxifen for breast cancer",
"    </span>",
"   </p>",
"   <p>",
"    For women taking tamoxifen as adjuvant therapy for breast cancer, the usual recommendation is for a five year course of therapy. However, the results of the Adjuvant Tamoxifen: Longer Against Shorter (ATLAS) trial found that women who took tamoxifen for ten years had a significantly lower risk of recurrence and mortality compared to women who took tamoxifen for five years [",
"    <a class=\"abstract\" href=\"UTD.htm?11/43/11962/abstract/8\">",
"     8",
"    </a>",
"    ]. A longer course of tamoxifen, however, also resulted in a significantly higher incidence of adverse events including endometrial cancer, pulmonary embolus, and ischemic heart disease. Overall, these results support the use of tamoxifen for ten years in women who are tolerating treatment rather than five years. This is particularly true for patients with a relatively higher risk of recurrence based on their tumor characteristics (ie, pathological node involvement, large tumor size, or high tumor grade). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/40/20106?source=see_link\">",
"     \"Adjuvant endocrine therapy for hormone receptor-positive breast cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Chemotherapy following resection of a locoregional breast cancer recurrence",
"    </span>",
"   </p>",
"   <p>",
"    The administration of chemotherapy following resection of a locoregional breast cancer recurrence was controversial because of limited data showing a benefit in survival. However, the results of the Chemotherapy as Adjuvant for LOcally Recurrent breast cancer (CALOR) trial, presented at the 2012 San Antonio Breast Cancer Conference, support the use of post-excision (or adjuvant) treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?11/43/11962/abstract/9\">",
"     9",
"    </a>",
"    ]. In the CALOR trial, patients who underwent surgical resection of locally recurrent breast cancer were randomly assigned to adjuvant chemotherapy or to no treatment. Compared to no treatment, adjuvant chemotherapy resulted in a significant improvement in disease-free (DFS) and overall survival (OS) at five years. However, when stratified by hormone-receptor status, a significant benefit in DFS with adjuvant chemotherapy was reported for women with estrogen receptor (ER)-negative disease, but not ER-positive disease. While only presented in abstract form, these data support the use of chemotherapy in women with breast cancer following resection for locoregional recurrence, particularly for ER-negative disease. We await the full publication to inform the role of adjuvant chemotherapy for women with ER-positive disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/45/30426?source=see_link&amp;anchor=H35227675#H35227675\">",
"     \"Management of locoregional recurrence of breast cancer after mastectomy\", section on 'Chemotherapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Tamoxifen therapy for men with breast cancer",
"    </span>",
"   </p>",
"   <p>",
"    Five years of tamoxifen is recommended for men diagnosed with hormone receptor-positive breast cancer. Data about compliance in men are limited. In a study of 116 men, adherence rates fell from 65 percent at year 1 to 18 percent by year 5 [",
"    <a class=\"abstract\" href=\"UTD.htm?11/43/11962/abstract/10\">",
"     10",
"    </a>",
"    ]. Compared with men who were adherent to tamoxifen, low-adherence was associated with significantly lower rates of disease-free survival (42 versus 73 percent) and overall survival (50 versus 80 percent) at 10 years. Significant factors associated with low adherence included age &le;60 years, lack of social support, and adverse effects. Over 60 percent experienced adverse effects, including fatigue, anxiety, sleep disorders, decreased libido, and weight gain. Thus, the tolerability of tamoxifen may significantly limit its efficacy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/36/26186?source=see_link&amp;anchor=H954644#H954644\">",
"     \"Breast cancer in men\", section on 'Tamoxifen'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Ado-trastuzumab emtansine as second-line treatment for HER2-positive metastatic breast cancer",
"    </span>",
"   </p>",
"   <p>",
"    There are multiple options for women with HER2-positive metastatic breast cancer. In February 2013, the US Food and Drug Administration (FDA)&nbsp;approved ado-trastuzumab emtansine (trastuzumab emtansine or T-DM1) for use in&nbsp;women with HER2-positive metastatic breast cancer who experienced disease progression on a trastuzumab containing regimen. FDA approval was based on a phase III trial that assigned almost 980 women previously treated with trastuzumab plus a taxane to treatment with T-DM1 or to capecitabine plus lapatinib [",
"    <a class=\"abstract\" href=\"UTD.htm?11/43/11962/abstract/11\">",
"     11",
"    </a>",
"    ]. T-DM1 significantly improved the overall response rate, progression-free survival, and overall survival compared to capecitabine plus lapatinib. These data support the administration of T-DM1 for women with disease progression following trastuzumab-containing treatment. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/43/22202?source=see_link&amp;anchor=H720673240#H720673240\">",
"     \"Systemic treatment for metastatic breast cancer: Molecular targeted therapy\", section on 'Ado-trastuzumab emtansine'",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/16/11527?source=see_link\">",
"     \"Ado-trastuzumab emtansine: Drug information\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Reactivation of ovarian function with aromatase inhibitors",
"    </span>",
"   </p>",
"   <p>",
"    The aromatase inhibitors (AIs) are commonly administered to postmenopausal women with hormone receptor-positive breast cancer. However, their use in premenopausal women is contraindicated because of concerns that AIs may induce ovarian reactivation and negatively impact breast cancer survival. In a study of women with breast cancer and chemotherapy-induced amenorrhea who began treatment with tamoxifen (for at least two years) and then were changed to the AI exemestane, 32 percent experienced resumption of ovarian function [",
"    <a class=\"abstract\" href=\"UTD.htm?11/43/11962/abstract/12\">",
"     12",
"    </a>",
"    ]. Compared to those who did not resume ovarian function, those who recovered ovarian function had a significantly lower two-year disease free survival rate. Although this was a relatively small study, it supports the risk of ovarian reactivation from AIs. Therefore, AIs should not be used in premenopausal women, even in those with chemotherapy-induced amenorrhea. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/40/20106?source=see_link&amp;anchor=H5674202#H5674202\">",
"     \"Adjuvant endocrine therapy for hormone receptor-positive breast cancer\", section on 'Reactivation of ovarian function'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Locoregional recurrence after breast conservation therapy",
"    </span>",
"   </p>",
"   <p>",
"    Repeat breast conserving therapy (BCT) is an investigational alternative to mastectomy for patients who experience a local recurrence. A retrospective study concluded that this approach was appropriate for patients with tumor size &le;2 cm and &gt;48 months to relapse [",
"    <a class=\"abstract\" href=\"UTD.htm?11/43/11962/abstract/13\">",
"     13",
"    </a>",
"    ]. In this study, 161 patients who were treated with breast conserving surgery for recurrent tumors &le;2 cm and &gt;48 months time to relapse had significantly fewer second recurrences compared with patients with tumors &gt;2 cm and &lt;48 months time to relapse (15.2 versus 31.2 percent). In addition, 71.2 percent of patients with tumors &gt;2 cm treated with repeat breast conserving surgery had a second recurrence, regardless of time to relapse interval. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/53/34650?source=see_link&amp;anchor=H16#H16\">",
"     \"Management of locoregional recurrence of breast cancer after breast conserving therapy\", section on 'Breast conserving surgery'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     CANCER SCREENING AND PREVENTION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Aspirin for the primary prevention of cardiovascular disease and cancer",
"    </span>",
"   </p>",
"   <p>",
"    Meta-analyses of randomized trials have shown aspirin to reduce the risk of non-fatal myocardial infarction [",
"    <a class=\"abstract\" href=\"UTD.htm?11/43/11962/abstract/14\">",
"     14",
"    </a>",
"    ],&nbsp;and long-term aspirin use reduces overall cancer risk [",
"    <a class=\"abstract\" href=\"UTD.htm?11/43/11962/abstract/15\">",
"     15",
"    </a>",
"    ]. While several published guidelines have considered the benefit of aspirin for&nbsp;the prevention of either cardiovascular disease (CVD)&nbsp;or cancer versus&nbsp;the risk of increased bleeding, most have not addressed the&nbsp;potential net benefit of aspirin in preventing both CVD and cancer.&nbsp;A meta-analysis addressing this combined outcome suggests that aspirin use in 1000 average risk patients at age 60 years would be expected to result, over a 10-year period, in&nbsp;six fewer deaths, 19 fewer non-fatal myocardial infarctions, 14 fewer cancers, and 16 more major bleeding events (",
"    <a class=\"graphic graphic_table graphicRef86941 \" href=\"UTD.htm?39/47/40702\">",
"     table 1",
"    </a>",
"    ).&nbsp;For individuals age 50 years or greater without excess bleeding risks, we suggest daily aspirin at a dose of 75 to 100 mg. Patients who are more concerned about the bleeding risks than the potential benefits may reasonably choose to not take aspirin for primary prevention. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/62/23529?source=see_link&amp;anchor=H1761594#H1761594\">",
"     \"Aspirin in the primary prevention of cardiovascular disease and cancer\", section on 'Recommendations for primary prevention'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Screening colonoscopy and incidence of late stage colorectal cancer",
"    </span>",
"   </p>",
"   <p>",
"    There are no randomized trials of the effectiveness of screening colonoscopy in average-risk patients, and some observational data suggest that colonoscopy might not be effective in detecting right-sided (proximal) colon lesions. In a case-control study in four health plans in the United States in which rates of screening colonoscopy were low in both cases and matched controls (reflecting practice patterns going back 17 years), late stage (IIb or higher) colorectal cancer was associated with failure to undergo screening colonoscopy [",
"    <a class=\"abstract\" href=\"UTD.htm?11/43/11962/abstract/16\">",
"     16",
"    </a>",
"    ]. The association was the same for right- and left-sided cancers. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/9/38042?source=see_link&amp;anchor=H16#H16\">",
"     \"Tests for screening for colorectal cancer: Stool tests, radiologic imaging and endoscopy\", section on 'Evidence of effectiveness'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Screening women with a familial ovarian cancer syndrome for ovarian cancer",
"    </span>",
"   </p>",
"   <p>",
"    In the largest cohort study of high-risk women, the United Kingdom Familial Ovarian Cancer Screen Study (UK FOCSS), 3563 women with a familial ovarian cancer syndrome (estimated minimum lifetime risk of 10 percent) who had declined or deferred risk reducing salpingo-oophorectomy (RRSO) were screened annually for a mean of 3.2 years with a combination of transvaginal ultrasound and CA-125 [",
"    <a class=\"abstract\" href=\"UTD.htm?11/43/11962/abstract/17\">",
"     17",
"    </a>",
"    ]. Sensitivity for the detection of incident ovarian",
"    <span class=\"nowrap\">",
"     cancer/fallopian",
"    </span>",
"    tube cancer was 81.0 to 87.5 percent. The positive predictive value of incident screening was 25.5 percent, which exceeds the threshold of 10 percent considered necessary for ovarian cancer screening. 30.8 percent (4 of 13) of incident cancers were stage I or II.&nbsp;",
"    <br/>",
"    <br/>",
"    Although&nbsp;RRSO&nbsp;remains the only reliable method of decreasing mortality from ovarian cancer in this high-risk population, this study suggests that screening&nbsp;has the potential to somewhat reduce risk for women who wish to maintain their childbearing potential until they are ready to undergo surgery. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/14/10474?source=see_link&amp;anchor=H17#H17\">",
"     \"Screening for ovarian cancer\", section on 'High-risk women'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Rescreening for colorectal cancer",
"    </span>",
"   </p>",
"   <p>",
"    Although colonoscopy is frequently chosen for the first-round of screening for colorectal cancer (CRC), the choice of screening modality following an initial negative study may differ. Since the risk of disease is significantly lower for second-round screening and beyond, options for subsequent testing may include no screening or testing using less-invasive or less-costly modalities. In the absence of trial data, a computer simulation model found that, compared with no screening, rescreening by any method following an initial negative colonoscopy reduced the risk of CRC&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?11/43/11962/abstract/18\">",
"     18",
"    </a>",
"    ]. Rescreening with colonoscopy was projected to cause more complications and greater cost compared&nbsp;with other modalities (highly sensitive stool guaiac, fecal immunochemical testing, or CT colonography), with equivalent benefit measured as life-years. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/10/37034?source=see_link&amp;anchor=H3759928#H3759928\">",
"     \"Screening for colorectal cancer: Strategies in patients at average risk\", section on 'Other factors that may impact screening test choice'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     CANCER SURVIVORSHIP",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     ASCO promoted a shared care model for cancer survivorship",
"    </span>",
"   </p>",
"   <p>",
"    The Cancer Survivorship Committee of the&nbsp;American Society of Clinical Oncology has issued a statement&nbsp;regarding management of cancer survivors [",
"    <a class=\"abstract\" href=\"UTD.htm?11/43/11962/abstract/19\">",
"     19",
"    </a>",
"    ]. The&nbsp;committee encouraged a&nbsp;shared-care model for cancer survivorship care, which uses a risk-stratified approach and aims to help patients transition from an oncology to a primary care posttreatment setting. Strategies are presented to ensure that every cancer survivor receives a written coordinated treatment summary and follow-up care plan. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/6/32873?source=see_link&amp;anchor=H418030697#H418030697\">",
"     \"Overview of cancer survivorship care for primary care and oncology providers\", section on 'Shared care'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     GASTROINTESTINAL CANCER",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Multiple pancreatic cysts and risk for high-grade dysplasia or invasive cancer",
"    </span>",
"   </p>",
"   <p>",
"    Typically, pancreatic resection (partial or total) is recommended for patients with pancreatic cysts&nbsp;and features that&nbsp;suggest an increased risk for malignancy&nbsp;(eg, main pancreatic duct dilation to 10 mm or more, mural nodularity, or wall thickening). However, some data suggest that patients with multiple pancreatic cysts may have high-grade dysplasia or invasive carcinoma, even in the absence of worrisome computed tomographic (CT) findings [",
"    <a class=\"abstract\" href=\"UTD.htm?11/43/11962/abstract/20\">",
"     20",
"    </a>",
"    ]. In a retrospective study of 43 patients with &ge;4 pancreatic&nbsp;cysts who underwent resection, 7 patients (16 percent) lacked worrisome CT findings but were found to have high-grade dysplasia or invasive carcinoma on pathologic examination. If these findings are confirmed in prospective studies, it may be reasonable to consider total pancreatectomy for young patients with multiple cysts who are good surgical candidates.&nbsp;(See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/49/41753?source=see_link&amp;anchor=H5510679#H5510679\">",
"     \"Diagnosis and treatment of intraductal papillary mucinous neoplasm of the pancreas\", section on 'Surgery'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Regorafenib for refractory GIST",
"    </span>",
"   </p>",
"   <p>",
"    In February 2013, regorafenib, an orally active tyrosine kinase inhibitor (TKI) that targets a variety of kinases including KIT, was approved in the United States for treatment of advanced gastrointestinal stromal tumors (GIST) that no longer respond to imatinib or sunitinib. The efficacy of regorafenib&nbsp;in&nbsp;this setting&nbsp;was shown in a phase III trial in which 199 patients with imatinib- and sunitinib-refractory GIST were randomly assigned to best supportive care plus regorafenib or placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?11/43/11962/abstract/21\">",
"     21",
"    </a>",
"    ]. Regorafenib was associated with significantly better&nbsp;progression free survival (4.8 versus 0.9 months).&nbsp;(See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/58/34730?source=see_link&amp;anchor=H355376706#H355376706\">",
"     \"Tyrosine kinase inhibitor therapy for advanced gastrointestinal stromal tumors\", section on 'Regorafenib'",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/16/32006?source=see_link\">",
"     \"Regorafenib: Drug information\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Revised listing criteria for liver transplantation in patients with cirrhosis and HCC",
"    </span>",
"   </p>",
"   <p>",
"    Orthotopic liver transplantation (OLT)&nbsp;is the only potentially curative treatment for hepatocellular cancer (HCC) arising in a cirrhotic liver that is not amenable to resection.&nbsp;To be eligible for OLT, and to receive exception MELD (Model for End Stage Liver Disease) points to prioritize for donor organ allocation,&nbsp;patients with HCC must meet strict criteria developed by the Organ Procurement and Transplantation",
"    <span class=\"nowrap\">",
"     Network/United",
"    </span>",
"    Network for Organ Sharing",
"    <span class=\"nowrap\">",
"     (OPTN/UNOS).&nbsp;A",
"    </span>",
"    prelisting biopsy is not mandatory; however,&nbsp;patients must have imaging findings that are consistent with HCC.",
"    <br/>",
"    <br/>",
"    The UNOS allocation policy previously included vague language as to acceptable imaging findings.&nbsp;However, as of December 2012, there are specific imaging criteria for HCC diagnosis and classification in cirrhotic livers&nbsp;(",
"    <a class=\"graphic graphic_table graphicRef87919 \" href=\"UTD.htm?39/30/40428\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/43/11962/abstract/22\">",
"     22",
"    </a>",
"    ]. OPTN Class 5 nodules correspond to an imaging diagnosis of HCC. Class 5B and 5T nodules are eligible for prioritization with a higher MELD score. A single OPTN Class 5A nodule corresponds to a&nbsp;T1 stage HCC and does not qualify for automatic priority MELD points. However, combinations of two to three class 5A nodules that meet stage T2 criteria are eligible for prioritization. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/32/36362?source=see_link&amp;anchor=H713421#H713421\">",
"     \"Liver transplantation for hepatocellular carcinoma\", section on 'United States'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Gemcitabine plus nab-paclitaxel for metastatic pancreatic cancer",
"    </span>",
"   </p>",
"   <p>",
"    The&nbsp;optimal chemotherapy regimen for patients with metastatic pancreatic cancer&nbsp;is not established. The previously published ACCORD-11 trial established the superiority of the four-drug regimen FOLFIRINOX&nbsp;over&nbsp;gemcitabine monotherapy (median survival 11.1 versus 6.8 months) in patients with an excellent performance status and normal or near-normal total bilirubin levels, but at the cost of significant treatment-related toxicity. The combination of weekly&nbsp;nanoparticle albumin-bound (nab)&nbsp;paclitaxel followed by gemcitabine was directly compared to weekly gemcitabine alone in 861 patients with previously untreated metastatic pancreatic adenocarcinoma in the multinational MPACT trial [",
"    <a class=\"abstract\" href=\"UTD.htm?11/43/11962/abstract/23\">",
"     23",
"    </a>",
"    ]. In a preliminary report presented at the 2013 ASCO GI Cancers Symposium, combined therapy was associated with significantly higher objective response rate and significantly longer median overall survival (8.5 versus 6.7 months). Grade 3 or 4 adverse events that were seen more often with combined therapy included neutropenia, fatigue, and neuropathy.&nbsp;",
"    <br/>",
"    <br/>",
"    For patients with a good performance status who are willing to sacrifice some survival benefit for a potentially less toxic regimen, gemcitabine plus nab paclitaxel represents an&nbsp;acceptable alternative to FOLFIRINOX. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/12/39114?source=see_link&amp;anchor=H24#H24\">",
"     \"Chemotherapy for advanced exocrine pancreatic cancer\", section on 'Gemcitabine plus a taxane'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Adjuvant S-1 for resected pancreatic cancer",
"    </span>",
"   </p>",
"   <p>",
"    The optimal approach to adjuvant therapy after resection of pancreatic cancer is debated; in the United States, chemoradiotherapy followed by single agent gemcitabine is the most common approach, whereas in Europe and elsewhere, chemotherapy alone (typically with gemcitabine monotherapy)&nbsp;is preferred.&nbsp;S-1 is an oral fluoropyrimidine that is approved in Japan for adjuvant treatment of gastric cancer and in Europe for treatment of advanced gastric cancer; it is not available in the United States. S-1 was directly compared to gemcitabine in a noninferiority&nbsp;trial conducted in 378 Japanese patients with resected pancreatic cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?11/43/11962/abstract/24\">",
"     24",
"    </a>",
"    ]. In a preliminary report presented at the 2013 ASCO Gastrointestinal Cancers Symposium, S-1 was not inferior to gemcitabine in terms of survival, and&nbsp;there was some suggestion&nbsp;that S-1 might be superior&nbsp;(two-year survival rate 70 versus 53 percent). Although both treatments were associated with similarly low rates of grade 3 or 4 anorexia, thrombocytopenia, and anemia, gemcitabine was associated with more leukopenia&nbsp;and transaminitis.",
"    <br/>",
"    <br/>",
"    Where available, S-1 represents a reasonable and more convenient alternative to gemcitabine when adjuvant chemotherapy alone is recommended following resection of a pancreatic cancer. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/33/22042?source=see_link&amp;anchor=H1309507546#H1309507546\">",
"     \"Adjuvant and neoadjuvant therapy for exocrine pancreatic cancer\", section on 'Gemcitabine versus S-1'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Universal tumor testing for Lynch syndrome",
"    </span>",
"   </p>",
"   <p>",
"    A number of different strategies have been proposed to identify patients with colorectal cancer (CRC) who are at risk for Lynch syndrome (hereditary nonpolyposis colorectal cancer). One of the largest studies to compare the performance characteristics of universal tumor testing (testing all colorectal cancers for microsatellite instability or loss of mismatch repair proteins by immunohistochemistry) with other strategies included over 10,000 patients with CRC&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?11/43/11962/abstract/25\">",
"     25",
"    </a>",
"    ].&nbsp;While universal tumor testing had a higher diagnostic yield compared to a &ldquo;selective strategy&rdquo; of testing individuals who met one or more Bethesda guidelines or were diagnosed with CRC prior to age 70, the incremental diagnostic yield of universal testing over the selective strategy was small (0.11 percent). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/59/19386?source=see_link&amp;anchor=H16#H16\">",
"     \"Clinical features and diagnosis of Lynch syndrome (hereditary nonpolyposis colorectal cancer)\", section on 'Universal testing strategies'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     GENITOURINARY ONCOLOGY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Intermittent versus continuous androgen deprivation for hormone sensitive metastatic prostate cancer",
"    </span>",
"   </p>",
"   <p>",
"    An intergroup trial compared intermittent androgen deprivation (IAD) with continuous androgen deprivation therapy (ADT) for its impact on overall survival and quality of life in patients with metastatic, hormone sensitive prostate cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?11/43/11962/abstract/26\">",
"     26",
"    </a>",
"    ]. After an initial course of ADT, patients were randomly assigned to either continuous ADT or to a break in treatment (IAD), with ADT resumed when disease progressed.&nbsp;Survival appeared to be worse with the IAD regimen, although this was statistically nonsignificant and the confidence interval was wide. Improvements in quality of life with IAD were small and transient. Continuous ADT remains the standard of care for patients with metastatic disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/20/1353?source=see_link&amp;anchor=H261289169#H261289169\">",
"     \"Initial hormone therapy for metastatic prostate cancer\", section on 'Metastatic disease'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Zoledronic acid in castration sensitive prostate cancer with bone metastases",
"    </span>",
"   </p>",
"   <p>",
"    Zoledronic acid delays the onset of skeletal related events (spinal cord compression, pathologic bone fracture, or need for external beam RT)&nbsp;in men with bone metastases from castration resistant prostate cancer. However, the initial report from the CALGB 90202 randomized trial that compared zoledronic acid with placebo found no statistically-significant difference in the time to first skeletal related event or in overall survival in&nbsp;men with castration sensitive disease [",
"    <a class=\"abstract\" href=\"UTD.htm?11/43/11962/abstract/27\">",
"     27",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/8/36999?source=see_link&amp;anchor=H19251602#H19251602\">",
"     \"Management of bone metastases in advanced prostate cancer\", section on 'Effect on progression of bone metastasis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Axitinib as first-line treatment of metastatic renal cell carcinoma",
"    </span>",
"   </p>",
"   <p>",
"    Axitinib is an orally available inhibitor of the vascular endothelial growth factor receptors (VEGFR 1, 2, and 3) and is&nbsp;currently approved in the US as a second-line treatment of patients with metastatic renal cell carcinoma (RCC). The results of a randomized trial comparing axitinib and sorafenib in previously untreated patients were presented at the 2013 Genitourinary Cancers Symposium [",
"    <a class=\"abstract\" href=\"UTD.htm?11/43/11962/abstract/28\">",
"     28",
"    </a>",
"    ].&nbsp;Compared to sorafenib, axitinib resulted in a higher median progression-free survival, although&nbsp;this did not reach statistical significance. Axitinib also&nbsp;resulted in a higher overall response rate but&nbsp;was associated with more adverse events. Based on these data, axitinib appears to be another option for the first-line treatment of metastatic RCC. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/32/28170?source=see_link&amp;anchor=H465740478#H465740478\">",
"     \"Anti-angiogenic and molecularly targeted therapy for advanced renal cell carcinoma\", section on 'First-line setting'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Adjuvant non-platinum therapy for muscle invasive bladder cancer",
"    </span>",
"   </p>",
"   <p>",
"    For highly selected patients with locally advanced bladder cancer (especially&nbsp;those with&nbsp;pathologically confirmed node involvement), cisplatin-based chemotherapy is often recommended.&nbsp;The limited available&nbsp;data suggest that non-platinum based therapy should not be administered. In a phase III trial presented at the 2013 Genitourinary&nbsp;Cancers Symposium, patients who underwent a radical cystectomy for locally advanced bladder cancer were randomly assigned to treatment with adjuvant gemcitabine or to gemcitabine at the time of disease progression [",
"    <a class=\"abstract\" href=\"UTD.htm?11/43/11962/abstract/29\">",
"     29",
"    </a>",
"    ]. Although the adjuvant administration of gemcitabine increased the&nbsp;rates of progression-free, cancer specific,&nbsp;and overall survival at three years, none of these results reached statistical significance. This study supports continued evaluation of non-platinum based adjuvant treatment in clinical trials, but does not justify&nbsp;its routine administration in this population. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/4/29766?source=see_link&amp;anchor=H1490335977#H1490335977\">",
"     \"Adjuvant chemotherapy for muscle invasive urothelial (transitional cell) carcinoma of the bladder\", section on 'Non-platinum based treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     Initial systemic therapy in hormone sensitive prostate cancer",
"    </span>",
"   </p>",
"   <p>",
"    Androgen deprivation therapy (ADT) is the standard of care for systemic treatment of metastatic hormone sensitive prostate cancer; chemotherapy is used in combination with ADT when disease becomes castrate resistant. A phase III trial in men with hormone sensitive metastatic prostate cancer compared ADT plus docetaxel versus ADT alone; the combination did not significantly improve overall survival and was associated with increased toxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?11/43/11962/abstract/30\">",
"     30",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/12/10442?source=see_link&amp;anchor=H456228329#H456228329\">",
"     \"Overview of the treatment of disseminated prostate cancer\", section on 'ADT plus chemotherapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h2\">",
"     Proton beam therapy for prostate cancer",
"    </span>",
"   </p>",
"   <p>",
"    There are no randomized trials that compare proton beam therapy with contemporary conformal radiation therapy (RT) techniques such as intensity modulated RT (IMRT) for the definitive treatment of localized prostate cancer. Three retrospective studies [",
"    <a class=\"abstract\" href=\"UTD.htm?11/43/11962/abstract/31-33\">",
"     31-33",
"    </a>",
"    ] and a systematic review of the available evidence from the American Society of Radiation Oncology [",
"    <a class=\"abstract\" href=\"UTD.htm?11/43/11962/abstract/34\">",
"     34",
"    </a>",
"    ] have not found that proton beam therapy results in a clinically meaningful improvement in either efficacy or toxicity compared with either IMRT or brachytherapy, despite the higher costs associated with proton beam therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/47/23290?source=see_link&amp;anchor=H2#H2\">",
"     \"External beam radiation therapy for localized prostate cancer\", section on 'External beam RT techniques'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h2\">",
"     Abiraterone in metastatic prostate cancer",
"    </span>",
"   </p>",
"   <p>",
"    Two phase III trials provide insight into the efficacy of abiraterone in men with castrate resistant metastatic prostate cancer:",
"    <br/>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a phase III trial in men who had received prior docetaxel chemotherapy, abiraterone plus prednisone significantly prolonged overall survival compared with placebo plus prednisone [",
"      <a class=\"abstract\" href=\"UTD.htm?11/43/11962/abstract/35\">",
"       35",
"      </a>",
"      ]. In secondary analyses, treatment with abiraterone resulted in better pain palliation and a statistically significant delay in the time to skeletal related complications (pathologic fracture, spinal cord compression, or palliative radiation therapy",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      surgery to bone) [",
"      <a class=\"abstract\" href=\"UTD.htm?11/43/11962/abstract/36\">",
"       36",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/7/16503?source=see_link&amp;anchor=H1135663811#H1135663811\">",
"       \"Castrate resistant prostate cancer: Treatments targeting the androgen pathway\", section on 'Prior docetaxel chemotherapy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A planned interim analysis from a phase III trial found that abiraterone plus prednisone prolonged progression-free survival and overall survival compared with placebo plus prednisone in men with asymptomatic or minimal symptomatic castration resistant prostate cancer who had not received prior docetaxel chemotherapy [",
"      <a class=\"abstract\" href=\"UTD.htm?11/43/11962/abstract/37\">",
"       37",
"      </a>",
"      ]. This trial formed the basis for the US Food and Drug Administration extension of the indication for abiraterone to include all patients with metastatic castration resistant disease [",
"      <a class=\"abstract\" href=\"UTD.htm?11/43/11962/abstract/38\">",
"       38",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/7/16503?source=see_link&amp;anchor=H1135663818#H1135663818\">",
"       \"Castrate resistant prostate cancer: Treatments targeting the androgen pathway\", section on 'Chemotherapy naive patients'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h1\">",
"     GYNECOLOGIC ONCOLOGY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h2\">",
"     Adjuvant treatment of intermediate-risk early stage cervical cancer",
"    </span>",
"   </p>",
"   <p>",
"    Some women with early stage cervical cancer and&nbsp;factors such as lymphovascular space invasion,&nbsp;cervical stromal",
"    <span class=\"nowrap\">",
"     invasion,&nbsp;and/or",
"    </span>",
"    large tumor size are felt to have intermediate-risk disease, for which&nbsp;adjuvant&nbsp;radiation therapy (RT)&nbsp;is indicated. Whether chemotherapy plus&nbsp;RT would improve outcomes in these women is not known. In a retrospective study of almost 130 patients, chemoradiation resulted in a lower rate of recurrence and a higher rate of progression-free survival at five years compared to&nbsp;RT alone, but&nbsp;was not associated with an improvement in overall survival&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?11/43/11962/abstract/39\">",
"     39",
"    </a>",
"    ]. In the absence of high quality data to inform both the benefits and the risks of chemoradiation following hysterectomy in these patients, we prefer RT as a single modality adjuvant treatment. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/14/9449?source=see_link&amp;anchor=H618915851#H618915851\">",
"     \"Management of early stage cervical cancer\", section on 'Treatment of intermediate-risk disease'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39\">",
"    <span class=\"h2\">",
"     PET/CT scan in the work-up of suspected recurrent endometrial cancer",
"    </span>",
"   </p>",
"   <p>",
"    Although surveillance imaging is not used for asymptomatic women after treatment for endometrial cancer, imaging should be performed for patients who are symptomatic or have abnormal findings on physical examination. For women suspected of having recurrent disease, positron emissions tomography (PET) scan is a reasonable imaging study. This is supported by a&nbsp;2013 meta-analysis that showed PET (particularly when performed with computerized tomography) had excellent sensitivity and specificity in this setting [",
"    <a class=\"abstract\" href=\"UTD.htm?11/43/11962/abstract/40\">",
"     40",
"    </a>",
"    ].&nbsp;(See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/7/21624?source=see_link&amp;anchor=H1048815#H1048815\">",
"     \"Overview of endometrial carcinoma\", section on 'Surveillance protocols'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H40\">",
"    <span class=\"h2\">",
"     Hormone receptor expression and prognosis in ovarian cancer",
"    </span>",
"   </p>",
"   <p>",
"    Hormone receptor expression is a prognostic factor in breast cancer, but whether it is a prognostic factor in ovarian cancer is unclear. The results of a 2013&nbsp;meta-analysis indicate that while high progesterone receptor expression is associated with improved overall&nbsp;survival in patients with ovarian cancer, estrogen receptor expression is not [",
"    <a class=\"abstract\" href=\"UTD.htm?11/43/11962/abstract/41\">",
"     41",
"    </a>",
"    ]. The relevance of these findings&nbsp;to treatment requires further study. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/31/5624?source=see_link&amp;anchor=H6099435#H6099435\">",
"     \"Overview of epithelial carcinoma of the ovary, fallopian tube, and peritoneum\", section on 'Prognosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H41\">",
"    <span class=\"h2\">",
"     Chemotherapy plus bevacizumab for recurrent, advanced, or metastatic cervical cancer",
"    </span>",
"   </p>",
"   <p>",
"    Women with recurrent, metastatic, or advanced cervical cancer should receive treatment consisting of a platinum-based combination chemotherapy plus the angiogenesis inhibitor bevacizumab. This recommendation is based on the results of the GOG 240 study, in which over 400 women with stage IVB recurrent or persistent cervical squamous cell cancer or adenocarcinoma were randomly assigned to chemotherapy (paclitaxel plus either&nbsp;cisplatin or topotecan) with or without bevacizumab. Although the final data have yet to be reported, results from the second interim analysis showed the addition of bevacizumab to chemotherapy improved overall survival by four months compared to chemotherapy alone (17 versus 13 months) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/43/11962/abstract/42\">",
"     42",
"    </a>",
"    ].",
"    <br/>",
"    <br/>",
"    While we await the final analysis of GOG 240 to better evaluate the toxicity profile of treatment and whether the specific chemotherapy regimen had an impact on survival, bevacizumab should be incorporated into the first-line treatment of metastatic or recurrent cervical cancer. Although the preferred chemotherapy combination to use with bevacizumab has not been established, the choice of chemotherapy should mirror the approach to selection of agents for patients who do not receive bevacizumab. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/37/33368?source=see_link&amp;anchor=H2177909474#H2177909474\">",
"     \"Management of recurrent or metastatic cervical cancer\", section on 'First-line treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H42\">",
"    <span class=\"h2\">",
"     Intraoperative myometrial inspection for endometrial cancer",
"    </span>",
"   </p>",
"   <p>",
"    Surgical staging for endometrial cancer includes gross inspection of the uterine specimen. Invasion of &gt;50 percent of the thickness of the myometrium is associated with lymph node metastases and may impact whether lymphadenectomy is performed. A meta-analysis of 16 studies including 2567 women with endometrial cancer evaluated the diagnostic performance of intraoperative gross inspection to detect &gt;50 percent invasion compared to estimates from final histology and found a sensitivity of 75 percent and a specificity of 92 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?11/43/11962/abstract/43\">",
"     43",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/23/18810?source=see_link&amp;anchor=H8#H8\">",
"     \"Endometrial carcinoma: Pretreatment evaluation, staging and surgical treatment\", section on 'Intraoperative gross inspection and frozen section'",
"    </a>",
"    .)&nbsp;&nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H43\">",
"    <span class=\"h1\">",
"     HEAD AND NECK CANCER",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H44\">",
"    <span class=\"h2\">",
"     Cabozantinib",
"    </span>",
"   </p>",
"   <p>",
"    In 2012, cabozantinib was approved by the US Food and Drug Administration for the treatment of progressive, metastatic medullary thyroid cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?11/43/11962/abstract/44\">",
"     44",
"    </a>",
"    ]. Cabozantinib is an oral, small molecule&nbsp;tyrosine kinase inhibitor&nbsp;that targets VEGFRs 1 and 2, c-MET, and RET. In a randomized trial, 330 patients with progressive, metastatic, or unresectable locally advanced medullary thyroid cancer were randomly assigned to receive either cabozantinib or placebo once daily [",
"    <a class=\"abstract\" href=\"UTD.htm?11/43/11962/abstract/44,45\">",
"     44,45",
"    </a>",
"    ]. A significant prolongation in progression free survival was observed for cabozantinib treatment compared with placebo. Partial responses were observed in 27 versus 0 percent. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/47/23288?source=see_link&amp;anchor=H652134#H652134\">",
"     \"Chemotherapy and immunotherapy for medullary thyroid cancer\", section on 'Cabozantinib'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H45\">",
"    <span class=\"h2\">",
"     Organ-preserving approaches for advanced laryngeal cancer",
"    </span>",
"   </p>",
"   <p>",
"    In the&nbsp;Radiation Therapy Oncology Group (RTOG) 91-11 trial, 547 patients with advanced laryngeal cancer were randomly assigned to induction chemotherapy followed by radiation therapy (RT), RT with concurrent&nbsp;chemotherapy, or RT alone [",
"    <a class=\"abstract\" href=\"UTD.htm?11/43/11962/abstract/46\">",
"     46",
"    </a>",
"    ]. Laryngectomy free survival was improved with&nbsp;both combined modality approaches compared with RT alone, although there was no difference in overall survival among the three treatment approaches.&nbsp;(See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/45/41689?source=see_link&amp;anchor=H432436853#H432436853\">",
"     \"Treatment of locoregionally advanced (stage III and IV) head and neck cancer: The larynx and hypopharynx\", section on 'Comparison of organ-preserving approaches'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H46\">",
"    <span class=\"h1\">",
"     MELANOMA AND OTHER SKIN CANCER",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H47\">",
"    <span class=\"h2\">",
"     Merkel cell polyomavirus and Merkel cell carcinoma",
"    </span>",
"   </p>",
"   <p>",
"    Most studies of the relationship between Merkel cell polyomavirus and Merkel cell carcinoma (MCC)&nbsp;have detected the virus in around 80 percent of Merkel cell tumors. However, a study that utilized new techniques to detect the virus found evidence to suggest that Merkel cell polyomavirus may be present in all MCC tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?11/43/11962/abstract/47\">",
"     47",
"    </a>",
"    ]. In the study, use of an expanded repertoire of PCR primers led to the detection of viral DNA in all 60 tumor specimens tested. In addition, use of a novel monoclonal antibody against the Merkel cell polyomavirus T antigen resulted in the detection of the virus in 56 of 58 tumors (97 percent).&nbsp;(See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/35/6712?source=see_link&amp;anchor=H5#H5\">",
"     \"Clinical features and diagnosis of Merkel cell (neuroendocrine) carcinoma and sebaceous cell carcinoma of the skin\", section on 'Merkel cell polyomavirus'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H48\">",
"    <span class=\"h1\">",
"     NEUROONCOLOGY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H49\">",
"    <span class=\"h2\">",
"     Risk of meningioma from dental x-ray exposure",
"    </span>",
"   </p>",
"   <p>",
"    Exposure to ionizing radiation is the only established environmental risk factor for the development of meningioma. Most studies have focused on relatively high-dose exposure from therapeutic radiation or atomic bomb fallout, but small studies have also suggested risk from medical imaging such as dental x-rays. In a recent population-based case-control study including over 2500 patients, meningioma cases were twice as likely as controls to report ever having had a bitewing dental x-ray [",
"    <a class=\"abstract\" href=\"UTD.htm?11/43/11962/abstract/48\">",
"     48",
"    </a>",
"    ]. Patients who reported having at least one panorex film before the age of ten had a 4.9 times increased risk of meningioma. This study suggests that dental x-rays, even in the modern era, may be a potentially modifiable risk factor for meningioma. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/54/20328?source=see_link&amp;anchor=H627075228#H627075228\">",
"     \"Meningioma: Epidemiology, risk factors, and pathology\", section on 'Incidental radiation exposure'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H50\">",
"    <span class=\"h1\">",
"     THORACIC ONCOLOGY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H51\">",
"    <span class=\"h2\">",
"     Guidelines for subsolid pulmonary nodules",
"    </span>",
"   </p>",
"   <p>",
"    The Fleischner Society has proposed new guidelines for the management of subsolid (ground glass or mixed ground glass and solid) solitary pulmonary nodules [",
"    <a class=\"abstract\" href=\"UTD.htm?11/43/11962/abstract/49\">",
"     49",
"    </a>",
"    ]. An important recommendation is that subsolid solitary nodules &gt;5 mm be monitored by serial thin-slice computed tomography for at least three years due to the risk of adenocarcinoma in situ or minimally invasive adenocarcinoma (formerly called bronchioloalveolar carcinoma or BAC), which tend to be slow-growing. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/31/44537?source=see_link&amp;anchor=H1770441#H1770441\">",
"     \"Diagnostic evaluation and management of the solitary pulmonary nodule\", section on 'Guidelines for ground-glass and part-solid nodules'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H52\">",
"    <span class=\"h2\">",
"     Denosumab for lung cancer patients with bone metastases",
"    </span>",
"   </p>",
"   <p>",
"    A phase III trial compared denosumab with zoledronic acid in patients with bone metastases from primary sites other than breast and prostate cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?11/43/11962/abstract/50\">",
"     50",
"    </a>",
"    ]. A secondary analysis of the 811 patients with lung cancer (702 with non-small cell carcinoma and 109 with small cell carcinoma) found that treatment with denosumab significantly improved overall survival compared with zoledronic acid [",
"    <a class=\"abstract\" href=\"UTD.htm?11/43/11962/abstract/51\">",
"     51",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/18/13608?source=see_link&amp;anchor=H17#H17\">",
"     \"Bisphosphonates and denosumab in patients with metastatic cancer\", section on 'Lung cancer and other solid cancers'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H53\">",
"    <span class=\"h2\">",
"     Prognosis of non-small cell lung cancer in HIV-infected patients",
"    </span>",
"   </p>",
"   <p>",
"    HIV-infected patients with non-small cell lung cancer should be treated in the same way as those without HIV infection if their overall medical condition permits. A retrospective analysis of outcomes found no significant difference in overall survival between patients with and without HIV infection who had non-small cell lung cancer, when analyzed on a stage by stage basis [",
"    <a class=\"abstract\" href=\"UTD.htm?11/43/11962/abstract/52\">",
"     52",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/31/30202?source=see_link&amp;anchor=H1560506361#H1560506361\">",
"     \"HIV infection and malignancy: Management considerations\", section on 'Lung cancer'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H54\">",
"    <span class=\"h1\">",
"     OTHER ONCOLOGY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H55\">",
"    <span class=\"h2\">",
"     ASCO guidelines for the outpatient management of neutropenia",
"    </span>",
"   </p>",
"   <p>",
"    In 2013, the American Society of Clinical Oncology (ASCO) published guidelines for antimicrobial prophylaxis of adult neutropenic oncology outpatients, for selection of patients with neutropenic fever who could be treated as outpatients, and treatment recommendations for outpatient management of such patients [",
"    <a class=\"abstract\" href=\"UTD.htm?11/43/11962/abstract/53\">",
"     53",
"    </a>",
"    ]. These guidelines focus on patients who are generally considered to be at low risk for medical complications of neutropenic fever, such as patients receiving chemotherapy for solid tumors. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/37/22106?source=see_link\">",
"     \"Treatment and prevention of neutropenic fever syndromes in adult cancer patients at low risk for complications\"",
"    </a>",
"    .)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/43/11962/abstract/1\">",
"      Darby SC, Ewertz M, McGale P, et al. Risk of ischemic heart disease in women after radiotherapy for breast cancer. N Engl J Med 2013; 368:987.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/43/11962/abstract/2\">",
"      Steen ST, Chung AP, Han SH, et al. Predicting nipple-areolar involvement using preoperative breast MRI and primary tumor characteristics. Ann Surg Oncol 2013; 20:633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/43/11962/abstract/3\">",
"      Pestalozzi BC, Holmes E, de Azambuja E, et al. CNS relapses in patients with HER2-positive early breast cancer who have and have not received adjuvant trastuzumab: a retrospective substudy of the HERA trial (BIG 1-01). Lancet Oncol 2013; 14:244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/43/11962/abstract/4\">",
"      Maaskant-Braat AJ, Roumen RM, Voogd AC, et al. Sentinel Node and Recurrent Breast Cancer (SNARB): results of a nationwide registration study. Ann Surg Oncol 2013; 20:620.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/43/11962/abstract/5\">",
"      Goetz MP, Suman VJ, Hoskin TL, et al. CYP2D6 metabolism and patient outcome in the Austrian Breast and Colorectal Cancer Study Group trial (ABCSG) 8. Clin Cancer Res 2013; 19:500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/43/11962/abstract/6\">",
"      Goss PE, Smith IE, O'Shaughnessy J, et al. Adjuvant lapatinib for women with early-stage HER2-positive breast cancer: a randomised, controlled, phase 3 trial. Lancet Oncol 2013; 14:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/43/11962/abstract/7\">",
"      Bachelot T, Romieu G, Campone M, et al. Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study. Lancet Oncol 2013; 14:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/43/11962/abstract/8\">",
"      Davies C, Pan H, Godwin J, et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet 2012.",
"     </a>",
"    </li>",
"    <li>",
"     Aebi S, Gelber S, L&aacute;ng I, et al. Chemotherapy prolongs survival for isolated local or regional recurrence of breast cancer: the CALOR trial (Chemotherapy as Adjuvant for Locally Recurrent breast cancer; IBCSG 27-02, NSABP B-37, BIG 1-02). 2012 CTRC-AACR San Antonio Breast Cancer Symposium; Abstract S3-2.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/43/11962/abstract/10\">",
"      Xu S, Yang Y, Tao W, et al. Tamoxifen adherence and its relationship to mortality in 116 men with breast cancer. Breast Cancer Res Treat 2012; 136:495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/43/11962/abstract/11\">",
"      Verma S, Miles D, Gianni L, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 2012; 367:1783.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/43/11962/abstract/12\">",
"      Guerrero A, Gavil&aacute; J, Folkerd E, et al. Incidence and predictors of ovarian function recovery (OFR) in breast cancer (BC) patients with chemotherapy-induced amenorrhea (CIA) who switched from tamoxifen to exemestane. Ann Oncol 2013; 24:674.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/43/11962/abstract/13\">",
"      Gentilini O, Botteri E, Veronesi P, et al. Repeating conservative surgery after ipsilateral breast tumor reappearance: criteria for selecting the best candidates. Ann Surg Oncol 2012; 19:3771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/43/11962/abstract/14\">",
"      Seshasai SR, Wijesuriya S, Sivakumaran R, et al. Effect of aspirin on vascular and nonvascular outcomes: meta-analysis of randomized controlled trials. Arch Intern Med 2012; 172:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/43/11962/abstract/15\">",
"      Rothwell PM, Price JF, Fowkes FG, et al. Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials. Lancet 2012; 379:1602.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/43/11962/abstract/16\">",
"      Doubeni CA, Weinmann S, Adams K, et al. Screening colonoscopy and risk for incident late-stage colorectal cancer diagnosis in average-risk adults: a nested case-control study. Ann Intern Med 2013; 158:312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/43/11962/abstract/17\">",
"      Rosenthal AN, Fraser L, Manchanda R, et al. Results of annual screening in phase I of the United Kingdom familial ovarian cancer screening study highlight the need for strict adherence to screening schedule. J Clin Oncol 2013; 31:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/43/11962/abstract/18\">",
"      Knudsen AB, Hur C, Gazelle GS, et al. Rescreening of persons with a negative colonoscopy result: results from a microsimulation model. Ann Intern Med 2012; 157:611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/43/11962/abstract/19\">",
"      McCabe MS, Bhatia S, Oeffinger KC, et al. American Society of Clinical Oncology statement: achieving high-quality cancer survivorship care. J Clin Oncol 2013; 31:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/43/11962/abstract/20\">",
"      Raman SP, Kawamoto S, Blackford A, et al. Histopathologic findings of multifocal pancreatic intraductal papillary mucinous neoplasms on CT. AJR Am J Roentgenol 2013; 200:563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/43/11962/abstract/21\">",
"      Demetri GD, Reichardt P, Kang YK, et al. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 2013; 381:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/43/11962/abstract/22\">",
"      Wald C, Russo MW, Heimbach JK, et al. New OPTN/UNOS policy for liver transplant allocation: standardization of liver imaging, diagnosis, classification, and reporting of hepatocellular carcinoma. Radiology 2013; 266:376.",
"     </a>",
"    </li>",
"    <li>",
"     Von Hoff DD, Ervin TJ, Arena FP, et al. Randomized phase III study of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patietns with metastatic adenocarcinoma of the pancreas (MPACT). Abstract. Data presented at the 2013 ASCO Gastrointestinal Cancers Symposium, San Francisco, CA, January 24-26, 2013. Abstract available online at file://www.asco.org/ASCOv2/Meetings/Abstracts?&amp;vmview=abst_detail_view&amp;confID=133&amp;abstractID=106143&amp;et_cid=30928363&amp;et_rid=463567184&amp;linkid=http%3A%2F%2Fwww.asco.org%2FASCOv2%2FMeetings%2FAbstracts%3F%26amp%3Bvmview%3Dabst_detail_view%26amp%3BconfID%3D133%26amp%3BabstractID%3D106143 (Accessed on February 07, 2013).",
"    </li>",
"    <li>",
"     Uesaka K, Fukutomi A,  Boku N, et al. Randomized phase III trial of adjuvant chemotherapy with gemcitabine versus S-1 for patients with resected pancreatic cancer (JASPAC-01 study) (abstract). J Clin Oncol 30: 2012 (suppl 34; abstr 145). file://www.asco.org/ASCOv2/Meetings/Abstracts?&amp;vmview=abst_detail_view&amp;confID=133&amp;abstractID=105691 (Accessed on February 08, 2013).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/43/11962/abstract/25\">",
"      Moreira L, Balaguer F, Lindor N, et al. Identification of Lynch syndrome among patients with colorectal cancer. JAMA 2012; 308:1555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/43/11962/abstract/26\">",
"      Hussain M, Tangen CM, Berry DL, et al. Intermittent versus continuous androgen deprivation in prostate cancer. N Engl J Med 2013; 368:1314.",
"     </a>",
"    </li>",
"    <li>",
"     Smith MR, Halabi S, Ryan CJ, et al. Efficacy and safety of zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: Results of CALGB 90202 (Alliance). J Clin Oncol 2013; 31: (suppl 6; abstr 27).",
"    </li>",
"    <li>",
"     Hutson TE, Gallardo J, Lesovoy V, et al. Axitinib versus sorafenib as firstline therapy in patients with metastatic renal cell carcinoma (mRCC). J Clin Oncol 31, 2013 (suppl 6; abstr LBA348).",
"    </li>",
"    <li>",
"     Lehmann J, Kuehn M, Fischer C, et al. Randomized phase III study of adjuvant versus progression-triggered treatment with gemcitabine (G) after radical cystectomy (RC) for locally advanced bladder cancer (LABC) in patients not suitable for cisplatin-based chemotherapy (CBC) (AUO-trial AB22/00). J Clin Oncol 21, 2013 (suppl 6; abstr 250).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/43/11962/abstract/30\">",
"      Gravis G, Fizazi K, Joly F, et al. Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial. Lancet Oncol 2013; 14:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/43/11962/abstract/31\">",
"      Sheets NC, Goldin GH, Meyer AM, et al. Intensity-modulated radiation therapy, proton therapy, or conformal radiation therapy and morbidity and disease control in localized prostate cancer. JAMA 2012; 307:1611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/43/11962/abstract/32\">",
"      Yu JB, Soulos PR, Herrin J, et al. Proton versus intensity-modulated radiotherapy for prostate cancer: patterns of care and early toxicity. J Natl Cancer Inst 2013; 105:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/43/11962/abstract/33\">",
"      Coen JJ, Zietman AL, Rossi CJ, et al. Comparison of high-dose proton radiotherapy and brachytherapy in localized prostate cancer: a case-matched analysis. Int J Radiat Oncol Biol Phys 2012; 82:e25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/43/11962/abstract/34\">",
"      Allen AM, Pawlicki T, Dong L, et al. An evidence based review of proton beam therapy: the report of ASTRO's emerging technology committee. Radiother Oncol 2012; 103:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/43/11962/abstract/35\">",
"      Fizazi K, Scher HI, Molina A, et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 2012; 13:983.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/43/11962/abstract/36\">",
"      Logothetis CJ, Basch E, Molina A, et al. Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial. Lancet Oncol 2012; 13:1210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/43/11962/abstract/37\">",
"      Ryan CJ, Smith MR, de Bono JS, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 2013; 368:138.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.accessdata.fda.gov/drugsatfda_docs/label/2012/202379s005lbl.pdf (Accessed on December 11, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/43/11962/abstract/39\">",
"      Okazawa M, Mabuchi S, Isohashi F, et al. Impact of the addition of concurrent chemotherapy to pelvic radiotherapy in surgically treated stage IB1-IIB cervical cancer patients with intermediate-risk or high-risk factors: a 13-year experience. Int J Gynecol Cancer 2013; 23:567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/43/11962/abstract/40\">",
"      Kadkhodayan S, Shahriari S, Treglia G, et al. Accuracy of 18-F-FDG PET imaging in the follow up of endometrial cancer patients: systematic review and meta-analysis of the literature. Gynecol Oncol 2013; 128:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/43/11962/abstract/41\">",
"      Zhao D, Zhang F, Zhang W, et al. Prognostic role of hormone receptors in ovarian cancer: a systematic review and meta-analysis. Int J Gynecol Cancer 2013; 23:25.",
"     </a>",
"    </li>",
"    <li>",
"     NCI Press Release: Bevacizumab significantly improves survival for patients with recurrent and metastatic cervical cancer. file://cancer.gov/newscenter/newsfromnci/2013/GOG240 (Accessed on February 19, 2013).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/43/11962/abstract/43\">",
"      Mavromatis ID, Antonopoulos CN, Matsoukis IL, et al. Validity of intraoperative gross examination of myometrial invasion in patients with endometrial cancer: a meta-analysis. Acta Obstet Gynecol Scand 2012; 91:779.",
"     </a>",
"    </li>",
"    <li>",
"     US Food and Drug Administration. FDA approves Cometriq to treat rare type of thyroid cancer. file://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm330143.htm (Accessed on December 03, 2012).",
"    </li>",
"    <li>",
"     Schoffski P, Elisei R, Muller S, et al. An international, double-blind, randomized, placebo-controlled phase III trial (EXAM) of cabozantinib (XL184) in medullary thyroid carcinoma (MTC) patients (pts) with documented RECIST progression at baseline. J Clin Oncol 2012; 30 (suppl):5508. file://meeting.ascopubs.org/cgi/content/abstract/30/15_suppl/5508 (Accessed on January 25, 2013).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/43/11962/abstract/46\">",
"      Forastiere AA, Zhang Q, Weber RS, et al. Long-term results of RTOG 91-11: a comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer. J Clin Oncol 2013; 31:845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/43/11962/abstract/47\">",
"      Rodig SJ, Cheng J, Wardzala J, et al. Improved detection suggests all Merkel cell carcinomas harbor Merkel polyomavirus. J Clin Invest 2012; 122:4645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/43/11962/abstract/48\">",
"      Claus EB, Calvocoressi L, Bondy ML, et al. Dental x-rays and risk of meningioma. Cancer 2012; 118:4530.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/43/11962/abstract/49\">",
"      Naidich DP, Bankier AA, MacMahon H, et al. Recommendations for the management of subsolid pulmonary nodules detected at CT: a statement from the Fleischner Society. Radiology 2013; 266:304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/43/11962/abstract/50\">",
"      Henry DH, Costa L, Goldwasser F, et al. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol 2011; 29:1125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/43/11962/abstract/51\">",
"      Scagliotti GV, Hirsh V, Siena S, et al. Overall survival improvement in patients with lung cancer and bone metastases treated with denosumab versus zoledronic acid: subgroup analysis from a randomized phase 3 study. J Thorac Oncol 2012; 7:1823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/43/11962/abstract/52\">",
"      Rengan R, Mitra N, Liao K, et al. Effect of HIV on survival in patients with non-small-cell lung cancer in the era of highly active antiretroviral therapy: a population-based study. Lancet Oncol 2012; 13:1203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/43/11962/abstract/53\">",
"      Flowers CR, Seidenfeld J, Bow EJ, et al. Antimicrobial prophylaxis and outpatient management of fever and neutropenia in adults treated for malignancy: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 2013; 31:794.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8361 Version 2390.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-200.131.240.2-C9BE2142DC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_43_11962=[""].join("\n");
var outline_f11_43_11962=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      BREAST CANCER",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      Cardiotoxicity in women with breast cancer after radiation therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Detection of breast cancer near the nipple areolar complex",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Adjuvant trastuzumab and the risk of brain metastases in women with HER2-positive breast cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Repeat sentinel lymph node dissection after previous axillary procedures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      CYP2D6 genotypes, SSRIs, and breast cancer treatment with tamoxifen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Lapatinib following adjuvant chemotherapy for HER2-positive breast cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Lapatinib plus capecitabine for brain metastases in patients with HER2-positive breast cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Duration of adjuvant tamoxifen for breast cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Chemotherapy following resection of a locoregional breast cancer recurrence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Tamoxifen therapy for men with breast cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Ado-trastuzumab emtansine as second-line treatment for HER2-positive metastatic breast cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Reactivation of ovarian function with aromatase inhibitors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Locoregional recurrence after breast conservation therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      CANCER SCREENING AND PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Aspirin for the primary prevention of cardiovascular disease and cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Screening colonoscopy and incidence of late stage colorectal cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Screening women with a familial ovarian cancer syndrome for ovarian cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Rescreening for colorectal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      CANCER SURVIVORSHIP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      ASCO promoted a shared care model for cancer survivorship",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      GASTROINTESTINAL CANCER",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Multiple pancreatic cysts and risk for high-grade dysplasia or invasive cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Regorafenib for refractory GIST",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Revised listing criteria for liver transplantation in patients with cirrhosis and HCC",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Gemcitabine plus nab-paclitaxel for metastatic pancreatic cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Adjuvant S-1 for resected pancreatic cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Universal tumor testing for Lynch syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      GENITOURINARY ONCOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Intermittent versus continuous androgen deprivation for hormone sensitive metastatic prostate cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Zoledronic acid in castration sensitive prostate cancer with bone metastases",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Axitinib as first-line treatment of metastatic renal cell carcinoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Adjuvant non-platinum therapy for muscle invasive bladder cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      Initial systemic therapy in hormone sensitive prostate cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      Proton beam therapy for prostate cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      Abiraterone in metastatic prostate cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      GYNECOLOGIC ONCOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      Adjuvant treatment of intermediate-risk early stage cervical cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H39\">",
"      PET/CT scan in the work-up of suspected recurrent endometrial cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H40\">",
"      Hormone receptor expression and prognosis in ovarian cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H41\">",
"      Chemotherapy plus bevacizumab for recurrent, advanced, or metastatic cervical cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H42\">",
"      Intraoperative myometrial inspection for endometrial cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H43\">",
"      HEAD AND NECK CANCER",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H44\">",
"      Cabozantinib",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H45\">",
"      Organ-preserving approaches for advanced laryngeal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H46\">",
"      MELANOMA AND OTHER SKIN CANCER",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H47\">",
"      Merkel cell polyomavirus and Merkel cell carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H48\">",
"      NEUROONCOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H49\">",
"      Risk of meningioma from dental x-ray exposure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H50\">",
"      THORACIC ONCOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H51\">",
"      Guidelines for subsolid pulmonary nodules",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H52\">",
"      Denosumab for lung cancer patients with bone metastases",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H53\">",
"      Prognosis of non-small cell lung cancer in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H54\">",
"      OTHER ONCOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H55\">",
"      ASCO guidelines for the outpatient management of neutropenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/8361\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/8361|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?39/47/40702\" title=\"table 1\">",
"      Aspirin for CVD and cancer prevention",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?39/30/40428\" title=\"table 2\">",
"      OPTN classification for nodules in cirrhotic livers",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/33/22042?source=related_link\">",
"      Adjuvant and neoadjuvant therapy for exocrine pancreatic cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/4/29766?source=related_link\">",
"      Adjuvant chemotherapy for muscle invasive urothelial (transitional cell) carcinoma of the bladder",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/40/20106?source=related_link\">",
"      Adjuvant endocrine therapy for hormone receptor-positive breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/7/11384?source=related_link\">",
"      Adjuvant medical therapy for HER2-positive breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?11/16/11527?source=related_link\">",
"      Ado-trastuzumab emtansine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/32/28170?source=related_link\">",
"      Anti-angiogenic and molecularly targeted therapy for advanced renal cell carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/62/23529?source=related_link\">",
"      Aspirin in the primary prevention of cardiovascular disease and cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/18/13608?source=related_link\">",
"      Bisphosphonates and denosumab in patients with metastatic cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/36/26186?source=related_link\">",
"      Breast cancer in men",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/21/34137?source=related_link\">",
"      Cardiotoxicity of radiation therapy for malignancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/7/16503?source=related_link\">",
"      Castrate resistant prostate cancer: Treatments targeting the androgen pathway",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/47/23288?source=related_link\">",
"      Chemotherapy and immunotherapy for medullary thyroid cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/12/39114?source=related_link\">",
"      Chemotherapy for advanced exocrine pancreatic cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/59/19386?source=related_link\">",
"      Clinical features and diagnosis of Lynch syndrome (hereditary nonpolyposis colorectal cancer)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/35/6712?source=related_link\">",
"      Clinical features and diagnosis of Merkel cell (neuroendocrine) carcinoma and sebaceous cell carcinoma of the skin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/49/41753?source=related_link\">",
"      Diagnosis and treatment of intraductal papillary mucinous neoplasm of the pancreas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/31/44537?source=related_link\">",
"      Diagnostic evaluation and management of the solitary pulmonary nodule",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/23/18810?source=related_link\">",
"      Endometrial carcinoma: Pretreatment evaluation, staging and surgical treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/47/23290?source=related_link\">",
"      External beam radiation therapy for localized prostate cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/31/30202?source=related_link\">",
"      HIV infection and malignancy: Management considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/20/1353?source=related_link\">",
"      Initial hormone therapy for metastatic prostate cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/32/36362?source=related_link\">",
"      Liver transplantation for hepatocellular carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/8/36999?source=related_link\">",
"      Management of bone metastases in advanced prostate cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/0/19464?source=related_link\">",
"      Management of brain metastases in breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/14/9449?source=related_link\">",
"      Management of early stage cervical cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/53/34650?source=related_link\">",
"      Management of locoregional recurrence of breast cancer after breast conserving therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/45/30426?source=related_link\">",
"      Management of locoregional recurrence of breast cancer after mastectomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/37/33368?source=related_link\">",
"      Management of recurrent or metastatic cervical cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/18/12586?source=related_link\">",
"      Mastectomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/2/7210?source=related_link\">",
"      Mechanisms of action of selective estrogen receptor modulators",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/54/20328?source=related_link\">",
"      Meningioma: Epidemiology, risk factors, and pathology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/6/32873?source=related_link\">",
"      Overview of cancer survivorship care for primary care and oncology providers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/7/21624?source=related_link\">",
"      Overview of endometrial carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/31/5624?source=related_link\">",
"      Overview of epithelial carcinoma of the ovary, fallopian tube, and peritoneum",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/12/10442?source=related_link\">",
"      Overview of the treatment of disseminated prostate cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?31/16/32006?source=related_link\">",
"      Regorafenib: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/10/37034?source=related_link\">",
"      Screening for colorectal cancer: Strategies in patients at average risk",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/14/10474?source=related_link\">",
"      Screening for ovarian cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/47/36602?source=related_link\">",
"      Sentinel lymph node dissection for breast cancer: Indications and outcomes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/43/22202?source=related_link\">",
"      Systemic treatment for metastatic breast cancer: Molecular targeted therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/9/38042?source=related_link\">",
"      Tests for screening for colorectal cancer: Stool tests, radiologic imaging and endoscopy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/37/22106?source=related_link\">",
"      Treatment and prevention of neutropenic fever syndromes in adult cancer patients at low risk for complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/35/44601?source=related_link\">",
"      Treatment of brain metastases in favorable prognosis patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/45/41689?source=related_link\">",
"      Treatment of locoregionally advanced (stage III and IV) head and neck cancer: The larynx and hypopharynx",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/58/34730?source=related_link\">",
"      Tyrosine kinase inhibitor therapy for advanced gastrointestinal stromal tumors",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f11_43_11963="Signs of meningeal irritation";
var content_f11_43_11963=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F82677&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F82677&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Signs of meningeal irritation",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Signs of meningeal irritation",
"      </td>",
"      <td class=\"subtitle1\">",
"       Maneuver",
"      </td>",
"      <td class=\"subtitle1\">",
"       Positive test",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Kernig's sign",
"      </td>",
"      <td>",
"       Place patient supine with hip flexed at 90 degrees. Attempt to extend the leg at the knee.",
"      </td>",
"      <td>",
"       The test is positive when there is resistance to extension at the knee to &gt;135 degrees or pain in the lower back or posterior thigh.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Brudzinski's sign",
"      </td>",
"      <td>",
"       Place patient in the supine position and passively flex the head towards the chest.",
"      </td>",
"      <td>",
"       The test is positive when there is flexion of the knees and hips of the patient.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Jolt accentuation of headache",
"      </td>",
"      <td>",
"       Patient rotates his/her head horizontally two to three times per second.",
"      </td>",
"      <td>",
"       The test is positive if the patient reports exacerbation of his/her headache with this maneuver.",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_43_11963=[""].join("\n");
var outline_f11_43_11963=null;
var title_f11_43_11964="Category I II and III FHR tracings";
var content_f11_43_11964=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F57583&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F57583&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Fetal heart rate (FHR) interpretation system",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Category I",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        All of the following criteria must be present. Tracings meeting these criteria are predictive of normal fetal acid-base balance at the time of observation.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Baseline rate: 110-160 beats per minute (bpm)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Moderate baseline FHR variability",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        No late or variable decelerations",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Early decelerations may be present or absent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Accelerations may be present or absent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Category III",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Criteria for (1) or (2) should be present. Category III tracings are predictive of abnormal fetal acid-base status at the time of observation. Prompt evaluation is indicated and most parturients will require expeditious intervention, such as provision of supplemental oxygen, change in position, treatment of hypotension, and discontinuation of any uterotonic drugs being administered.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        (1) Absent baseline FHR variability and any of the following:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        &bull; Recurrent late decelerations",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        &bull; Recurrent variable decelerations",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        &bull; Bradycardia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        (2) Sinusoidal pattern",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Category II",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <strong>",
"         FHR tracing does not meet criteria for either category I or III and is considered indeterminate.",
"        </strong>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     From: Macones GA, Hankins GD, Spong CY, et al. The 2008 National Institute of Child Health and Human Development Workshop Report on Electronic Fetal Monitoring: Update on Definitions, Interpretation, and Research Guidelines. Obstet Gynecol 2008; 112:661.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_43_11964=[""].join("\n");
var outline_f11_43_11964=null;
var title_f11_43_11965="Burkitt therapy CALGB 9251";
var content_f11_43_11965=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F76650&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F76650&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Intensive treatment for Burkitt leukemia/lymphoma: CALGB 9251 (revised*)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Cycle 1",
"        <span class=\"small\">",
"         &bull;",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cyclophosphamide: 200 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        IV per day on days 1 through 5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Prednisone: 60 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        PO per day on days 1 through 7",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Cycles 2, 4, and 6",
"        <span class=\"small\">",
"         &bull;",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ifosfamide: 800 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        over one hour IV per day on days 1 through 5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mesna: 200 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        IV per day on days 1 through 5 at 0, 4, and 8 hours after ifosfamide",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Methotrexate: 150 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        IV over 30 minutes on day 1, then 1.35 g/m",
"        <sup>",
"         2",
"        </sup>",
"        IV over the next 23.5 hours, for a total dose of 1.5 g/m",
"        <sup>",
"         2",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Leucovorin: 50 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        IV 36 hours after initiation of methotrexate, then 15 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        every 6 hours until serum methotrexate concentration &lt;0.05 micromolar",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vincristine: 2 mg IV push on day 1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cytarabine: 150 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        per day by continuous IV infusion on days 4 and 5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Etoposide: 80 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        per day IV over one hour on days 4 and 5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dexamethasone: 10 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        PO per day on days 1 through 5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Cycles 3, 5, and 7",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cyclophosphamide: 200 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        per day IV on days 1 through 5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Methotrexate: 150 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        IV over 30 minutes on day 1, then 1.35 g/m",
"        <sup>",
"         2",
"        </sup>",
"        IV over the next 23.5 hours, for a total dose of 1.5 g/m",
"        <sup>",
"         2",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Leucovorin: 50 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        IV 36 hours after initiation of methotrexate, then 15 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        every 6 hours until serum methotrexate concentration &lt;0.05 micromolar",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vincristine: 2 mg IV push on day 1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Doxorubicin: 25 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        per day by IV bolus on days 4 and 5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dexamethasone: 10 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        PO per day on days 1 through 5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Intrathecal chemotherapy with cycles 2 through 7 (amended)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Methotrexate: 15 mg IT on day 1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cytarabine: 40 mg IT on day 1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hydrocortisone: 50 mg IT on day 1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Cranial irradiation (amended)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2400 cGy administered in 12 fractions after chemotherapy for cycle 7 completed, only for patients who had prior bone marrow involvement at the time of presentation",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     CALGB: Cancer and Leukemia Group B; IV: intravenously; PO: by mouth; IT: intrathecal injection.",
"     <br>",
"      * Revised protocol as given to Cohort 2 of the study in order to reduce the incidence and severity of neurotoxicity.",
"      <br>",
"       <span class=\"bullet\">",
"        &bull;",
"       </span>",
"       All cycles are repeated at 21-day intervals except cycle 1, which lasts 7 days.",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Modified from: Lee, EJ, et al. J Clin Oncol 2001; 19:4014 and Rizzieri, DA, et al. Cancer 2004; 100:1438.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_43_11965=[""].join("\n");
var outline_f11_43_11965=null;
var title_f11_43_11966="Bogalusa threshold boys";
var content_f11_43_11966=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F51934&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F51934&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 560px\">",
"   <div class=\"ttl\">",
"    Thresholds for defining cardiovascular risk in boys, Bogalusa Heart Study",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 540px; height: 186px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Smoothed body mass index (BMI) and waist circumference thresholds for predicting risk factor clustering among male children and adolescents in the Bogalusa Heart Study (1992-1994). Each curve defines the optimal BMI or waist circumference which predicts having three or more cardiovascular risk factors (high blood pressure; low high-density lipoprotein cholesterol concentration; or high low-density lipoprotein cholesterol, triglyceride, glucose, or insulin concentration, adjusted for age) at a given age.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Katzmarzyk PT, Srinivasan SR, Chen W, et al. Body mass index, waist circumference, and clustering of cardiovascular disease risk factors in a biracial sample of children and adolescents. Pediatrics 2004; 114:e198.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_43_11966=[""].join("\n");
var outline_f11_43_11966=null;
var title_f11_43_11967="Internal nasal exam";
var content_f11_43_11967=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F52743&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F52743&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 499px\">",
"   <div class=\"ttl\">",
"    Internal examination of the nose",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 479px; height: 293px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_43_11967=[""].join("\n");
var outline_f11_43_11967=null;
